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ABSTRACT 
Previous studies with the vanilloid spice principle capsaicin have shown a 
biphasic V02 response, with increased perfusion pressure (PP or vasoconstriction), in 
the perfused rat hindlimb that has led to suggestions of vanilloid receptor subtypes 
(VNI/VN2) in this preparation (Colquhoun et al., 1995). The present study attempted to 
further define the role of vanilloid receptors by the use of selective competitive 
(capsazepine or CPZ) and non-competitive (ruthenium red) vanilloid antagonists. CPZ 
inhibited capsaicin-mediated effects in the perfused hindlimb in a competitive manner 
with an affinity, estimated by Schild plot analysis, comparable to that seen in other 
preparations. Submicromolar concentrations of CPZ selectively inhibited the increased 
VO2 produced by the putative VNI receptor, and inhibited all effects at higher 
concentrations.. Submicromolar concentrations of ruthenium red, a vanilloid cation 
channel blocker, selectively inhibited the putative VN2 receptor-mediated effects of 
capsaicin (strong vasoconstriction and inhibition of V02). These observations, showing 
different sensitivity to blockade by CPZ and ruthenium red, further support the presence 
of two vanilloid receptor/ion channel subtypes in the rat hindlimb. 
Tetrodotoxin (TTX) failed to attenuate any changes produced by capsaicin, 
suggesting that the mechanism of action of capsaicin in the rat hindlimb may differ from 
other tissues where TTX-sensitive an insensitive cellular mechanisms operate. 
Moreover, 12-phenylacetate 13-acetate 20-homovanillate (PPAHV), shown to bind to 
vanilloid receptors in a non-cooperative manner, induced very similar effects to 
capsaicin and provided preliminary evidence that the biphasic effects of capsaicin on 
VO2 are not likely to be due to cooperativity of binding to vanilloid receptors. 
The role of capsaicin-sensitive neurons and their peptide neurotransmitters in 
capsaicin-induced responses in the perfused hindlimb were also studied. Non-peptide 
antagonists for tachykinin NK1 and NK2 receptors (CP-99,994 and SR 48968) 
selectively blocked the stimulation of VO2 produced by submicromolar concentrations 
of capsaicin. Furthermore, infused substance P (SP), neurokinin A (NKA) and 
neurokinin B (NKB) stimulated VO2 and induced mild vasoconstriction with a rank 
order of potency NKA>NICB>SP. These data support a role for the tachykinins, acting 
primarily at NK2 receptors, in capsaicin-induced stimulation of V0 2 . Infused calcitonin 
gene-related peptide (CGRP) did not alter basal VO 2 or PP. However, the CGRP 
receptor antagonist CGRP(8_37) potentiated both V0 2 and PP responses to capsaicin in 
the rat hindlimb indicating a vasodilator role for endogenously released CGRP. 
The stimulation of V0 2 and PP increase produced by low concentrations of 
infused capsaicin were absent one day after capsaicin pretreatment supporting a role for 
capsaicin-sensitive neurons in these responses. Conversely, the inhibition of V0 2 and 
increased PP produced by micromolar concentrations of capsaicin were potentiated 1, 7 
and 14 days after capsaicin pretreatment and may either support a vasodilator role for 
endogenously released neuropeptides (e.g. CGRP), which are known to be depleted by 
capsaicin pretreatment, or upregulation of VN2 receptors. 
The vascular actions of CGRP, SP and NKA were further examined in the 
perfused rat hindlimb under noradrenalin (NOR)-induced vasoconstriction. CGRP 
caused strong, sustained dilatation that was nitric oxide (NO)-independent, while SP 
and NKA elicited transient dilatation that was partly NO-dependent. Conversely, a low 
concentration of capsaicin elicited strong vasoconstriction in the NA-stimulated 
perfused hindlimb. The metabolic effects of these agents was unclear from these studies 
given the strong V0 2-stimulating effect of NOR. 
The studies undertaken support the notion that at least two vanilloid receptor 
subtypes mediate the vascular and metabolic effects of capsaicin in the perfused rat 
hindlimb. The effects of capsaicin in this tissue may result from a combination of 
dilatation and V02 stimulation induced by endogenous sensory neuropeptides, and the 
predominant vasoconstrictor effect of capsaicin via stimulation of specific vanilloid 
receptors. These findings underline the complex nature of capsaicin's novel actions in 
perfused rat skeletal muscle. 
Introduction 	 1 
Chapter 1 
Introduction 
1.1. The Vanilloid Spice Principles 
The consumption of spices as flavour enhancers has been common practice in 
many traditional communities for centuries, and is now increasingly widespread in 
'western' societies. The ability of these foods to induce a local sensation of warmth can 
be attributed the presence of structurally similar pungent compounds including 
capsaicin (from chillies of the genus Capsicum) (Fig. 1.1), piperine (from black 
peppers), and gingerols and shogaols (from ginger root). Recently included in this class 
of naturally-occurring `vanilloid' agents is the ultrapotent analogue resiniferatoxin 
(from the latex of some members of the genus Euphorbia) which is not only structurally 
similar to capsaicin (Fig. 1.1), but is also capsaicin-like in terms of its irritancy (Szallasi 
and Blumberg, 1989). 
In the field of neuroscience, capsaicin and related compounds are best known for 
their ability to induce pain and inflammatory responses followed by a state of 
antinociception (desensitisation) in most mammalian species (Holzer, 1991). The 
sensitivity of these tissues to capsaicin and other vanilloid agents is typically due to the 
selective action of these compounds on capsaicin-sensitive primary afferent neurons 
(CSPANs) (see section 1.3 and sections therein) which have their cell bodies in the 
dorsal root ganglia of the spinal cord, and nerve endings in most body tissues/organs 
(Holzer, 1988). CSPANs can be identified with a population of sensory neurons with 
small diameter somata and either unmyelinated (C-type) or thinly myelinated (AS-type) 
fibres, although these morphological characteristics are not exclusive to CSPANs and it 
is their capsaicin sensitivity that distinguishes them from other primary afferent neurons 
(Holzer, 1991; Maggi, 1993). In addition to the transmission of nociceptive information 
to the CNS (afferent function) CSPANs also have a local efferent function usually 
involving the initiation of inflammatory events (neurogenic inflammation) mediated by 
the secondary release various neuropeptides. These include, most notably, the 
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tachykinins — substance P (SP), neurokinin A (NKA) and neurokinin B (NKB) - and 
calcitonin gene-related peptide (CGRP) (Buck and Burks, 1986; Maggi and Meli, 
Resiniferatoxin 
H 11. 
Me0 
HO 
HO 	 Capsazepine 
Fig. 1.1. The chemical structures of capsaicin, the ultrapotent analogue 
resiniferatoxin, and the competitive antagonist capsazepine. A commonly adopted 
approach in vanilloid structure-activity considerations is to divide the molecule 
into three regions: A (a 4-hydroxy, 3-methoxy aromatic ring); B (an amide 
`linker'); and C (a hydrophobic sidechain), as shown for capsaicin. 
1988; Holzer, 1988). The sensory efferent functions of CSPANs are well characterised 
in many smooth muscle organs including the lung (Lou, 1993; Lundberg, 1993), urinary 
bladder (Maggi, 1992), and vasculature (Holzer, 1993; Holzer, 1998) where release of 
Introduction 	 3 
their peptide neuromodulators tends to elicit smooth muscle contraction, inflammation, 
and endothelium-dependent vasodilatation by stimulation of their respective receptors 
(Otsuka and Yoshioka, 1993; Bell and McDermott, 1996). 
1.2. The Perfused Rat Hindlimb and the Metabolic Actions of Vanilloids 
1.2.1. Use of the perfused rat hindlimb for metabolic studies in skeletal muscle 
In studies exploring the factors controlling skeletal muscle metabolism, two 
techniques have been favoured; isolated and incubated (or perifused) muscle 
preparations, and the perfused rat hindlimb (hindquarter) preparation (reviewed by 
Bonen et al., 1994). While incubated muscle techniques have been popular in the past, 
due largely to their simplicity, perfiised rat hindlimb preparations offer the advantage of 
having nutrient supply by their own vascular networks, rather than relying on simple 
diffusion to parenchymal tissue. This latter consideration is particularly important in 
view of the evidence supporting a role for the vasculature in many of the metabolic 
responses in muscle (reviewed by Clark et al., 1995; 1997). 
Since the early report by Ruderman et al. (1971) describing a stable technique for 
rat hindlimb perfusion, use of the preparation has become widespread. The technique 
has been central to a variety of skeletal muscle metabolic studies including those into 
carbohydrate metabolism (Ploug et al., 1987); oxygen consumption (V02 — an indirect 
measure of thermogenesis) (Grubb and Folk, 1976; 1977); exercise physiology (Cote et 
al., 1985), vascular properties (Rippe et al., 1978) and pharmacological studies 
(Kobinger and Pichler, 1981; Ye et al., 1995; Hall et al., 1997). In fact, the use of 
perfused hindlimb preparations has contributed significantly to a growing body of 
evidence that the vasculature plays a key role in regulating the metabolic behaviour of 
skeletal muscle (Clark et al., 1995; 1997). Several reports have demonstrated the ability 
of vasoconstrictors (termed 'type A' vasoconstrictors) to increase hindlimb VO2 (reduce 
venous P02), including catecholamines (Grubb and Folk, 1977; Richter et al., 1982; 
Cote et al., 1985; Colquhoun et al., 1990; Dora et al., 1992), peptides such as 
angiotensin II and vasopressin (Colquhoun et al., 1988) and a number of spice 
principles (see section 1.2.3). Furthermore, these agents have been shown to increase 
the efflux of other metabolic indicators including lactate, glycerol, and purine and 
pyrimidine metabolites (Clark et al., 1995). Conversely, the net inhibition of hindlimb 
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V02 (increased venous P02) has been observed with the infusion of other 
vasoconstrictors (termed 'type B' vasoconstrictors) such as 5-hydroxytryptamine (5-HT 
or serotonin) (Dora et al., 1991; 1992), high concentrations of noradrenalin (NOR) 
(Grubb and Folk, 1976; Cote et al., 1985; Dora et al. ,1992) and high dose vanilloids 
(section 1.2.3.). 
1.2.2. Proposed mechanisms for vasoconstrictor-induced alteration of muscle 
metabolism 
1.2.2.1. Working (contracting) vascular smooth muscle (7-lot Pipes') 
The metabolic and vascular effects of type A vasoconstrictors, and to a slightly 
lesser extent type B vasoconstrictors, in the constant flow perfused rat hindlimb appear 
to be closely linked since all previous attempts to separate the two using 
nitrovasodilators (Ye et al., 1990; Colquhoun et al., 1990; Rattigan et al., 1993), Ca2+ 
channel blockers (Colquhoun et al., 1990), or metabolic poisons (Dora et al., 1992; 
Richards et al., 1992) were unsuccessful. The close association between 
vasoconstriction and oxygen uptake lead to the original proposal that stimulation of 
metabolism (including V02) by type A vasoconstrictors was largely the result of 
working (contracting) vascular smooth muscle ('hot pipes') (reviewed by Colquhoun 
and Clark, 1991). However, based on this model alone, it is difficult to account for the 
negative metabolic effects of strong vasoconstrictors such as serotonin. Furthermore, 
the efficacy of type A vasoconstrictors for increasing perfusion pressure does not show a 
simple direct relationship to their ability for increasing V02 (Clark et al., 1995). 
Nonetheless, experiments using the isolated rat tail artery preparation have 
demonstrated the presence of sufficient mitochondrial and cytochrome oxidase activity 
for a potentially significant thermogenic contribution by this tissue (Clark et al., 1995). 
1.2.2.2. Nutritive and non-nutritive flow patterns 
Of the possible explanations to account for the metabolic actions of both type A 
and type B vasoconstrictors in the constant flow perfused hindlimb, the currently 
favoured hypothesis involves the stimulation of site-specific receptors promoting flow 
redistribution within this tissue (Clark et al., 1995; 1997). That is, vasoconstrictors that 
increase hindlimb V0 2, and efflux of metabolic by-products, probably do so by 
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redistributing perfusate flow to the network of vessels supplying skeletal muscle cells, 
resulting in greater total nutrient exchange. Indeed, there is a growing body of evidence 
from Clark's group in particular that the proposed increase in 'nutritive' flow in 
response to type A vasoconstrictors is responsible for increased resting metabolism in 
this tissue. This evidence includes: improved aerobic muscle contraction coincides with 
the infusion of type A vasoconstrictors, while type B vasoconstrictors inhibit 
contraction (Dora et al., 1994; Rattigan et al., 1996); in the rat hindlimb perfused at 
constant flow with erythrocyte-free medium, type A vasoconstrictors elicit a wash-out 
of red blood cells from previously under-perfused regions of the tissue (Newman et al., 
1996); FITC-labelled dextran can be entrapped in and released from the hindlimb by 
low-dose NOR suggesting the recruitment of a separate vascular network by this agent 
(Newman et al., 1996); type A concentrations of NOR increase the conversion of 1- 
methyl xanthine to 1-methyl urate by the capillary enzyme xanthine oxidase, while the 
type B vasoconstrictor serotonin decreases conversion (Clark et al., 1997). Recent 
evidence has also indicated that in addition to promoting a redistribution of perfusate 
flow, type A vasoconstrictors may stimulate resting muscle metabolism by a mechanism 
involving the activation of voltage-dependent Na+ channels, possibly by the release of a 
veratridine-like substance (Tong et al., 1998). This evidence coincides with the earlier 
suggestion that the metabolic actions of type A vasoconstrictors are likely to involve the 
release of an endogenous paracrine or autocrine signal (Clark etal., 1995; 1997). 
There is also convincing evidence that strong vasoconstrictors that reduce VO2 in 
the perfused hindlimb do so by shunting perfusate away from nutritive vessels to so-
called 'non-nutritive' vessels in this tissue (Clark et al., 1995; 1997). Recent evidence 
from surface fluorometry experiments measuring FITC-dextran flow on the tendon of 
the biceps femoris, in response to serotonin, suggests that these vessels may supply 
hindlimb connective tissue such as the septa and tendons (Newman et al., 1997). These 
authors propose that these vessels may represent a functional vascular shunt in this 
tissue. 
1.2.3. Vanilloid actions in the perfused rat hindlimb 
The serendipitous discovery that submicromolar concentrations of capsaicin and 
dihydrocapsaicin, the active pungent ingredients in chilli, could increase resting 
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Fig. 1.2. The effects of capsaicin on perfusion pressure and venous P02 (and hence 
V02) in the perfused rat hindlimb. A) Typical tracings of the effects of low 
(submicromolar) (i and ii) and high (micromolar) (iii and iv) capsaicin 
concentrations on venous P02 (i and iii) and arterial perfusion pressure (ii and iv) 
in the perfused rat hindlimb. Low concentrations of infused capsaicin induce a 
sustained steady state reduction in venous P02 (increase V02) (i) and mild 
sustained increase in perfusion pressure (ii) indicating increased vascular 
resistance (vasoconstriction). Removal of the vanilloid results in return of venous 
P02 and perfusion pressure to basal (unstimulated) levels. The effects of high 
capsaicin concentrations on venous P02 are triphasic (iii). Infusion of capsaicin 
causes an initial transient reduction in venous P02 (phase 1) followed by a rapid 
increase in venous P02 to a steady state value above basal venous P02 (phase 2) 
(inhibition of V02). Finally, the removal of capsaicin results in a second, but 
stronger, transient decrease in venous P02 (phase 3) before recovery to basal. 
High capsaicin concentrations also elicit a strong, sustained increase in arterial 
perfusion pressure (iv). B) Concentration-response curves for capsaicin induced 
changes in V02 (i) and perfusion pressure (ii). Venous P02 (V02) and perfusion 
pressure values for each concentration of capsaicin are taken from the steady state 
phase of the responses shown in A). 
hindlimb V02 (reduce venous PO2) revealed these compounds as an exciting prospect 
for their use as in vivo metabolic stimulants (Cameron-Smith et al., 1990). Findings 
very similar to those seen in this study are presented in Fig 1.2, with the inclusion of the 
negative metabolic effects observed at micromolar concentrations of capsaicin. Other 
naturally occurring members of the vanilloid class of molecules, such as gingerols and 
shogaols (Eldershaw et al., 1992), and resiniferatoxin (RTX) and piperine (Eldershaw 
et al., 1994), were shown to produce qualitatively and quantitatively similar effects on 
hindlimb V02. It was also revealed in these studies that in addition to stimulating V02 
at low effective concentrations, all of these compounds induced a steady state reduction 
in hindlimb V02 (increase venous P02) at high effective concentrations. Further 
analysis of the effects of capsaicin showed a very similar biphasic effect on resting 
hindlimb VO2 (Colquhoun et al., 1995). Interestingly, the cessation of exposure to high 
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effective concentrations of vanilloids results in a transient stimulation of V0 2 (reduction 
in venous P02) (Fig. 1.2Aiii) before recovery to basal values (not shown). 
Associated with the biphasic V02 effect of all vanilloid analogues is a 
concentration-dependent increase in perfusion pressure, indicating increased vascular 
resistance and, therefore, constriction of the hindlimb vasculature (Fig 1.2). As for 
other vasoconstrictors, the vascular and metabolic effects of vanilloids seem to be linked 
since nitrovasodilators were able to inhibit both responses (Cameron-Smith et al., 1990; 
Eldershaw et al., 1992; 1994). Furthermore, several vanilloid agents have been shown 
to induce a biphasic effect on lactate efflux where lactate is increased at low effective 
concentrations, and reduced at higher effective concentrations (Eldershaw et al., 1992; 
Colquhoun et al., 1995). 
The mechanisms by which vanilloids induce these effects in the perfused rat 
hindlimb were not clear from these initial studies. Unlike the effects seen on whole 
body V02 (see section 1.2.4.), the actions of capsaicin do not appear to involve the 
secondary release of catecholamines given the failure of adrenergic blockers to inhibit 
capsaicin-mediated changes in V0 2 or vascular resistance (vascular tension) (Cameron-
Smith et al., 1990). It is apparent, however, that the effects induced by low and high 
effective vanilloid concentrations have different metabolic requirements, including a 
differing dependence on extracellular calcium (Colquhoun et al., 1995). Based on these 
findings, these authors propose that the mechanisms of capsaicin action in the perfused 
rat hindlimb may differ at low and high concentrations, possibly involving the 
stimulation of different vanilloid receptor subtypes. 
1.2.4. In vivo thermogenic actions of vanilloids 
While the thermogenic effect of vanilloids on skeletal muscle metabolism may 
represent a potentially interesting way to induce whole-body energy expenditure and 
weight loss, there are few reports describing the metabolic effects of these agents in 
vivo. Some indirect evidence was obtained in the study of Henry and Emery (1986) 
who noted a marked increase (approximately 25%) in whole-body oxygen consumption 
(thermogenesis) in 12 healthy human subjects fed a pungent mixture of chilli and 
mustard sauces. This thermogenic effect was sustained for at least 180 minutes (post-
meal measurement period), however it is unclear whether or not the effect was caused 
specifically by vanilloids, or other ingredients contained in the sauces. Indeed, a later 
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study using a similar dietary treatment showed that a spicy meal did not significantly 
alter whole-body oxygen consumption, but did lead to sleep disturbances which may 
have been indicative of a thermoregulatory effect (Edwards etal., 1992). 
Studies on the metabolic effects of vanilloids in the rat have been more 
conclusive. The intraperitoneal injection of capsaicin (Kawada et al., 1986) or piperine 
(Kawada et al., 1988), at doses calculated to occur in a highly spiced diet, increased 
oxygen consumption in these animals. However, the effects of vanilloids on energy 
metabolism in rats is likely to be due to the stimulation of catecholamine secretion by 
these agents (Watanabe etal. ,1987; Kawada et al., 1988) via activation of the CNS by 
CSPAN impulses (Watanabe et al., 1991). Indeed, the in vivo oxygen consumption 
response to capsaicin was shown to be sensitive to the fl-adrenergic blocker propranolol 
(Kawada et al., 1986). 
1.3. Aspects of Vanilloid Actions on Sensory Neurons 
The mechanism by which vanilloid spice principles elicit their effects on a variety 
of target tissues has been the subject of extensive reviews (Holzer, 1991; Wood, 1993). 
Most studies on the actions of the vanilloids have been restricted largely to capsaicin 
and its excitatory, desensitising and toxic effects on CSPANs (Holzer, 1988; 1991; 
Szolcsanyi, 1993). The sensitivity of these neurones to capsaicin is likely to be due to 
the presence of a receptor-coupled cation channel that, when stimulated by vanilloids, 
allows the influx of various cations facilitating the release of several neuropeptide 
modulators (Holzer, 1991; Bevan and Szolcsanyi, 1990). Thus there is an ionic basis 
for the excitatory, desensitising and neurotoxic effects of capsaicin which is mediated 
by the stimulation of specific vanilloid recognition sites. Such 'cell-selective' effects of 
capsaicin are distinct from the 'non-selective' effects of this pungent spice principle 
(reviewed by Holzer, 1991, Szallasi, 1994) discussed in section 1.4. 
1.3.1. Evidence for the existence of vanilloid receptors 
1.3.1.1. Historical aspects 
The existence of a specific capsaicin receptor was first proposed by the Hungarian 
group of Szolcsanyi and Jansco-Gabor (1975; 1976) who observed a structural 
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relationship between various synthetic vanilloid analogues and their pain-producing 
activity. Since these early studies, substantial evidence has accumulated indicating that 
the actions of both capsaicin and the ultrapotent analogue resiniferatoxin (RTX) are 
mediated via specific vanilloid receptors that are believed to be related intimately with a 
capsaicin-operated cation channel (James et al., 1993). With the recent cloning of a 
capsaicin receptor-channel complex from rat DRG cDNA (Caterina et al., 1997), there 
is now compelling evidence that this initial hypothesis was correct. However, prior to 
this breakthrough there were other important lines of evidence in support of the 
existence of vanilloid recognition sites. Most notably, the discovery of capsazepine, the 
first competitive vanilloid antagonist (Dickenson and Dray, 1991; Urban and Dray, 
1991) and the development of a radioligand binding assay (Szallasi and Blumberg, 
1990a; 1990b) were important steps in the progression of vanilloid receptor 
pharmacology. To a lesser but important extent, studies using the functional, non-
competitive antagonist ruthenium red have also contributed to our understanding of 
these novel binding sites (reviewed by Amman and Maggi, 1991). 
1.3.1.2. Ruthenium red 
Prior to the development of the competitive antagonist capsazepine, ruthenium red 
was the only known capsaicin antagonist. Preceding the discovery of this polycationic 
dye as a blocker of capsaicin-mediated responses (Wood et al., 1988; Maggi et al., 
1988b), it was widely used in the 1960's as a pectin stain in plant physiology and 
subsequently as an inhibitor of calcium transport in mitochondria at high micromolar 
concentrations (Moore, 1971; Vasington et al., 1972). Further testament to the ability of 
this compound to inhibit membrane calcium fluxes was. obtained when it was 
discovered that millimolar concentrations of ruthenium red were able to inhibit smooth 
muscle contraction by blockade of voltage-sensitive calcium channels (Greenberg et al., 
1973). Subsequent studies in both smooth muscle and skeletal muscle have 
demonstrated that micromolar concentrations of the dye are able to inhibit caffeine-
induced release of intracellular calcium stores from the sarcoplasmic reticulum in these 
tissues (Salviati and Volpe, 1988; Kanmura et al., 1989). 
In view of the ability of ruthenium red to induce such general inhibition of 
intracellular and extracellular calcium fluxes, it is reasonable to assume that this may be 
related to its ability to block capsaicin-mediated responses. However, in a large number 
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of preparations, ruthenium red has been shown to selectively block the excitatory 
actions of capsaicin without blocking the effects of other stimuli (reviewed by Amann 
and Maggi, 1991), as well as blocking the unique desensitising properties of this 
pungent principle (Chahl, 1989; Amann et al., 1990). For example, measurements of 
calcium influx into rat DRG neurons showed that ruthenium red (100 nM) was able to 
inhibit capsaicin-induced increases in intracellular calcium (measured using the calcium 
sensitive fluophore Fura-2), but not those induced by bradykinin (Dray et al., 1990a). 
Using patch-clamp techniques, these authors also demonstrated the ability of low 
concentrations of ruthenium red to selectively inhibit capsaicin-activated single ion 
channel currents in rat DRG neurons, and concluded from the pattern of the blockade 
that it was occurring at a site distinct from the channel itself. Thus, although the 
mechanism of ruthenium red inhibition of the capsaicin-operated channel is not fully 
understood, it is likely to involve impairment of the receptor-channel coupling 
mechanism (Dray et al., 1990a). It is unlikely that ruthenium red blocks the binding of 
capsaicin to its receptor by a competitive interaction given that the dye was unable to 
displace the specific binding of [ 3F1]-RTX to rat DRG membranes (Szallasi and 
Blumberg, 1990a). Furthermore, ruthenium red caused a characteristic non-competitive 
antagonism of capsaicin-mediated effects in cultured rat DRG neurons (Bevan et al., 
1992) and in rat urinary bladder and vas deferens (Maggi et al., 1993a), that was distinct 
from the competitive inhibition produced by capsazepine in these studies. 
Ruthenium red represents a useful pharmacological tool for the study of capsaicin-
operated cation channels at submicromolar to micromolar concentrations with higher 
concentrations (usually >1 1.tM) resulting in the loss of selectivity for the capsaicin 
receptor cation channel complex (reviewed by Amann and Maggi, 1991). Nonetheless, 
moderately high micromolar concentrations (10 ptM) of the dye have still demonstrated 
selectivity for the actions of capsaicin, including the release of CGRP from the perfused 
guinea-pig lung (Amann et al., 1989) and capsaicin-evoked relaxation of human isolated 
ileum (Giuliani et al., 1991). Further confirmation of the ability of this 'functional' 
antagonist to selectively block the capsaicin ligand-gated channel was obtained recently 
in whole-cell patch clamp studies where ruthenium red completely attenuated the 
inward current evoked by capsaicin in Xenopus oocytes expressing cloned vanilloid 
receptors (Caterina et al., 1997). 
Introduction 	 12 
1.3.1.3. Capsazepine 
At the time of its development, capsazepine provided one of few useful 
pharmacological tools to characterise the little known vanilloid receptor. Structurally, 
capsazepine is similar to capsaicin (Fig. 1.1) with three major changes present on the 
antagonist: a) the methoxy group on position 3 of the aromatic ring (A-region) of 
capsaicin has been substituted for a hydroxyl group creating a 3,4-dihydroxy phenyl 
ring, permitting ease of synthesis (Walpole and Wrigglesworth, 1993); b) the amide 
'linker' region (B-region) of capsaicin has been replaced by a thiosemicarbazide in 
capsazepine; and c) replacing the long hydrophobic sidechain of capsaicin (C-region) is 
a 4-chlorophenylethyl side chain in capsazepine. From the conformational analysis of 
capsazepine, with respect to agonist structures, it has been proposed that the 
pharmacological change from agonist to antagonist is likely to be due to constraints 
placed on the A- and B-regions by the presence of the seven-membered saturated ring in 
capsazepine (Walpole et al., 1994). Thus, capsazepine adopts a `pseudochair' 
conformation where the plane of the B- and C-regions are held approximately 
perpendicular to the aromatic ring. 
The first compelling evidence that capsazepine competes directly for the vanilloid 
(capsaicin) receptor came with the study of Bevan et al. (1992) who demonstrated the 
ability of this compound to inhibit RTX-induced 45Ca2+ uptake by cultured rat dorsal 
root ganglion (DRG) neurons, capsaicin- and RTX-induced 86Rb+ efflux by DRG 
neurons, and capsaicin-induced [ 14q-guanidinium efflux from rat vagus nerves. In all 
studies, increasing the capsazepine concentration caused a parallel shift to the right in 
the concentration-response curves for capsaicin and RTX, without reducing the maximal 
/ 
response to either agonik Supporting the apparent competitive nature of this inhibition 
was the Schild analysis which yielded slopes close to unity (where slopes equal to 1 are 
indicative of a competitive relationship between agonist and antagonist). In addition, 
capsazepine failed to alter the effects of other depolarising stimuli (high potassium 
concentrations, low pH, GABA, ATP), at concentrations capable of almost completely 
blocking the effects of capsaicin and RTX, confirming its selectivity for the vanilloid 
binding site. 
Maggi and his co-workers showed a similar ability of capsazepine to 
competitively inhibit the actions of capsaicin at peripheral vanilloid receptors in the rat 
urinary bladder and vas deferens (Maggi et al., 1993). Concentration-response curves 
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for capsaicin-induced urinary bladder contraction and inhibition of electrically-evoked 
twitches of the vas deferens showed a parallel shift to the right, without a reduction of 
the maximal response, in the presence of 3-30 j.tM capsazepine. Capsazepine failed to 
inhibit post-junctional stimulation of these tissues by NKA (bladder) and CGRP (vas 
deferens) again indicating selective blockade of a prejunctional vanilloid receptor. 
Since these early pioneering studies, capsazepine has been used to block the 
actions of vanilloids in functional studies in numerous tissues including rat lung (Lou 
and Lundberg, 1992; Lee and Lundberg, 1994), vas deferens (Wardle et al., 1996), 
skeletal muscle (Santicioli et al., 1993), knee joint (Davis and Perkins, 1996), and skin 
(Seno and Dray, 1993), as well as guinea pig airways (Belvisi et al., 1992; Ellis and 
Undem, 1994) and heart (Franco-Cereceda et al., 1993). In addition, capsazepine was 
shown to inhibit the binding of [ 3I-1]-RTX to rat spinal cord vanilloid receptors without 
reducing the maximum binding (B max) of the radioligand (Szallasi et al., 1993c). Other 
radioligand binding studies have shown capsazepine to inhibit [ 3f1]-RTX binding to 
vanilloid receptors in membrane preparations from rat DRG (Szallasi et al., 1993c; Acs 
et al., 1994b, 1996), lung (Szallasi et al., 1993c), colon (Goso et al., 1993b), urinary 
bladder (Szallasi et al., 1993c; Acs et al., 1994b) and sciatic nerve (Acs et al., 1994b), 
as well as membrane preparations the dorsal horn of human spinal cord (Acs et al., 
1994a). More recently, capsazepine was shown to block capsaicin- and RTX-induced 
calcium influx into Xenopus oocytes and human HEK cells expressing cloned vanilloid 
receptors (Caterina et al., 1997). 
While the above evidence is quite compelling, the uncontrolled use of capsazepine 
should be avoided given that, inevitably, some studies question the spectrum of actions 
this compound and its selectivity for vanilloid receptors at high concentrations. In the 
rabbit iris sphincter both capsazepine and ruthenium red, at concentrations up to 100 
1.M, not only inhibit the constriction induced by capsaicin but also that induced by 
bradykinin, NKA and electrical field stimulation (Wang and HAkanson, 1993). In 
addition, capsazepine and ruthenium red act as partial agonists in this preparation. 
Furthermore, micromolar concentrations of capsazepine were recently shown to produce 
slowly developing, but irreversible, inhibition of voltage-activated calcium channels in 
cultured rat DRG (Docherty et al., 1997) and Xenopus embryo spinal neurons (Kuenzi 
and Dale, 1996). Docherty et al. (1997) propose that this observation may account for 
capsazepine's blockade of neuropeptide release induced by non-vanilloid stimuli such as 
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protons (eg. Franco-Cereceda and Lundberg, 1992; Franco-Cereceda et al. 1993; 
Santicioli et al., 1993), rather than the release of an endogenous vanilloid-like mediator. 
Of greater concern is the ability of 10 iiM capsazepine to reversibly inhibit the currents 
induced by 100RM nicotine in rat trigemminal ganglia suggesting that the antagonist 
may bind to other ligand-gated channels (nicotinic acetylcholine receptors) distinct from 
the vanilloid channel (Liu and Simon, 1997). 
1.3.1.4. Radiolabelled resiniferatoxin ([31-1]-RTX) 
Attempts in the 1980's to demonstrate the existence of capsaicin (vanilloid) 
receptors by the use of radiolabelled dihydrocapsaicin (Miller et al., 1982) or a 
capsaicin-like photoaffinity probes (James et al.,. 1988) were unsuccessful due to the 
relatively poor potency and high lipophilicity of these compounds. During this time, an 
important step in the development of a radiolabelled ligand for the identification of 
vanilloid receptors was the discovery that a naturally occurring phorbol ester, isolated 
from the latex of Eurphobia spp., was an ultrapotent capsaicin analogue (deVries and 
Blumberg, 1989; Szallasi and Blumberg, 1989). From the appropriately named 
resiniferatoxin (RTX) (Fig. 1.1), a radiolabelled (tritiated) analogue ([ 311]-RTX) was 
developed resulting in the first studies identifying vanilloid receptors in radioligand 
binding studies using rat DRG membranes (Szallasi and Blumberg, 1990a; 1990b), and 
subsequently by autoradiography (Szallasi et al., 1994; Szallasi, 1995; Szallasi et al., 
1995). Vanilloid receptors have since been identified in several species (reviewed by 
Szallasi, 1994), including man (Acs et al., 1994a; Acs et al., 1996), but not in species 
that are insensitive to vanilloids, such as the chicken (Szallasi and Blumberg, 1990b). 
Not only was conclusive proof obtained for the existence of the long-sought 
vanilloid receptor, the [ 31-1]-RTX binding assay has also revealed important information 
on the function of this novel binding site. The binding of [ 31-I]-RTX to vanilloid 
receptors was shown to have marked temperature dependence and also showed 
sensitivity to sulfhydryl-reactive agents, indicating that the receptor is dependent on free 
sulfhydryl groups for agonist binding (Szallasi and Blumberg, 1993). Furthermore, 
numerous studies have now shown that the binding of [ 31-11-RTX to membrane 
preparations from several sources can be selectively inhibited by capsazepine (see 
sections 1.3.1.3 and 1.3.2.1) and various other natural and synthetic vanilloid analogues 
(Szallasi and Blumberg, 1990a; 1990b; Szallasi et al., 1993a; 1993b; 1993c; Acs and 
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Blumberg, 1994a; 1994b; Acs et al., 1994b; Acs et al., 1996; Szallasi et al., 1996) 
indicating the presence of a common binding site for these ligands. 
While the first studies using the [ 311]-RTX binding assay were successful, several 
methodological limitations were apparent, most of which related to the high level of 
non-specific binding (approximately 50%) seen with the use of this extremely lipophilic 
molecule (Szallasi and Blumberg, 1990a). These limitations made it difficult to analyse 
[ 31-1]-RTX binding at low or high concentrations, or to identify vanilloid receptors in the 
spinal cord and peripheral tissues (reviewed by Szallasi, 1994). Improvement in the 
[ 31-1]-RTX binding assay came with the discovery that the serum protein a l -acid 
glycoprotein (orosomucoid) could bind RTX with micromolar affinity that is many 
times lower than the affinity of [ 311]-RTX for its receptors, and could bind RTX at 0°C 
where the association and dissociation of RTX and vanilloid receptors is immeasurably 
slow (Szallasi et al., 1992). Hence the addition of a l -acid glycoprotein at the 
termination of the [31-1]-RTX binding reaction (i.e. by cooling the assay mixture on ice) 
resulted in a substantial reduction in non-specific binding to approximately 10% of total 
binding (Szallasi et al., 1992; Szallasi et al. 1993b, Acs and Blumberg, 1994b). This 
improvement in the [ 31-1]-RTX binding assay permitted, for the first time, the analysis of 
binding at low [ 31-1]-RTX concentrations (low fractional receptor occupancy) and 
revealed sigmoidal binding kinetics in rat DRG and spinal cord preparations that was 
indicative of cooperativity of binding (Szallasi et al., 1993b). Furthermore, the 
cooperativity indices, estimated by Hill slope analysis, and curved (bell-shaped) 
Scatchard plots derived from these experiments were indicative of positive 
cooperativity. Additional evidence for the presence of an allosteric interaction was 
obtained by the observation that at low receptor occupancies, the binding of [ 311]-RTX 
showed marked enhancement then inhibition with the addition of increasing 
concentrations of non-radioactive RTX or capsaicin (i.e. biphasic competition curves) 
(Szallasi et al., 1993b, Acs and Blumberg, 1994a; 1994b; Acs et al., 1994). 
The improvements in the [31-1]-RTX assay also permitted the characterisation of 
vanilloid receptors in peripheral tissues including the urinary bladder (Szallasi et al., 
1993a; 1993c), urethra (Parlani et al., 1993), airways (Szallasi et al., 1993c) and gut 
(Goso et al., 1993). These studies have revealed an interesting distinction between 
peripheral receptors and those of the CNS with regard to the nature of agonist binding 
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and have, in part, contributed to the evidence for the existence of vanilloid receptor 
subtypes (see section 1.3.2). 
1.3.1.5. Molecular cloning strategies 
In conjunction with functional and radioligand binding and/or autoradiographic 
studies, an important step in the characterisation of a receptor type or family is the 
identification and cloning of the gene encoding a particular binding protein. Until 
recently, strategies for the cloning of vanilloid receptors were unsuccessful, due largely 
to the inability to detect expressed vanilloid binding proteins and the lack of information 
regarding their molecular structure. The use of an RTX photoaffinity label (RTX-PAL) 
for the detection of RTX binding proteins in bacterial systems expressing transcripts of 
DRG cDNA has been moderately successful yielding several candidate clones (James et 
al., 1993). However, analysis of the tissue distribution of mRNA for these clones was 
not consistent with the typical tissue distribution exhibited by sensory neuron 
membrane-associated receptors (James et al., 1993). 
The recent successful cloning of the vanilloid receptor was based on the well-
known ability of capsaicin to activate ion channels resulting in the intracellular 
accumulation of calcium, and the detection of calcium build-up by microscopic 
fluorescence imaging (Caterina et al., 1997). This innovative functional screening 
strategy was adopted for the isolation of candidate cDNA clones expressed in a non-
neuronal mammalian cell line, and did not rely on the binding of a labelled ligand to 
poorly understood vanilloid binding sites. A cDNA library was constructed from rat 
DRG neuron mRNA and subsequently subdivided into large pools each containing 
approximately 16,000 clones. Each pool of clones was transiently transfected into 
human embryonic kidney derived HEK293 cells loaded with the fluorescent calcium-
sensitive dye Fura-2, and the cells were then microscopically examined for changes in 
intracellular calcium in response to capsaicin exposure. Using this functional assay 
technique, a positive pool of clones was identified, subdivided and reassayed until a 
single 3-kilobase cDNA insert conferring capsaicin and resiniferatoxin sensitivity was 
obtained. This cloned cDNA was aptly named VR1 for vanilloid receptor subtype 1 
(Caterina et al., 1997). 
Despite the fact that the cells expressing the VR1 cDNA insert in the study of 
Caterina et al. (1997) were non-neuronal cells, they still exhibited the 'classical' cellular 
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responses to capsaicin and resiniferatoxin that are ordinarily exclusive to small diameter 
neurons expressing native vanilloid receptors (reviewed by Bevan and Docherty, 1993). 
Whole-cell voltage clamp analysis of Xenopus oocytes expressing VR1 showed that at 
negative holding potentials both capsaicin and resiniferatoxin evoked a concentration-
dependent inward current that was completely blocked by capsazepine (10 gM) or 
ruthenium red (10 gM) (Caterina et al., 1997). This study also showed that at positive 
holding potentials, vanilloid agonists evoked an outward current with the reversal 
potential close to 0 mV, an observation that is consistent with the activation of a cation 
channel (Bevan and Forbes, 1988). Furthermore, in ion replacement studies, cells 
expressing VR1 did not discriminate between different cations when stimulated by 
capsaicin, but did show greater permeability to divalent cations (permeability sequence: 
Ca2+ > Mg2+ > Na+ > K+ = Cs), consistent with observations made in rat DRG neurons 
(Bevan and Docherty, 1993). 
Analysis of the VR1 cDNA product revealed an 838 amino acid protein with a 
molecular mass of —95K (Caterina et al., 1997), a finding that is not consistent with 
earlier (but probably less accurate) estimates of vanilloid receptor size in pig DRG 
(-270K) (Szallasi and Blumberg, 1991). This discrepancy may also reflect the proposed 
species heterogeneity of vanilloid receptors (Szallasi, 1994). Interestingly, the deduced 
amino acid sequence of VR1 showed a high degree of homology with store-operated 
calcium channels (SOCs) that are believed to be involved in the regulation of 
intracellular calcium stores (Clapham, 1997), although Caterina et al. (1997) could not 
ascribe an SOC function to VR1. Indeed it is more likely that these receptors are 
involved in the perception of thermal stimuli given the ability of noxious heat to activate 
cation fluxes in both HEK293 cells and Xenopus oocytes expressing VR1 (Caterina et 
al., 1997). 
1.3.2. Vanilloid receptor subtypes 
There is now mounting evidence that vanilloid recognition sites not only represent 
a novel type of 'pain' receptor, but that they may also represent an entire new receptor 
family. Indeed, the concept of vanilloid receptor subtypes has recently been the central 
topic of some excellent review articles (Szallasi, 1994; Szallasi and Blumberg, 1996; 
Appendino and Szallasi, 1997). Several convincing, albeit indirect, lines of evidence 
have now emerged in favour of vanilloid receptor heterogeneity, some of which are 
Introduction 	 18 
discussed below and others, including that obtained in the perfused rat hindlimb, are 
outlined later in Chapter 2. 
1.3.2.1. Evidence from [3 H]-RTX binding studies 
Radioligand binding studies using [31-1]-RTX not only permitted the biochemical 
characterisation of the vanilloid receptor (Szallasi and Blumberg, 1990a; 1990b; 1993) 
but also demonstrated species heterogeneity of receptor binding, as well as possible 
intraspecies receptor subtypes (Szallasi, 1994). Peripheral vanilloid receptors in the 
urinary bladder (Szallasi et al., 1993a), colon (Goso et al., 1993b), and urethra (Parlani 
et al., 1993) of the rat all bind [ 31-1]-RTX in a non-cooperative fashion, and show 
decreased affinity for RTX, that is distinct from the positive cooperativity of [ 3 1-1]-RTX 
binding central receptors (Szallasi and Blumberg, 1993; Szallasi et al., 1993a; 1993b). 
In addition, capsaicin inhibits specific [ 31-1]-RTX binding to central vanilloid receptors 
with a 7 to 10-fold higher affinity than the competitive antagonist capsazepine (Goso et 
al., 1993a), while at peripheral receptors in the colon, the order of potency is reversed 
(Goso et al., 1993b). However, the binding behaviour of [ 31-1]-RTX and affinity of 
capsazepine for central and peripheral vanilloid receptors is not as clear-cut as the above 
studies indicate. A recent study did not show any major differences between the 
binding behaviour (i.e. cooperative vs. non-cooperative) of [ 31-I]-RTX to vanilloid 
receptors in CNS and peripheral tissues in the same species, nor was there any 
difference in the affinity of capsazepine for receptors in these tissues (Acs et al., 1994b). 
The apparent discrepancy between the positive cooperativity of [ 31-1]-RTX binding in the 
urinary bladder in this study, and the non-cooperative nature of [ 311]-RTX binding in the 
same tissue in the study of Szallasi et al. (1993a) is not clear at present. Different assay 
conditions between the studies (eg. temperature and buffer composition), has been cited 
as a potential source of this discrepancy (Acs etal., 1994b). 
1.3.2.2. Evidence from the study of vanilloid-induced ion currents in vitro 
The work of Simon and his colleagues has provided evidence for CNS vanilloid 
receptor subtypes in patch-clamped studies in rat trigeminal (Liu and Simon 1994; 
1996) and DRG (Liu et al., 1996) neurons. Most, but not all, of these neurons exhibit 
two types of inward current in response to capsaicin - one fast and one slow 
activating/inactivating - both of which are sensitive to capsazepine and ruthenium red 
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(Liu and Simon, 1994). Other neurons responded to capsaicin by the activation of a 
rapid inward current only, while RTX stimulates only slowly-activating currents (Liu 
and Simon, 1994; 1996). This latter finding was consistent with earlier findings for 
RTX actions on DRG neurons (Winter et al., 1990) and may reflect the increased ability 
of this ultrapotent agent to induce desensitisation and cell death (Liu and Simon, 1996). 
Not only was there heterogeneity with respect to the currents activated by these pungent 
spice principles, but they also induced different degrees of desensitisation, with different 
calcium dependencies. This may reflect the presence of receptor/channel subtypes with 
different activation and desensitisation kinetics (Liu and Simon, 1996). 
Further to these studies, this group recently presented evidence for the presence of 
receptor/channel subtypes on rat trigeminal ganglion neurons by use of the non-pungent 
RTX analogue phorbol 12-phenylacetete 13-acetate 20-homovanillate (PPAHV) (Liu et 
al., 1998). PPAHV evoked three types of inward current in some trigeminal neurons 
that displayed different reversal potentials when current-voltage curves were 
constructed. Currents induced by PPAHV were kinetically distinct from the two inward 
currents evoked by capsaicin, however two of these showed very similar reversal 
potentials to those of capsaicin. In addition, repeated application of PPAHV prevented 
the rapidly-activating currents but only slightly reduced the slowly-activating current 
indicating that the different current types were separable. Furthermore, a high 
concentration of capsazepine (10 gM) failed to inhibit the inward currents activated by 
PPAHV in some, but not all, trigeminal neurons. Taken together, these findings 
indicate that there are likely to be receptor/ion channel subtypes that are activated by 
PPAHV with different activation and desensitisation kinetics, and that some of these 
complexes may represent a newly defined capsazepine-insensitive subtype of vanilloid 
receptor (Liu et al., 1998). 
1.3.2.3. Evidence from vanilloid structure-activity relationships 
Structure-activity relations for receptor binding versus calcium uptake of some 
vanilloid analogues also provide indirect evidence for the existence of vanilloid receptor 
subtypes. RTX and related compounds (eg. tinyatoxin) are at least 10-fold more potent 
for binding vanilloid receptors than for inducing calcium uptake by sensory neurons 
(Acs et al., 1996; Walpole et al., 1996). However, the same studies showed that for 
capsaicin and its synthetic analogues, such as nuvanil, the reverse is apparent (i.e. they 
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are 10-fold more potent at inducing calcium uptake than for inhibiting [ 311]-RTX 
binding) suggesting that [ 31-1]-RTX binding and calcium uptake assays detect different 
types of vanilloid receptor (Szallasi and Blumberg, 1996). 
At present there is no direct genetic evidence for the existence of vanilloid 
receptor subtypes, although such evidence may soon be obtained now that the molecular 
structure of a rat DRG vanilloid receptor is known (see section 1.3.1.5.). The fact that 
VR1 mRNA could not be detected in several peripheral tissues (Caterina et al., 1997) 
known to express [ 31-1]-RTX binding sites (Szallasi, 1994) may itself reflect the 
heterogeneity of these novel receptors. 
1.3.3. Van illoid cellular mechanisms 
A number of studies, mostly on rat DRG neurons, have contributed to our 
understanding of how capsaicin and related compounds elicit their excitatory, 
desensitising and neurotoxic effects on CSPANs, and the ionic basis for these actions 
(reviewed by Holzer, 1991; Bevan and Docherty, 1993). Moreover, knowledge of the 
ion fluxes induced by vanilloids in sensory neurons has lead to better understanding of 
how these agents elicit the release of neuropeptide modulators from CSPANs (reviewed 
by Holzer, 1991; Maggi, 1993). 
Microelectrode recordings on rat DRG neurons showed that the application 
capsaicin to the extracellular surface of these cells induces a rapid depolarisation in 
neurons with low axonal conductance velocities (C-type cells), but not fast-conducting 
neurons (A-type cells) (Heyman and Rang, 1985). This depolarisation is not sustained 
in the continued presence of capsaicin, and the membrane potential hyperpolarises back 
to negative values (Marsh et al., 1987). Several lines of evidence from these and 
subsequent patch-clamp studies revealed that the initial depolarisation evoked by 
capsaicin involves the opening of cation channels in the membrane of CSPANs that are 
non-selective in terms of their permeability. Most notably: a) the depolarisation is 
accompanied by a decrease in cell input resistance; b) at positive holding potentials 
capsaicin and RTX evoke an outward current with the reversal potential for the inward 
current at 0 mV; and c) ion replacement studies show that the ion channel activated by 
capsaicin and RTX will permit the passage of different types of monovalent and 
divalent cations (Marsh et al., 1987; Bevan and Forbes, 1988; Bevan and Szolcsanyi, 
1990; Winter et al., 1990). These findings were supported by radiotracer flux 
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experiments in rat DRG which showed that capsaicin and RTX could increase the 
uptake of various cations, as well as the efflux of other such as 86Rb+ (used as an 
indicator of potassium flux) (Wood et al., 1988; Winter et al., 1990). Although non-
selective, the vanilloid-operated cation channel does hold a preference for permitting the 
passage of divalent cations, such as calcium, with a permeability sequence Ca2+ > Mg2+ 
> guanidinium+ > K+ > Na+ > choline (Bevan and Szolcsanyi, 1990; Bevan and 
Docherty, 1993). Indeed, recent studies with cloned vanilloid receptor-channel 
complexes indicate that they permit the passage of calcium and sodium in the ratio of 
approximately 10:1 in response to capsaicin (Caterina et al., 1997, Clapham, 1997). 
Thus, capsaicin and RTX activate the same recognition site on CSPANs that leads to the 
opening of a channel that is permeable to different cations, particularly Ca2+, and is 
distinct from voltage-sensitive Ca2+ channels (VSCCs) since blockers of several 
different VFCCs failed to inhibit the stimulant effect of capsaicin (Maggi et al., 1988a; 
1989; Wood et al., 1988; Dray et al., 1990b). In fact, the intracellular accumulation of 
Ca2+ in CSPANs leads to the inhibition of VSCCs, but promotes Ca 2+—dependent 
enzyme activation and, most importantly, neuropeptide release (Holzer, 1991). 
1.3.4. Neuropeptide release 
While capsaicin-induced generation of afferent impulses and local neuropeptide 
release (efferent function) both have ionic requirements, they differ in their dependence 
on external calcium. Afferent impulse discharge by capsaicin is not inhibited by the 
absence of external calcium, and can rely on other external cations for propagation 
(Marsh et al., 1987; Dray et al., 1990b). Conversely, capsaicin-induced neuropeptide 
release, by exocytosis, has shown a marked extracellular calcium-dependence in tissue 
or organ studies in, for example, isolated guinea-pig and rat bladder where low external 
calcium concentrations inhibited capsaicin-induced, peptide-mediated bladder 
contractions (Maggi et al., 1989). In this particular study, the calcium chelator 
ethylenediaminetetraacetate (EDTA) was essential for complete inhibition of capsaicin's 
effects, thus demonstrating the ability of this compound to accumulate intracellular 
calcium in the presence of low external calcium concentrations. 
Maggi (1993) has summarised the available evidence indicating the presence of 
dual cellular mechanisms for the release of sensory transmitters from nerve endings in 
CSPANs, both involving the influx of external calcium. The first of these mechanisms 
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(mode A) occurs at high capsaicin concentrations and involves the intracellular 
accumulation of calcium through the capsaicin-operated non-selective cation channel 
that is itself sufficient to evoke neuropeptide release by calcium-induced exocytosis. 
The second mechanism (mode B) occurs at low capsaicin concentrations that do not 
induce sufficient intracellular calcium accumulation to cause peptide release, but 
instead propagate a tetrodotoxin (TTX)-sensitive action potential which in turn 
stimulates calcium influx through VSCCs, and subsequent neuropeptide release. Hence 
in addition to its TTX-sensitivity, mode B is also sensitive to VSCC blockers such as 
the co-conotoxin (CTX). Conversely, mode A is both TTX- and CTX resistant. This 
hypothesis has been supported by the functional studies of Lou et al. (1992) in the 
perfused guinea-pig lung where the bronchoconstriction induced by neuropeptide 
release at low capsaicin concentrations was sensitive to both TTX and the N-type 
VSCC blocker co-CTX GVIA. Conversely, the effects of high capsaicin concentrations 
were TTX- and CTX-resistant in these studies. 
1.3.5. Desensitisation 
The excitatory actions of capsaicin and other vanilloids on sensory neurons are 
followed by a refractory state of reduced or non-responsiveness, with prolonged or 
repeated administration, that is loosely termed 'desensitisation' (see Holzer, 1991; 
Szolcsanyi, 1993 and references therein). This 'trademark' ability of capsaicin and 
related compounds has promoted intense interest in their use as non-steroidal analgesic 
and anti-inflammatory agents (Craft and Porecca, 1992; Maggi, 1992; Dray, 1992; Dray 
and Urban, 1996). More recent attention has focused on RTX and related synthetic, 
low-pungency compounds such as PPAHV, which show markedly improved 
desensitising properties relative to their excitatory effects (Szallasi et al., 1996; Szallasi 
and Blumberg, 1996; Appendino and Szallasi, 1997). 
1.3.5.1. Acute versus long-term desensitisation 
The effectiveness of capsaicin-induced desensitisation depends on a number of 
factors including dose, route and frequency of administration (Holzer, 1991; Craft and 
Porecca, 1992; Dray, 1992), and is broadly divided into the categories of 'acute' and 
long-term' (chronic) desensitisation. Based on a large number of capsaicin-induced 
desensitisation studies, Szolcsanyi (1993) describes a four-part sequence of events with 
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capsaicin treatment on sensory neurons: (1) excitation involving release of 
neuropeptides within seconds; (2) "sensory neuron block" where sensory neurons are 
unresponsive to capsaicin (i.e., neuropeptides are not released) which lasts for hours to 
several days; (3) degeneration of some neurons and recovery of function of others over 
several days to weeks; (4) complete degeneration of affected neurons (Table 1.1). Acute 
desensitisation to capsaicin and related compounds ('specific' desensitisation) is 
represented by stage 2 of this model and is generally observed when capsaicin is applied 
repeatedly (with short intervals) to sensory neurons, or at concentrations that are 
several-fold higher than the threshold for stimulation (excitation) in a given tissue. 
Conversely, long-term desensitisation is represented by stages 3 and/or 4 of 
Szolcsanyi's model and is more likely to involve neurotoxic impairment of capsaicin-
sensitive neurons, and desensitisation to a range of noxious stimuli ('nonspecific' or 
'functional' desensitisation) (Holzer, 1991). This form of desensitisation is also more 
likely to be irreversible, particularly in the neonate or with high dose (>10 mg/kg) 
systemic capsaicin pretreatment in the adult animal (Holzer, 1991). In the adult, more 
pronounced systemic desensitisation is achieved using higher total doses (>50 mg/kg), 
given in three to four injections to minimise death due to respiratory distress and other 
acute reflexes induced by the agent (Szolcsanyi, 1993). However, although 
pretreatment can ensue irreversible, selective destruction of some CSPANs, it should be 
noted from Table 1.1 that other CSPANs will continue to show unchanged sensitivity to 
vanilloids and other noxious stimuli. 
1.3.5.2. Mechanisms of vanilloid-induced desensitisation 
The mechanisms underlying desensitisation to capsaicin are poorly understood, 
but it appears likely that those responsible for acute and long-term desensitisation are 
both distinct and complex (Holzer, 1991; Szolcsanyi, 1993; Szallasi, 1994). 
Desensitisation to capsaicin has been observed in single neuronal cells (eg. Marsh et al., 
1987) and is thought to be related to the intracellular accumulation of cations 
(particularly calcium), osmotic swelling and ultrastructural changes, such as swelling of 
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TABLE 1.1. Response stages of capsaicin-sensitive primary afferents to vanilloids 
(reproduced from Szolcsanyi, 1993). 
Stage 1 Excitation 
(1) Depolarisation of the peripheral, central terminals or the cell body by increasing 
cation permeability through a tetrodotoxin insensitive and relatively calcium 
resistant process. 
(2) Local depolarisation initiates regenerative spike potentials. 
(3) Calcium-dependent release of substance P and other neuropeptides 
(4) Time course: seconds; recovery seconds or minutes 
Stage 2 Sensory neuron blocking effect 
(1) Desensitisation of the sensory receptors to one or more types of stimuli; partial 
recovery from depolarisation. 
(2) No measurable depletion of substance P in peripheral terminals. 
(3) Ultrastructural changes, but no degeneration. 
(4) Start: immediately after Stage 1; recovery hours or days. 
Stage 3 Long-term selective neurotoxic impairment 
(1) Loss of excitability of the sensory receptors. 
(2) Inhibition of axonal transport and its antagonism by nerve growth factor. 
(3) Depletion of the neuropeptide content. 
(4) The cell body is preserved with swollen mitochondria, but the axonal processes 
might degenerate. 
(5) Start: within minutes; duration several weeks and some alterations are 
irreversible. 
Stage 4 Irreversible cell destruction 
(1) Calcium accumulation and karyolysis within 20 min in neonatal rats. 
(2) All types of C-afferents and some large cells are also affected by neonatal 
treatment. 
(3) Capsaicin-sensitive neurons with unchanged sensitivity are still present 
mitochondria, leading to impaired neuron function (Holzer, 1991; Szolcsanyi, 1993; 
Bevan and Docherty, 1993). Capsaicin-induced neurotoxicity has also been 
demonstrated in vitro (Wood et al., 1988; Winter et al., 1990) and is also dependent on 
the influx of calcium and/or sodium, resulting in the subsequent influx of water, 
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followed by osmotic swelling, damage and cell lysis (Bevan and Docherty, 1993). 
Interestingly, a cell death response unrelated to apoptosis has also been observed in non-
neuronal cells expressing cloned VR1 receptors after prolonged exposure to high 
external concentrations of capsaicin (Caterina et al., 1997). 
Long-term desensitisation may also involve a reduction in vanilloid receptor 
density since studies with [31-1]-RTX have shown receptor loss in several tissues 24 
hours after vanilloid pretreatment (Szallasi and Blumberg, 1992; Szallasi et al., 1995; 
Farkas-Szallasi et a/., 1996) requiring up to two months for near-complete recovery 
(Szallasi, 1995). Other possible sources to account for long-term desensitisation include 
the inhibition of sensory axonal transport depriving the somata of essential nerve growth 
factors (NGF) (Miller et al., 1982b) and the depletion of sensory neuropeptides, such as 
SP and CGRP, seen after vanilloid pretreatment (Buck and Burks, 1986; Holzer, 1988). 
However, none of the above are likely to be the sole cause of acute or long-term 
vanilloid-induced desensitisation. 
1.4. Non-selective effects of capsaicin 
The sensory neuron-selective actions of capsaicin described above are 
characterised by their occurrence at low effective concentrations of capsaicin and RTX, 
mediation by specific vanilloid receptor stimulation, and desensitisation with prolonged 
or repeated stimulation. Conversely, there are 'non-selective' effects of capsaicin that 
do not exhibit desensitisation, are not mimicked by other vanilloids, occur only at high 
effective concentrations, and are believed to result from interaction of these compounds 
with the plasma membrane (i.e. not vanilloid receptor-mediated) (reviewed by Holzer, 
1991; Szallasi 1994). Some of the known non-selective responses to capsaicin involve 
effects on non-mammalian neurons, such as the inhibition of potassium channels in the 
Ranvier ganglia of the frog (Dubois, 1982) and sodium channels in the giant axon of the 
crayfish (Yamanaka et al., 1984). In mammals, non-selective actions of capsaicin 
include effects on ion channels other than the capsaicin-operated channel (reviewed by 
Holzer, 1991), as well as effects on smooth muscle cells such as the inhibition of cardiac 
muscle (Franco-Cereceda and Lundberg, 1988) and contraction of vascular smooth 
muscle (Donnerer and Lembeck, 1982; Duckles, 1986; Saito et al., 1988; Edvinsson et 
al., 1990). 
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In the perfilsed rat hindlimb the repeated infusion of capsaicin-like agents does not 
induce acute desensitisation to the V02 and vasoconstrictor responses in this tissue 
(Eldershaw et a/., 1994) indicating that the effects of these agents may be of the non-
selective type described above. However, the concentration and frequency of vanilloid 
infusion in these studies may not have been sufficient to induce acute desensitisation. It 
remains to be seen whether or not the effects in this tissue are sensitive to other methods 
of inducing desensitisation, such as systemic capsaicin pretreatment. Indeed, this latter 
point is addressed in the studies presented later in this thesis. 
1.5. Objectives of the Present Study 
Although the metabolic and vascular effects of capsaicin and related compounds 
in the perfused rat hindlimb are well characterised and are likely to be linked, the 
mechanisms underlying these responses are poorly understood and have not been related 
to the mechanisms of capsaicin action in other tissues. The present study attempts to 
define a role for specific vanilloid receptors, and a sensory efferent function for 
CSPANs and their neuromodulators, in the responses to capsaicin in the perfused 
hindlimb preparation. Addressing these points may also determine whether or not the 
observed effects of vanilloids in this preparation are likely to be non-selective (section 
1.4.). Thus the aims of the study were: 
1. To determine the characteristics of vanilloid recognition site(s) which mediate the 
actions of capsaicin in the perfused rat hindlimb model by the use of known 
vanilloid antagonists. 
2. To investigate the possibility that the biphasic V0 2 effect of vanilloids is due to 
cooperativity of receptor-ligand binding (by use of the non-cooperative ligand 12- 
phenylacetate 13-acetate 20-homovanillate); or by separate cellular mechanisms 
described by others (by co-infusion of tetrodotoxin with capsaicin). 
3. To examine the effects of CSPAN ablation by systemic capsaicin pretreatment on 
the acute metabolic and vascular responses to capsaicin in perfused muscle. 
Introduction 	 27 
4. To determine the role of sensory neuropeptides in the metabolic and vascular 
responses to capsaicin in the perfused rat hindlimb by: 
a) studying the effect of post-junctional blockade of neuropeptide receptors, using 
specific and competitive tachykinin (NK1 and NK2 receptor) and CGRP 
antagonists, on the acute effects of capsaicin in the perfused rat hindlimb. 
b) Determining the effects of infused SP, NKA, and CGRP in the unstimulated 
(fully dilated) and NOR-stimulated (vascular preconstricted) perfused rat hindlimb. 
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Chapter 2 
Evidence for Peripheral Vanilloid Receptor Subtypes (VN 1/VN2) in the 
Perfused Rat Hindlimb by the use of Competitive and Non-
Competitive Capsaicin Antagonists. 
2.1 Introduction 
Three major developments in the field of vanilloid (capsaicin) pharmacology have 
had a significant impact on our understanding of their novel receptors (see section 1.3.1 
and subsections therein). The first of these was the discovery of capsazepine, an 
antagonist that is believed to compete directly and selectively for vanilloid receptors 
(Bevan et al., 1991, 1992; Dickenson and Dray, 1991; Dray et al., 1991; Urban and 
Dray, 1991). Prior to the discovery of this compound, ruthenium red, an inorganic dye 
that blocks the capsaicin receptor-cation channel coupling mechanism (Dray et al., 
1990a), was the only available capsaicin antagonist and its selectivity at higher 
concentrations was questionable (Amann and Maggi, 1991). 
As reported in section 1.3.1.3, the ability of capsazepine to act as a selective and 
competitive vanilloid antagonist has been well documented. Not only has this 
antagonist helped to confirm the presence of specific vanilloid binding proteins, it has 
also added support to the notion of vanilloid receptor subtypes since its affinity for 
vanilloid receptors shows intraspecies variation (Szallasi, 1994). Table 2.1 summarises 
the dissociation constant estimates for capsazepine at vanilloid receptors obtained from 
functional and radioligand binding studies in preparations from central nervous system 
(CNS) and peripheral tissues of the rat. It is evident that the affinity of capsazepine is 
greatest in peripheral tissues, such as the airways and colon, while binding in the urinary 
bladder and CNS shows low micromolar affinity. There is an apparent discrepancy in 
the estimated affinity of capsazepine for inhibiting capsaicin- and RTX-induced Ca 2+ 
uptake by cultured DRG neurons (Bevan et al., 1992) compared to that for blocking 
[3.1-1]-RTX binding to DRG membranes (Szallasi et al., 1993c). However, the latter 
authors point out that their studies were carried out• on adult DRG membrane 
Evidence for Peripheral Vanilloid Receptor Subtypes 	 29 
preparations, while Bevan and his co-workers used cultured DRG neurons from 
neonates, where a greater proportion of DRG neurons are sensitive to cap saicin (Lawson 
and Harper, 1984). 
TABLE 2.1. Affinity of capsazepine for vanilloid receptors in central nervous 
system and peripheral tissues of the rat. 
Tissue Assay Dissociation constant (KD 
or KO (i.tM) 
Reference 
Dorsal root ganglia 1 3.50 Szallasi et al., 1993c 
3 0.22 Bevan et al., 1992 
1 3.92 Acs et al., 1994b 
1 3.90 Acs et al., 1996 
Spinal cord 1 4.0 Szallasi et al., 1993c 
1 3.55 Acs 	and 	Blumberg, 
1994a 
2 1.30 Szallasi et al., 1995 
1 3.31 Acs et al., 1994b 
Urinary bladder 1 5.0 Szallasi et al., 1993c 
1 4.76 Acs et al., 1994b 
Airways 1 0.12 Szallasi et al., 1993c 
Sciatic nerve 1 3.43 Acs et al., 1994b 
Colon 1 0.10 Goso et al., 1993b 
Assays: 1, inhibition of 131-11-RTX binding (homogenate radioligand binding); 2, inhibition 
of 13111-RTX binding (autoradiography); 3, inhibition of RTX-induced Ca2+ uptake 
Based on the affinity and binding behaviour (i.e. cooperative vs. non-cooperative) 
of [314]-RTX (section 1.3.2.1.), and the affinity of capsazepine for vanilloid receptors 
from various tissues (Table 2.1), Szallasi et al. (1993c) have hypothesised that there 
may be at least three vanilloid receptor subtypes in the rat: 1) a CNS-type receptor that 
binds [311]-RTX with high affinity in a cooperative manner, but binds capsazepine with 
micromolar affinity; 2) a urinary bladder-type that binds [ 31-1]-RTX with high affinity 
and non-cooperatively, and also binds capsazepine with relatively low affinity; and 3) an 
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airway-type receptor that binds [ 31-1]-RTX with low affinity in a non-cooperative 
manner, but binds capsazepine with high (nanomolar) affinity. 
A recent study postulated the presence of two different vanilloid receptor types 
(designated VNI and VN2) in rat hindlimb tissue based on both functional and metabolic 
evidence (Colquhoun et al., 1995). Putative VI\I I and VN2 receptors were distinguished 
on the basis of their differing affinities for capsaicin, their different calcium and oxygen 
dependencies for mediating vasoconstriction, and their ability to stimulate or inhibit 
V02. The present study examines the effect of capsazepine on V02 and perfusion 
pressure concentration-response curves to capsaicin in the perfused rat hindlimb. The 
rationale behind the use of capsazepine in these studies was two-fold: firstly, the ability 
of capsazepine to competitively inhibit the actions of capsaicin in muscle would add 
strength to evidence supporting the presence of specific vanilloid receptors in this tissue; 
secondly, capsazepine may be able to distinguish between putative hindlimb vanilloid 
receptor subtypes (VNI and VN 2) given the variability of dissociation constant (KD) 
estimates for this antagonist in different vanilloid receptor assays (Table 2.1). In 
addition, the ability of the non-competitive blocker ruthenium red to act as a capsaicin 
antagonist was examined and compared to the actions of capsazepine in this preparation. 
Although non-competitive, ruthenium red is thought to selectively impair the vanilloid 
receptor-channel coupling mechanism by a rapid blocking and unblocking of the 
stimulated cation channel (Dray et al., 1990a) at low concentrations (10 -7 M - 10-6 M) 
(Amann and Maggi, 1991). These antagonists proved to be valuable in the present study 
in determining the nature of the biphasic V02 responses produced by vanilloids in the 
perfused rat hindlimb. 
In this chapter, the actions of the novel synthetic vanilloid analogue 12- 
phenylacetate 13-acetate 20-homovanillate (PPAHV) were also assessed in the hindlimb 
preparation and compared to capsaicin. In recent radioligand binding studies, PPAHV 
was shown to bind to central (DRG neuron) vanilloid receptors in a non-cooperative 
manner (Szallasi et al., 1996). Hence concentration-response curves for PPAHV were 
constructed in the perfused rat hindlimb and compared to those for capsaicin to 
determine the likely nature of binding (cooperative vs. non-cooperative) by natural 
vanilloid analogues in this preparation. The effects of PPAHV were also examined in 
the presence of a high concentration of capsazepine (10 uM) in order to provide 
evidence of vanilloid receptor binding by this agent. 
Evidence for Peripheral Vanilloid Receptor Subtypes 	 31 
It is also conceivable that the dual mechanisms of capsaicin in rat muscle are not 
the result of the stimulation of the separate receptor subtypes, but rather the separate 
post-receptor mechanisms described by Maggi (1993), one being TTX-sensitive (low 
capsaicin concentrations) while the other is TTX-resistant (high capsaicin 
concentrations) (see section 1.3.4.). Hence, in the present study, TTX was co-infused 
with low and high concentrations of capsaicin in an attempt to distinguish between these 
dual modes of action should they operate in rat muscle. 
2.2. Methods 
All experimental procedures used were approved by the University of Tasmania 
Animal Ethics Committee under the Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes (Australian Government Press, 1990). Perfusions were 
conducted using male, 180-200g hooded Wistar rats fed a commercial rat chow diet 
containing 21.4% protein, 4.6% lipid, 68% carbohydrate and 6% crude fibre with added 
vitamins and minerals (Gibson's, Hobart). Animals were housed in groups of 6-8 at 
21±1°C under a 12h:12h light/dark cycle with an accessible and plentiful water supply. 
2.2.1 Rat hindlimb perfusion surgery and procedures 
Anaesthesia, surgery and perfusion procedures were performed as described 
previously (Ruderman et al., 1971; Colquhoun et al., 1988). The animals were 
anaesthetised with pentobarbitone sodium (60 mg•kg -1 i.p.) and ligatures tied at the base 
of the tail and the left tarsus of the perfused leg. A lateral incision was made at the 
pubic region followed by an incision along the midline of the abdomen extending to the 
sternum. The posterior and anterior epigastric vessels, as well as vessels supplying the 
skin, were ligated and excess body-wall and skin tissue were removed with minimal 
bleeding. The testes, seminal vesicles, colon and duodenum were subsequently ligated 
and removed. Evisceration enabled access and ligation of the internal spermatic, 
iliolumbar and right common iliac vessels, as well as the ureters, to isolate perfusate 
flow to the left hindquarter. The abdominal aorta and vena cava were carefully 
separated prior to the injection of heparin (2000 IU•kg -I body weight) into the latter 
vessel. The vena cava was tied posterior to the branch of the renal veins and the vessel 
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was canriulated using a 16G surflo catheter (Terumo, USA), as was the aorta using a 
similar 20G catheter. A final ligature was placed around the abdomen (approximately 
Fig. 2.1. Constant flow perfused rat hindlimb apparatus 
L3 - L4 vertebrae region) to prevent access of perfusate to the muscles of the back. 
Following the commencement of perfusate flow, the animal was given a lethal 
intracardiac injection of pentobarbitone sodium. 
Perfusion was performed at 25°C, in a temperature-controlled cabinet (Fig. 2.1), 
with an erythrocyte-free, Krebs-Ringer bicarbonate buffer containing 8.3 mM glucose, 
1.27 mM CaC12 and 2% w/v dialysed bovine serum albumin (Fraction V). The 
perfusate reservoir was gassed with 95% 02-5% CO2 at 4°C and pumped by a peristaltic 
pump (Masterflex, Cole Palmer, USA) at a constant flow rate (4.0±0.1 mlmin -1 ; 0.27 
muscle-1 ) through a heat exchange coil, maintained at 25°C, and a sealed 
silastic lung continually gassed with the 02/CO2 mixture. This ensured constant 
perfusate temperature and arterial P02 levels. The oxygen tension of the venous 
effluent was measured continuously using an in-line Clark-type oxygen electrode (0.5 
ml capacity), maintained at a constant temperature (25°C) by a water jacket, where the 
activity of oxygen at the electrode is proportional to perfusate P0 2 . Perfusion (arterial) 
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pressure was monitored continuously at a bubble trap proximal to the arterial cannula 
using a gas-filled pressure transducer. 
In perfusions involving sympathetic nerve stimulation, the lumbar sympathetic 
trunk was ligated, cut and gently pulled away from the aorta in order to make contact 
with two stainless steel electrodes connected to a stimulator. Liquid paraffin and 
Parafilm® were placed under the electrodes to prevent stimulation of surrounding 
tissues. The hindlimb was perfused with the above medium also containing 1 1.1M 
tubocurarine to prevent motor neuron activity (Hall et al., 1997). After equilibration, 
the sympathetic trunk was stimulated electrically (Nerve-Muscle Stimulator, Hugo 
Sachs, Germany) using 5V square waves of 5 ms pulse width with variable frequency 
(0.5 and 5.0 Hz). 
2.2.2 Calculation of oxygen uptake 
The method of calculation of oxygen consumption (V0 2) has been described 
previously (Colquhoun et al., 1988). Values for V02 calculation and perfusion pressure 
were taken only after steady state conditions were obtained. Prior to and after each 
experiment, the oxygen electrode was calibrated with pure oxygen (CIG gases, 
Australia) and air (02 = —22%). Arterial P02 (Pa02) was determined by connecting the 
arterial cannula directly to the oxygen electrode, bypassing the perfused tissue. The 
V02 of the perfused tissue was calculated from the difference between Pa02 and venous 
P02 (Pv02), the flow rate, and the perfused muscle mass using the following equation: 
V02 (j.1mol.e.h-1 ) = [1.508 x (Pa02- Pv02) x flow rate]/[perfused muscle mass] 
where 1.508 (Rmolt -1 .mm Hg-1 ) is the Bunsen coefficient for the solubility of oxygen 
in human plasma at 25°C (Christoforides et al., 1969). Pa02 and Pv02 are in mm Hg; 
flow rate is in L.hf l ; and perfused muscle mass is in g (assumed to be 1/12 of total body 
mass in a 180-200 g rat; Ruderman et al., 1971). 
2.2.3. Materials 
Bovine serum albumin (Fraction V) was purchased from Boehringer Mannheim 
(Australia); pentobarbitone sodium (Nembutal, 60 mg/ml) from Bomac Laboratories 
Pty. Ltd. (Australia); heparin sodium from David Bull Laboratories (Australia); NaC1, 
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KC1, KH2PO4, MgSO4, NaHCO3, CaC12 and D-Glucose from Ajax Chemicals Ltd. 
(Australia). 
Capsaicin, noradrenalin (NOR), angiotensin II (All), ruthenium red, 5- 
hydroxytryptamine (serotonin or 5-HT), and tetrodotoxin were purchased from the 
Sigma Chemical Co. (USA); capsazepine was purchased from Research Biochemicals 
International (USA). Phorbol 12-phenylacetate 13-acetate 12-homovanillate (PPAHV) 
was a generous gift from Drs. Giovanni Appendino (University of Torino, Italy) and 
Arpad Szallasi (Washington University, St Louis, USA). Capsazepine was dissolved in 
ethanol (70-80%), as was capsaicin and PPAHV (50%). All other agents were dissolved 
in glass-distilled water or normal saline. Where ethanol was used as the vehicle, special 
care was taken to limit the infusion rate (usually to below 10 glimin) to avoid any 
undesired effects that may be produced by this organic solvent. 
2.2.4. Agent infusion 
The infusion of various agents into the hindlimb commenced only after steady 
state V02 and perfusion pressure had been reached. All agents were either freshly 
prepared before each experiment, or prepared and then stored at 4°C if chemically 
stable. Due to the lipophilic nature of vanilloids and their affinity for silicon-based 
tubing, capsaicin was infused using a syringe pump (Model 2620, Harvard apparatus, 
USA) driving a 1.0 ml glass syringe (SGE, Australia) equipped with teflon tubing. All 
other agents were infused with a second pump (Model 355, Sage instruments, Orion 
Research Inc., USA) using an identical 1.0 ml glass syringe and teflon tubing. 
For all experiments, the concentration-response curves for capsaicin or PPAHV 
were constructed in a cumulative manner with at least two low (nanomolar) and two 
high (micromolar) concentrations. Each concentration was infused only after VO2 and 
perfusion pressure had reached steady state with the preceding concentration. Where 
the effects of capsaicin were examined against capsazepine, ruthenium red, or TTX, the 
relevant inhibitor was first infused alone to detect any changes that these drugs might 
elicit. Increasing concentrations of capsaicin were subsequently co-infused. After the 
removal of the final capsaicin concentration, the inhibitor was also removed and the 
pieparation was allowed to recover to steady state basal values of VO 2 and perfusion 
pressure. 
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In a separate set of control perfusions, capsazepine and ruthenium red were tested 
against the V02 and perfusion pressure changes induced by serotonin (0.35 1.1M), low 
(50 nM) and high (5 iiM) concentrations of NOR, and All (3 nM) to establish selectivity 
of the antagonists for the effects of capsaicin. TTX (0.3 1.A.M) was also infused during 
the V02 and perfusion pressure changes induced by low (0.5 Hz) and high (5 Hz) 
frequency sympathetic nerve stimulation using the above mentioned protocol. 
2.2.5. Data analysis 
Statistical analysis of the data was performed by use of Student's t-test or by one-
way analysis of variance (ANOVA), where applicable. All values are given as the mean 
± standard error (s.e.) mean. The Schild plots were constructed from V0 2 and perfusion 
pressure log concentration-response curves. Dose ratios were estimated at responses 
between 15% and 85% of the maximum response to capsaicin. The antagonist 
dissociation constant (KB) of capsazepine was estimated from the intercept of the Schild 
regression and abscissa where the intercept = -logKB (Kenakin, 1993). 
2.3. Results 
2.3.1. Capsazepine 
For experiments with capsazepine, the mean basal arterial P02 was 695.7±5.1 mm 
Hg and the unstimulated mean venous P02 was 366.9±10.3 mm Hg (n=31) 
corresponding to a mean basal oxygen consumption (V02) of 7.9±0.3 umol. g. -1 h-1 . 
Mean arterial perfusion pressure was 28.5±0.7 mm Hg (n=31). 
Capsaicin produced a concentration-dependent biphasic response in V02 (Fig. 
2.2A) and an associated vasoconstriction-induced rise in perfusion pressure (Fig. 2.2B) 
similar to that reported by Colquhoun et al. (1995). A maximum increase in V02 
(1.2±0.1 umol. g. -1 h-1 ) was observed at 0.5 uM capsaicin coupled with an increase in 
perfusion pressure of 9.0±0.9 mm Hg. The highest concentration of capsaicin used (5 
laM) produced a strong inhibition of V02 (1.9±0.2 umol. g. -1 h-1 below basal) with a 
greater increase in perfusion pressure of 31.6±2.1 mm Hg above basal. 
The infusion of capsazepine alone at the concentrations used to inhibit responses 
to capsaicin failed to alter any basal parameters, and is therefore unlikely to be 
intrinsically active. Capsazepine did not cause statistically significant alterations 
Evidence for Peripheral Vanilloid Receptor Subtypes 	 36 
(P>0.05) in V0 2 and perfusion pressure changes induced by serotonin (5-HT), 
angiotensin II (All), or low and high concentrations of noradrenalin (NOR) (Table 2.2). 
TABLE 2.2. Changes in V02 (AV02) and perfusion pressure induced by serotonin 
(5-HT), angiotensin II (All), and low and high concentrations of noradrenalin 
(NOR), in the absence and presence of 32 ttM capsazepine (CPZ) in the perfused 
rat hindlimb. 
Agents AVO2 
(ftmol. g." 1 If) 
APerfusion 
pressure 
(mmHg) 
3nM All 3.43±0.55 14.0±3.5 
3nM AII + 321.1M CPZ 3.60±0.25 16.3±4.3 
0.3511M 5-HT -2.35±0.45 70.5±7. 5 
0.34IM 5-HT + 321..LM CPZ -2.33±0.43 69.5±4.7 
50nM NOR 3.47±0.32 18.3±2.4 
50nM NOR + 3211M CPZ 3.50±0.35 19.3±2.9 
51.1M NOR -0.83±0.19 181.0±8.6 
511M NOR + 321AM CPZ -0.93±0.15 175.7±11.1 
Values are mean ± s.e. of 3-4 perfusions. Negative AVO2 values occur where agents cause a 
decrease in V02 from basal. 
Capsazepine (0.32-32 gM) produced a concentration-dependent rightward shift in 
the concentration response curves to capsaicin, most evident in the perfusion pressure 
changes (Fig. 2.2B) and inhibition of VO 2 (Fig. 2.2A). The slopes of Schild plots 
constructed from dose ratios estimated at different levels of V0 2 inhibition show that as 
the response becomes greater (i.e. greater inhibition of V0 2) the Schild regressions 
approach a slope close to unity (Fig. 2.3A). 
With the infusion of 3.2 p.1\4 and 10 iiM capsazepine, the maximum perfusion 
pressure response was achieved with 5 piM of the agonist (capsaicin). The concentration 
producing maximum perfusion pressure change increased to 20 j.tM capsaicin at the 
highest dose of capsazepine (32 1.1M). Schild regressions constructed from the perfusion 
pressure data (Fig. 2.3B) showed a similar pattern to those for VO 2 in that a decrease in 
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Fig. 2.2 Effect of capsazepine (CPZ) on concentration-response curves for capsaicin- 
induced changes in (A) oxygen consumption (AV02), and (B) perfusion pressure in 
the isolated perfused rat hindlimb: control (0); 0.32 FLM CPZ (0); 1.0 AM CPZ (A); 
3.2 AM CPZ (A); 10.0 AM CPZ (•); and 32.0 1.01 CPZ (•) in 4-11 experiments. All 
values are mean ± s.e. mean, *P<0.05 **P<0.01 (ANOVA) against control. 
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Fig. 2.3 Multiple Schild plots of the data presented in Fig. 2.2. (A) Regressions were 
constructed from dose ratios estimated at four different levels of the inhibitory V02 
response: a. 0 lima g -1 . 11 1 , slope = 1.87; b. -0.5 ftmol. g -1 . 114 , slope = 1.61; c. -1.0 
gmol. g-1 . h -1 , slope = 1.37; and d. -1.5 ftmol. g -1 . h -1 , slope = 1.01. The mean Kg 
derived from the four Schild plots was 8.44 ± 2.08 RM. (B) Regressions constructed 
from dose ratios estimated at four perfusion pressure responses: a. 15 mm Hg, 
slope = 2.04; b. 20 mm Hg, slope = 1.52, c. 23 mm Hg, slope = 1.49; and d. 25 mm 
Hg, slope = 1.45. Mean Kg from the four regressions was 7.28 ± 0.78 piM. Reduction 
in the number of plot points occurs where some concentration-response curves 
were shifted to the left of the control curves. 
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Fig. 2.4. AVO2 response to 5 x 10 -7 M (panel A) and 5 x 1116 M (panel B) capsaicin 
with increasing concentrations of CPZ. The dotted line shows the control AVO2 at 
these concentrations of capsaicin (n = 4-11). 
slope is evident from dose ratios estimated at greater responses to capsaicin, although 
they differ in the range of their slopes and the points of intercept on the abscissa. Thus 
for Fig. 2.3A the slopes decreased progressively from 1.81 to 1.01, whereas the slopes 
from Fig. 2.3B decreased from 2.04 to 1.45. 
In contrast to capsaicin-induced changes in perfusion pressure, the V02 responses 
show aberrant behaviour in the presence of increasing concentrations of capsazepine 
(Fig 2.4). At 0.5 iiM capsaicin, low concentrations of capsazepine cause an initial fall 
in response (decreased stimulation of V02), followed by a temporary increase in 
response at higher concentrations of the antagonist (Fig 2.4A). A further increase in 
capsazepine concentration caused a second but steady decrease in response. At higher 
concentrations of capsaicin (2-5 IiM), the V02 response is initially enhanced by low 
concentrations of capsazepine (greater inhibition of V02) followed by a steady decrease 
in response at higher concentrations of the antagonist (Fig. 2.4B). It appears, therefore, 
that low concentrations of capsazepine are selectively blocking the stimulatory V02 
effects produced by low concentrations of capsaicin, resulting in the enhancement of the 
inhibitory V02 effects produced by high concentrations of the vanilloid. 
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Near maximal inhibition of V02 was obtained at high concentrations of the 
agonist with all concentrations of capsazepine. Maximal low dose responses to 
capsaicin (stimulation of V02) were not achieved at capsazepine concentrations of 1, 10 
or 32 uM, an observation likely to be a function of the capsaicin concentrations chosen 
in the initial infusion protocol. 
2.3.2. Ruthenium red 
Infusion of ruthenium red (0.01-1.0 1.1.M) alone did not affect mean basal arterial 
P02 (702.6±7.9 mm Hg), venous P02 (419.3±4.6 mm Hg), V02 (6.8±0.3 umol. g. -1 h. - 
1 ), or perfusion pressure (24.8±0.3 mm Hg, n=4). The antagonist also failed to show 
statistically significant inhibition (13 0.05) of the V02 and perfusion pressure changes 
induced by 5-HT, All, and low and high concentrations of NOR (Table 2.3). 
TABLE 2.3. Changes in oxygen consumption (AV02) and perfusion pressure 
induced by serotonin (5-HT), angiotensin II (An), and low and high concentrations 
of noradrenalin (NOR) in the presence and absence of 1 itiM ruthenium red (RR). 
AVO 2 
g." 1 
APerfusion 
pressure 
(mmHg) 
3nM All 3.30±0.06 16.0±2.0 
3nIVI AII + 111M RR 3.40±0.10 16.3±2.2 
0.3511M 5-HT -3.0±0.80 99.0±8.5 
0.35uM 5-HT + 1 uM RR -2.75±0.55 109.0±17.0 
50nM NOR 3.45±0.26 19.5±2.8 
50nM NOR + luM RR 3.40±0.25 19.5±2.9 
51.1,M NOR -0.85±0.17 186.8±6.3 
51iM NOR + luM RR -0.78±0.11 183.0±6.1 
Values are means±S.E. in 3-4 perfusions. Negative AVO 2 values occur where agents cause 
a decrease in V0 2 from basal. 
Ruthenium red produced a concentration-dependent inhibition of both V02 (Fig. 
2.5A) and perfusion pressure (Fig. 2.5B) responses induced by capsaicin. For both V02 
and perfusion pressure, the maximal response to the vanilloid agonist was markedly 
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depressed in comparison to the control curve, and was almost completely abolished by 
the infusion of 1 1.IM ruthenium red. The stimulation of V02 at 0.5 capsaicin was 
inhibited by only 18% with the infusion of 0.1 piN4 ruthenium red. The same 
concentration of the dye attenuated the inhibition of V02 produced by both 2 1.iM and 5 
capsaicin by 87% and 88% respectively. 
A similar response was evident for perfusion pressure changes to the infusion of 
0.5 1.1M and 5 p.M capsaicin in the presence of 0.1 1.iN4 ruthenium red. The increase in 
pressure produced by the lower dose of capsaicin was inhibited by 32%, while that for 
the higher doses was reduced by 82%, again indicating selectivity for the blockade of 
responses to high capsaicin concentrations. 
2.3.3. Phorbo112-phenylacetate 13-acetate 12-homovanillate (PPATIV) 
Figure 2.6 shows concentration-response curves for the effect of the synthetic 
vanilloid analogue PPAHV on V0 2 (panel A) and perfusion pressure (panel B) in the 
perfused rat hindlimb. PPAHV induced a biphasic effect on V0 2 , in association with 
concentration-dependent vasoconstriction, that is characteristic of the infusion of other 
natural vanilloids into this preparation. In the presence of capsazepine (10 piM), 
concentration-response curves for PPAHV-induced changes in V02 and perfusion 
pressure showed a parallel shift to the right (Fig. 2.6) similar to that seen for capsaicin in 
the presence of the antagonist (Fig. 2.2). The observed maximum stimulation of V02 
was obtained by the infusion of 0.2 [.i1\4 PPAHV (AV02, 0.83 ± 0.06 pimol g. -1 11 1 ) and 
was accompanied by a mild increase in PP (APP, 8.0 ± 1.1 mm Hg). This stimulation of 
V02 was significantly (P<0.05) inhibited by capsazepine (AV0 2 , -0.10 ± 0.04 psnol g. -1 
11 1 ), and there was no apparent perfusion pressure response. However, a similar 
observed maximum stimulation of V02, to that seen in the control concentration 
response curve, was evident with the infusion of 0.4 1.1M PPAHV in the presence of 
capsazepine (AV02 , 0.80 ± 0.10 [tmol g. -1 11 1 ). The highest concentration of PPAHV 
infused caused inhibition of V02 (AV02, -2.73 ± 0.51 mot g. -1 h-1 ) and a strong 
vasoconstrictor effect (APP, 42.0 ± 1.2 mm Hg). The inhibition of V0 2 at this 
concentration of PPAHV was not significantly (P>0.05) inhibited by capsazepine 
(AV02, -2.0 ± 0.35 gmol g. -1 h-1 ) suggesting that a depression of the maximum response 
to the agonist is unlikely. However, the highest observed perfusion pressure response 
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Values are mean ± s.e. mean. *P<0.05 PPAHV + capsazepine vs. PPAHV control. 
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was significantly (P<0.05) lowered by capsazepine (APP, 36.3 ± 1.1 mm Hg), although 
this could possibly be overcome by increasing the concentration of PPAHV. 
Comparison of the V02 and perfusion pressure concentration response curves for 
PPAHV and those for capsaicin from Fig. 2.2 (Fig. 2.6) reveals that PPAHV is slightly 
more potent than the natural analogue. This could not be confirmed by estimating the 
half-maximal effective concentration (EC 50) for these ligands as maximum responses for 
PPAHV-induced perfusion pressure change and inhibition of V02 were not observed at 
the concentrations used. 
2.3.4. Tetrodotoxin (TTX) 
The data presented in figure 2.7 shows that TTX (0.3uM) failed to inhibit the VO 2 
and perfusion pressure responses to both low (nanomolar) and high (micromolar) 
concentrations of capsaicin. In fact, in the presence of TTX, there was a statistically 
significant increase in AVO2 from the control curve (without TTX) that may reflect 
some sensitisation of the tissue during repeated infusion of capsaicin. 
-7 	 -6 	 -7 	 -6 
Log [capsaicin] (M) 
Fig. 2.7 Concentration-response curves for oxygen consumption (panel A) and 
perfusion pressure (panel B) for capsaicin in the perfused rat hindlimb alone (0), 
or in the presence of 0.3 ftM tetrodotoxin(•) (n = 4). *P<0.05. 
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Fig. 2.8. Inhibition by tetrodotoxin (TTX) (0.3 gM) of venous P02 and perfusion 
pressure changes induced by low (0.5 Hz) and high (5 Hz) sympathetic nerve 
stimulation. Repeat experiments with TTX produced very similar results. 
Conversely, the same concentration of TTX almost completely blocked the 
vasoconstriction (increased perfusion pressure) induced by low and high frequency 
sympathetic nerve stimulation, and altered the concomitant changes in venous P0 2 in 
the rat hindlimb preparation (Fig. 2.8). 
2.4. Discussion 
2.4.1 Van illoid receptor heterogeneity in a skeletal muscle preparation 
The biphasic nature of the capsaicin-induced muscle V0 2 responses alone 
suggests the operation of a dual vanilloid receptor mechanism, stimulated by a single 
agonist, where a higher affinity receptor may be responsible for the initial stimulation of 
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V02, and a lower affinity receptor is possibly responsible for the inhibition of V02. 
The argument in favour of this vanilloid receptor subtype hypothesis has been 
strengthened by recent studies examining the effect of submicromolar and micromolar 
concentrations of capsaicin under various conditions of metabolic challenge in the 
hindlimb preparation (Colquhoun et al., 1995). The ability of capsaicin to vasoconstrict 
and to stimulate (low concentrations) or inhibit (high concentrations) V02 was assessed 
for its dependence on external calcium; and its dependence on oxygen under conditions 
of hypoxia, and during disruption of cell mitochondria by cyanide and azide. The main 
findings to emerge from these studies are summarised in Table 2.4. 
Table 2.4. Proposed classification criteria for VN1 and VN2 receptors in perfused 
rat muscle (reproduced from Colquhoun et al., 1995, with permission from the 
authors). 
Receptor type VN I VN2 
Oxygen consumption increased decreased 
Vasoconstriction strong moderate 
Affinity for vanilloid 
Dependent on 
external Ca2+ 
high 
yes 
low 
o i n 
Dependent on 02 yes no 
Lactate production 
(steady state) 
increased decreased2 
'Independent of [Cal but may require some Ca 2+ for full agonist effect as inhibition of 
V02 is less than that in the presence of Ca 2+. 
2After removal of capsaicin there is a "wash-out" peak of lactate 
These results clearly indicate that the actions of low and high concentrations of 
capsaicin result from the activation of two separate mechanisms and, conceivably, these 
different actions of capsaicin may be under the control of at least two receptor subtypes 
(putative VN 1 and VN2 receptors) in muscle. 
The findings presented in this chapter, demonstrating the effect of infusing 
capsaicin into the perfused rat hindlimb, are in good agreement with those published 
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previously (Cameron-Smith et al., 1990; Colquhoun et al., 1995). By employing 
competitive and non-competitive vanilloid antagonists, the present data has added 
strength to the notion that capsaicin-mediated responses in perfused rat muscle are 
mediated by capsaicin binding to specific vanilloid recognition sites, and that there may 
be at least two receptor subtypes (VNI and VN2) controlling the observed actions of the 
vanilloid. 
Infusion of capsazepine into the rat hindlimb produced competitive antagonism of 
capsaicin-stimulated changes in V0 2 and perfusion pressure (Figs. 2.2A and 2.2B). The 
inability of capsazepine to inhibit the actions of other non-vanilloid agonists, that 
produce effects similar to those induced by vanilloids, suggests that capsazepine is 
highly specific for the actions of capsaicin. Similar patterns of specific competitive 
antagonism by capsazepine have been observed in other systems where the effects of 
capsaicin are believed to be receptor-mediated (Bevan et al., 1992; Maggi et al., 1993a) 
and, therefore, it is likely that capsaicin also binds to distinct vanilloid recognition sites 
in rat hindlimb tissue. 
Conceptually, the effects of overlapping and opposing receptor subtypes has been 
considered as an explanation for bell-shaped concentration-response curves (Rovati and 
Nicosia, 1994). These authors have attempted to distinguish the bell-shaped 
concentration-response curves produced by opposing receptor subtypes from those 
produced by partial agonists. A similar model developed earlier by Szabadi (1977) 
proposed that an antagonist acting preferentially on one of the opposing receptor types 
will potentiate the effect produced by the other, and that the net effect will be evident in 
the observed concentration-response curve. 
Data presented in this chapter have demonstrated similar effects by selectively 
inhibiting the stimulatory (low dose/\[N 1 ) component of the biphasic V0 2 response to 
capsaicin with 0.32 11M and 1 tiM capsazepine. This resulted in potentiation of the 
inhibitory (high dose/VN2) V02 component. That is, a single agonist (capsaicin) seems 
to act on two receptor types, one stimulatory and one inhibitory, to produce an overall 
biphasic curve, as demonstrated in Fig. 2.9. The data suggests that the VN I receptor is 
responsible for the increases in V02 seen at submicromolar concentrations of capsaicin. 
The lower affinity VN 2 receptor produces a more pronounced inhibitory effect on V0 2 
at capsaicin concentrations exceeding 1 [IM. The theoretical curve VN 1 +VN2 
represents the combined effect of the two receptors and closely resembles the biphasic 
I 	 I i 1 
2 	 
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curve derived from the infusion of increasing concentrations of capsaicin. It is 
proposed that low concentrations of capsazepine (0.32 [tNI and 1 iiM) have selectively 
blocked the putative VN I receptor and, consequently, the resultant stimulation of V02 . 
-7 	-6 	-5 -4 
Log [capsaicin] (M) 
Fig. 2.9 A concentration-response curve model of oxygen consumption for putative 
vanilloid subtypes VIVI and VN2 in the perfused rat hindlimb. VNI and VN2 curves 
were constructed by applying the four parameter logistic equation used by Rovati 
and Nicosia (1994). EC50 (0.3 AM) and IC50 (1.6 ftM) values for this equation were 
estimated from Fig.2.2. Maximal VNI and VN2 responses were estimated at 1.2 and 
-3.0 units, respectively. These receptor types show different affinities for capsaicin 
that is reflected in the observed concentration-response curve, represented by the 
sum of the theoretical VNI and VN2 curves (VNI-F YN2). The inhibition of the VNI 
receptor type by low concentrations of capsazepine shifts the balance of agonist 
occupancy in favour of the opposing VN2 receptor, hence causing the effect 
produced by this latter receptor type to predominate before it is also inhibited at 
higher capsazepine concentrations. 
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Hence a shift in the balance of agonist occupancy has occurred in favour of the putative 
VN2 (inhibitory) receptor. As a result, the inhibitory V0 2 response has become more 
pronounced in the overall concentration-response curves produced in the presence of 
low concentrations of capsazepine. 
The complex interaction of agonist and antagonist interacting with two opposing 
receptor types, having different affinities, may have altered the dose ratios sufficiently 
to account for the steepness of some of the Schild regression slopes. It is conceivable 
that as the inhibition of V02 becomes greater (by increasing the capsaicin 
concentration) the emphasis of binding is placed in favour of the putative VN2 receptor. 
As a result, the Schild plots derived at higher inhibitory V0 2 responses (having slopes 
close to unity) resemble more closely a single receptor-agonist/antagonist interaction. 
Steepness in Schild plots can also represent a non-equilibrium steady state between the 
antagonist and receptor, or the presence of a saturable antagonist removal mechanism 
(Kenakin, 1993). In this study, an antagonist removal mechanism may be present due 
to the use of bovine serum albumin (BSA) medium to act as the necessary oncotic 
agent. In perfusions where 2% BSA is replaced by 4% Ficoll® (Pharmacia, Sweden) in 
the perfusion medium, capsaicin shows a 10-20 fold greater potency for inducing 
changes in V02 and vascular tension (C.D. Griffiths, Honours Thesis, Division of 
Biochemistry, University of Tasmania, 1994). Capsazepine, being a structural analog 
of capsaicin, may also have a similar susceptibility to binding to BSA. However, on 
this basis alone it is difficult to account for the decreases in Schild plot slope when the 
dose ratios were estimated at greater agonist responses. 
By contrast, Schild regressions obtained for the perfusion pressure data do not 
fully support a dual receptor proposal (Fig 2.3B). These observations may be a result of 
the inability to distinguish between the similar vasoconstrictor responses produced by 
putative VN i and VN2 receptors, unlike the opposing responses on V0 2 where VN I 
and VN2 effects can be distinguished with the infusion of low concentrations of 
cap s azep ine. 
In the hindlimb preparation, 1 gM ruthenium red produced a specific but non-
competitive inhibition of capsaicin-induced responses (Fig. 2.5) similar to that seen in 
the rat vas deferens and urinary bladder where the maximal responses to the vanilloid 
are potently antagonised (Maggi et al., 1993a). Again, this inhibition has been shown 
to be specific since the above concentration of ruthenium red used to block the effects 
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of capsaicin did not alter the actions of other non-vanilloid agonists. The infusion of 
nanomolar concentrations of the dye produced strong inhibition of the V0 2 and 
perfusion pressure effects of high (micromolar) concentrations of capsaicin, while low 
dose capsaicin responses showed only mild inhibition. The apparent selective 
antagonism of high dose capsaicin responses by low concentrations of ruthenium red 
further supports the notion of a dual vanilloid receptor system. Given the suggested 
intimacy between putative vanilloid receptors and non-selective cation channels (James 
et al., 1993), it follows that if different vanilloid receptor types exist, then there could 
also be heterogeneity in the receptor-channel coupling system as a whole. The pattern 
of inhibition by low dose (nanomolar) ruthenium red in rat hindlimb tissue certainly 
suggests that this may be the case. 
2.4.2. Cooperative versus non-cooperative vanilloid receptor binding 
In rat DRG membrane preparations, increasing concentrations of unlabelled RTX 
produces a biphasic effect on [31-1]-RTX binding (an initial increase followed by 
inhibition) suggesting cooperativity of ligand binding to the vanilloid receptor (Szallasi 
et al., 1993b, Acs and Blumberg, 1994b). Hence, the binding of [ 31-1]-RTX is initially 
enhanced by low concentrations of unlabelled ligand, followed by concentration-
dependent inhibition of radioligand binding at higher RTX concentrations. However, 
when non-radioactive RTX is substituted with increasing concentrations of PPAHV, 
only monophasic inhibition of [31-1]-RTX binding is evident (Szallasi et al., 1996). 
Consequently, the binding behaviour of this ligand to CNS vanilloid receptors is 
thought to be non-cooperative in nature. 
The shape of the biphasic competition curves from CNS radioligand binding 
studies bears a striking resemblance to the biphasic nature of V02 concentration-
response curves for capsaicin in the perfused rat hindlimb (Colquhoun et al., 1995; 
section 1.2.3.), suggesting that vanilloids may bind to hindlimb receptors in a 
cooperative fashion. Hence if PPAHV were to produce monophasic V02 concentration-
response curves in rat muscle, then this may strengthen the above hypothesis. 
However, data presented in this chapter using increasing concentrations of PPAHV 
showed that this ligand induced a biphasic effect on muscle V02 , with vasoconstriction, 
similar to that seen with the infusion of increasing concentrations of capsaicin. The 
apparent affinity of this synthetic analogue, relative to the affinity of capsaicin and RTX 
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(Eldershaw et al., 1994), in this preparation is in excellent agreement with those 
determined in radioligand binding assays (Szallasi et al., 1996). Furthermore, it is very 
likely that PPAHV is inducing its effects by binding to specific vanilloid receptors since 
the vanilloid antagonist capsazepine (10 i.tM) caused a parallel shift to the right, without 
diminution of some observed maximum responses, in the concentration-response curves 
for this agonist (Fig. 2.6). This inhibition of PPAHV by capsazepine was very similar 
to that observed for capsaicin by the antagonist (Fig. 2.2), suggesting that all three 
ligands interact with the same vanilloid recognition sites. 
2.4.3. Capsaicin cellular mechanisms in muscle 
The observations with TTX in the perfused rat hindlimb are in contrast to those 
found by Lou et al. (1992) (see section 1.3.4.) using the same concentration of the toxin 
(0.3 gM). The TTX-resistant nature of all capsaicin-mediated changes in the rat 
hindlimb raises speculation regarding the cellular mechanisms promoted by vanilloids 
in this preparation. In view of recent reports by Akopian et al. (1996) of a TTX-
resistant voltage-gated sodium channel on capsaicin-sensitive rat dorsal root ganglion 
(DRG) neurones, it follows that capsaicin could possibly activate the opening of similar 
channels in rat skeletal muscle. However, attempts by these authors to detect such a 
channel in skeletal muscle were unsuccessful. Consequently, there exists the possibility 
that the cellular mechanisms promoted by capsaicin at low concentrations in the 
perfused rat hindlimb preparation could differ from other tissues, but more evidence is 
undoubtedly required. 
Thus the mechanisms by which capsaicin induces vascular and biphasic V02 
changes in the perfused rat hindlimb are likely to involve at least two distinct receptor 
subtypes. However, no attempt has been made in this chapter to assess the likely post 
receptor mechanisms employed by capsaicin in this tissue, such as involvement of 
capsaicin-sensitive neurons and their peptide transmitters. Instead, this forms the basis 
of the studies presented in Chapter 3. 
Role of Sensory Neuropeptides and Effects of Systemic Capsaicin Pretreatment 	 52 
Chapter 3 
The Potential Role for Capsaicin-Sensitive Neurons and Their Peptide 
Transmitters in the Acute Responses to Capsaicin in Perfused Rat 
Muscle. 
3.1 Introduction 
The findings from the previous chapter demonstrated that the dual effects of 
capsaicin in perfused muscle V0 2 are likely to be mediated by specific vanilloid 
receptor subtypes. However, the underlying mechanisms by which VN I and VN2 
receptors produce these responses are poorly understood. In other tissues, vanilloid 
receptors are thought to be coupled to non-selective cation channels on certain C-type 
and Ao-type sensory neurons (James et al., 1993) and the recent cloning of a capsaicin 
receptor from DRG has confirmed this long-held belief (Caterina et al., 1997). 
Stimulation of these ion-channel receptors facilitates the intracellular accumulation of 
calcium ions and co-release of several neuropeptide transmitters, most notably 
calcitonin gene-related peptide (CGRP), and the tachykinins substance P (SP), 
neurokinin A (NKA) and neurokinin B (NKB). These sensory peptides may produce a 
variety of biological responses, including changes in vascular tone and permeability 
(reviewed by Holzer, 1998), smooth muscle contraction, and inflammation (reviewed by 
Holzer, 1991). A hallmark of capsaicin action on peptide-containing sensory neurons is 
its ability to induce a refractory state of desensitisation with prolonged or repeated in 
vitro application, or following systemic administration (see section 1.3.5.). Indeed, it is 
this unique property of capsaicin and its structural analogues that has resulted in 
considerable interest in the use of these compounds as antinociceptive and anti-
inflammatory agents (Bevan and Szolcsanyi, 1990; Dray, 1992; Maggi, 1992; Campbell 
etal., 1993, Dray and Urban, 1996). 
The actions of the tachykinin peptides are mediated by at least three receptor 
subtypes: SP-preferring NK1, NKA-preferring NIC2 and NKB-preferring NK3 receptors 
(reviewed by Mussap et al., 1993; Maggi et al, 1993b; Regoli et al., 1994). All three of 
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the known tachykinin receptor subtypes have been cloned (Masu et al., 1987; Yokota et 
al., 1989; Shigemoto et al., 1990; Ingi et al., 1991) and are known to belong to the G-
protein-coupled receptor family (Nakanishi et al., 1993). NK1 receptors are widely 
distributed in both the CNS and peripheral tissues, whereas NK2 receptors are found 
mainly in peripheral tissues (predominantly on smooth muscle) and NIC3 receptors in 
the CNS, although the latter are expressed in the rat portal vein and guinea-pig 
myenteric plexus (Mastrangelo et al., 1987; Guard et al., 1990). While each of the 
tachykinins have preferred receptors, it is widely accepted that the selectivity of each 
peptide for these receptors is poor and that many of their physiological actions may 
result from their interaction with more than one tachykinin receptor type (reviewed in 
Otsuka and Yoshioka, 1993). To date, attempts to synthesize selective agonists, 
demonstrating high selectivity for each receptor type, have been met with limited 
success (Mussap et al., 1993; Regoli et al., 1994; McLean and Lowe, 1994). Although 
some synthetic peptide agonists display high selectivity for their preferred receptors, the 
lability of these peptides to enzymatic degradation raises concerns about their usefulness 
for characterising tachykinin receptors in different tissues (McLean and Lowe, 1994). 
Similarly, peptide antagonists for tachykinin receptors are prone to degradation and, in 
addition, may induce undesirable effects such as mast-cell degranulation, partial 
agonism, neurotoxicity and local anaesthetic properties (reviewed in Maggi et al., 
1993b). Hence the development of the first non-peptide antagonists for NK1 (Snider et 
al., 1991; Garret etal., 1991, McLean et al., 1993), NK2 (Emonds-Alt et al., 1992), and 
more recently NK3 receptors (Emonds-Alt et al., 1994), showing high receptor affinity 
and high selectivity, has made an important contribution to the study of tachykinin 
receptor pharmacology in individual tissues. 
Receptors for CGRP are tentatively divided into two distinct subtypes (CGRP1 
and CGRP2) based on the differing ability of C-terminal fragments of the peptide to 
antagonise the actions of intact CGRP in different preparations (reviewed by Poyner, 
1995). One of these fragments, CGRP(8_37), is the only commercially available CGRP 
antagonist at present and was first recognised for its ability to competitively inhibit 
CGRP- and calcitonin-induced cAMP production in a rat liver plasma membrane 
preparation (Chiba et al., 1989). Shorter C-terminal fragments retain similar selective 
antagonism, but possess markedly reduced affinity for CGRP receptors when compared 
to CGRP(8_3 7) (Bell and McDermott, 1996). Since its discovery, this truncated peptide 
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has been used in a variety of functional preparations from different species to 
competitively inhibit the actions of CGRP. The estimated affinity (given as pA2 ., the log 
concentration of antagonist required to produce a dose ratio equal to 2) of CGRP (8 _37) for 
its receptors in several rat tissue preparations is presented in Table 3.1, and 
demonstrates the ambiguity experienced with the use of this antagonist in different 
functional assays. 
TABLE 3.1 - pA2 estimates from CGRP(8.37) inhibition of CGRP responses in 
several rat tissue preparations 
Tissue Assay pA2 I Reference 
Liver membranes cAMP accumulation 8.35 Chiba et al, 1989 
Vas deferens relaxation 6.77 Dennis et al., 1990 
L6 myocytes cAMP accumulation 8.38 Poyner et al., 1992 
Vas deferens relaxation 5.85 Giuliani et al., 1992 
Adipocytes glycoprotein synthesis 6.91 Casini et al., 1991 
Mesentery vasodilatation 8.50 Foulkes et al., 1991 
1 pA2 is the log concentration of antagonist required to produce a two-fold shift to the 
right (i.e. dose ratio = 2) in a concentration-response curve for a competing agonist. 
The data presented in this chapter attempts to define a role for capsaicin-sensitive 
neurons, their major peptide transmitters (SP, NKA and CGRP), and neuropeptide 
receptors in capsaicin-induced responses in the perfused hindlimb by employing the 
following pharmacological tools and techniques: 
• non-peptide and peptide antagonists for tachykinin (NK1 and NK2) and CGRP 
(putative CGRP 1 ) receptors, respectively 
• endogenous peptide ligands for tachykinin (NK1, NK2 and NK3) and CGRP 
receptors 
• systemic capsaicin pretreatment which is known to ablate capsaicin-sensitive 
primary afferent neurons (CSPANs) (section 1.3.5.). 
Role of Sensory Neuropeptides and Effects of Systemic Capsaicin Pretreatment 	55 
Concentration-response curves for capsaicin-induced changes in perfused 
hindlimb V02 and perfusion pressure were constructed in the presence of the 
competitive non-peptide antagonists CP-99,994 (NK1 receptors) and SR 48968 (NK2 
receptors), and the truncated peptide antagonist CGRP(8_37) (CGRP 1 receptors). Animals 
were also pretreated with capsaicin and the perfused hindlimb responses to the vanilloid 
were recorded 1, 7 and 14 days after pretreatment. In addition, the effects of infusing 
the neuropeptides SP, NICA, NKB and CGRP were studied in an attempt to mimic the 
actions of capsaicin and to further characterise the peptides and receptors involved. 
3.2 Methods 
3.2.1. Rat hindlimb perfusion. 
Animals were anaesthetised with pentobarbitone sodium (60 mg/kg) and their left 
hindlimbs perfused according to the method described previously (section 2.2.1, 
Ruderman et al., 1971; Colquhoun et al., 1988). 
3.2.2. Materials 
Substance P, neurokinin A, neurokinin B, calcitonin gene-related peptide and 
CGRP(8_37) were purchased from Auspep (Australia); capsaicin, Sigmacote ® and 
phosphoramidon from the Sigma Chemical Company; bovine serum albumin (Fraction 
V) from Boehringer Mannheim (Australia) and pentobarbitone sodium (Nembutal, 60 
mg/ml) from Bomac Laboratories (Australia). Non-peptide tachykinin antagonists were 
generous gifts: (2S,3S)-3-(2-methoxybenzypamino-2-phenylpiperidine (CP-99,994) 
from Dr. S.B. Kadin, Pfizer Inc., Groton, CT, U.S.A., and (S)-N-methyl-N[4-(4- 
acetylamino-4-phenyl piperidino)-2-(3,4dichlorophenyl)butyl]benzamide (SR 48968) 
from Dr. X. Emonds-Alt, Sanofi Recherche, Montpellier, France. All other reagents 
were of analytical grade. 
Neuropeptides were dissolved into 20 gl aliquots using a 0.01 M acetic acid 
solution containing 1% 13-mercaptoethanol and stored at -20°C to maintain chemical 
stability. The aliquots were then diluted, as needed, with 0.9% NaC1 so that the acetate 
and [3-mercaptoethanol concentrations were negligible. Due to the lipophilic nature of 
capsaicin, it was dissolved in 50% ethanol and care was taken to keep the infusion rates 
Role of Sensory Neuropeptides and Effects of Systemic Capsaicin Pretreatment 	 56 
low (usually below 10 g1/min) to avoid vehicle-induced effects. All other agents were 
dissolved in normal saline (0.9% w/v). 
3.2.3 Agent infusion 
Capsaicin and the neuropeptides were infused using a syringe pump (Model 2620, 
Harvard Apparatus Inc., USA) driving a 1.0 ml glass syringe (SGE) equipped with 
teflon tubing. Other agents were infused using similar infusion pumps (Model 355, 
Sage instruments, Orion Research Inc. USA, or Model 11 microinfusion, Harvard 
Apparatus Inc., USA) also with an identical 1.0 ml glass syringe and teflon tubing. In 
perfusions using SP, NKA, NKB or CGRP, all glassware was cleaned and silanised with 
Sigmacote® (prior to infusion) to prevent peptide adhesion to glass surfaces. 
In perfusions using either CP-99994, SR 48968 or CGRP(8-37),  control 
concentration-response curves for V0 2 and perfusion pressure were first obtained by the 
cumulative infusion of increasing concentrations of capsaicin followed by a period of 
recovery after drug removal. Following re-establishment of basal V0 2 and perfusion 
pressure, either CP-99994 (0.1, 0.5 or 1 [tM), SR 48968 (0.1, 1 or 101.tM) or CGRP(8-37) 
(1 vtM) was infused alone for approximately 5 minutes, and then co-infused whilst the 
capsaicin concentration-response curve was repeated. When infused alone, none of the 
antagonists induced detectable changes in either basal V0 2 or perfusion pressure. 
The neutral endopeptidase inhibitor phosphoramidon (5 p,M) was co-infused with 
each neuropeptide (following phosphoramidon alone for 5 minutes) to prevent 
enzymatic degradation. Several concentrations of SP, NKA, NKB or CGRP were 
infused to enable the construction of concentration-response curves and estimation of 
half-maximal effective concentration (EC50) for each peptide. 
3.2.4. Capsaicin pretreatment 
Capsaicin pretreatment was given according to the pre-established method of Cui 
and Himms-Hagen (1992a; 1992b) with a minor modification to the anaesthetic used. 
Briefly, a total dose of 125 mg/kg capsaicin was administered, under anaesthesia (40-60 
mg/kg pentobarbitone), in four s.c. injections over a three day period (day 1, 12.5 
mg/kg; day 2, 2 x 25 mg/kg; day 3, 62.5 mg/kg). Care was taken to limit the dose of 
pentobarbitone on day two of the protocol where the animals were anaesthetised twice 
(morning and evening). Injections were given behind the neck or near the rump where 
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S.C. injection was easier due to the loose skin at these locations. Injections of the vehicle 
(10% Tween 80, 10% ethanol in normal saline) were given to control animals. 
Hindlimbs were perfused 1, 7 or 14 days after the final capsaicin (or vehicle) injection 
and the responses to the infusion of several concentrations of the vanilloid were 
recorded. The animals were weighed on each day of the injection protocol and prior to 
perfusion to examine the effect of the pretreatment on overall growth (see Appendix 2). 
3.2.5. Data analysis 
Statistical analysis was performed using Student's t-test, one-way analysis of 
variance (ANOVA) or ANOVA on ranks (Kruskal-Wallis analysis), or by one-way 
repeated measures ANOVA or one-way repeated measures ANOVA on ranks 
(Friedman analysis), where applicable. All ANOVAs were subjected to Student-
Newman-Keuls multiple comparisons where P<0.05 was considered statistically 
significant. The half maximal effective concentration (EC50) and maximum effect 
(Ernax) for SP, NKA and NKB were estimated from VO 2 and perfusion pressure 
concentration-response curves for individual experiments. For NKB, the maximum 
VO2 effect was not obtained, hence the EC 50 for this peptide was estimated using the 
mean Emax from the SP and NKA experiments. In capsaicin pretreatment experiments, 
the EC50 for the acute effects of capsaicin was estimated from individual concentration-
response curves for perfusion pressure. 
3.3. Results 
For all experiments, mean basal hindlimb VO 2 was 8.90 ± 1.13 grnol. gr l 
while that for perfusion pressure was 24.93 ± 0.35 mm Hg (n = 65). All drug-induced 
changes in these parameters were estimated under steady state conditions. At all 
concentrations tested, CP-99,994, SR 48968 and CGRP(8_37) failed to alter any of the 
above parameters when infused in the absence of other agents. 
3.3.1. CP-99,994 
Concentration-response curves for capsaicin were characteristically biphasic for 
V02, as seen previously (Colquhoun et al., 1995; Chapter 2), with a concentration-
dependent increase in perfusion pressure that is indicative of vasoconstriction (Fig. 3.1). 
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Consecutive concentration-response curves for capsaicin were very similar, as indicated 
by the data obtained using an ineffective concentration of CP-99,994 (Fig. 3.1A, D). 
The observed maximal stimulation of VO2 was induced by 0.4 pM capsaicin (AV02, 
1.350.14 prnol. g. -I W I above basal V02) followed by inhibition of VO2 at 
concentrations above 1 11M with the observed maximal inhibition of VO2 at 2 pM 
capsaicin (-2.25±0.35 pmol. g. -I h-I below basal V02, Fig 3.1C). The non-peptide NK-1 
receptor antagonist, CP-99,994 (1 pM), selectively inhibited some, but not all, of the 
stimulation of VO2 induced by capsaicin (AV02, 0.78 ± 0.06 pmol. g. -1 W I ; P<0.05, Fig 
3.1C ). 
A lower concentration of CP-99,994 (0.5 pM) had a similar but less pronounced 
effect on V0 2 , (P<0.05) (Fig. 3.1B). While some statistically significant (P<0.05) 
differences in the perfusion pressure responses to capsaicin were evident in the presence 
of CP-99,994, these changes were not consistent over the three antagonist 
concentrations used (Fig. 3.1D-F). 
3.3.2. SR 48968 
At a concentration of 1 pM, the selective NK2 receptor antagonist SR 48968 
significantly inhibited (P<0.05) the maximum stimulation of VO 2 induced by 0.4 pM 
capsaicin (AV02, control, 1.06±0.13 pmol. g. 4 11 1 ; SR 48968, 0.520.24 pimol. g. -I 
Fig. 3.2B). Although the stimulation of VO2 at a lower concentration of capsaicin (0.25 
gM) was potentiated in the presence of 1 gM SR 48968 (Fig 3.2B), this effect is 
unlikely to be caused by the antagonist since there is occasionally mild sensitisation to 
the VO2 stimulatory response when a capsaicin dose-response curve is repeated in the 
absence of other agents (Griffiths, Eldershaw and Colquhoun, unpublished 
observations). The infusion of a high concentration of SR 48968 (10 ptM) produced 
further blockade of the maximum capsaicin-induced stimulation of VO2 (AV02, control, 
1.03±0.08 jimol. g. - 
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P<0.05, Fig 3.2C), while the inhibition of V0 2 produced by a high concentration of the 
vanilloid (2 gM) was significantly (P<0.05) enhanced (AV02, control, -2.07±0.20 gmol. 
g. -1 h-1 ; SR48968, -3.04±0.26 gmol. g. -1 h-1 ). Vasoconstriction at all concentrations of 
capsaicin was also significantly (P<0.05) enhanced by 10 gM SR 48968 (Fig 3.2F). 
3.3.3. CGRP0-3 7) 
Infusion of the CGRP antagonist, CGRP(8_37), significantly (P<0.05) increased the 
stimulation of V02 induced by 0.125 and 0.25 uM capsaicin (AV02, control, 0.03 ± 
0.03 and 0.13±0.06 gmol. g. -1 h-1 ; CGRP(8_3 7), 0.28 ± 0.09 and 0.80±0.09 gmol. g. -1 h-1 , 
respectively) but did not significantly increase the observed maximal stimulation of 
V02 produced by the infusion of 0.4 111%.4 capsaicin (Fig 3.3A). The inhibition of V0 2 
induced by 1 gM capsaicin was significantly (P<0.05) enhanced by the co-infusion of 
CGRP(8_37) (AV02, control, -1.13±0.29 gmol. g. -1 h-1 ; CGRP(8-37), -2.08±0.15 gmol. g. -1 
h-1 , Fig 3.3A) while vasoconstriction at 1 and 2 gM capsaicin was markedly (P<0.05) 
increased (APP; control, 16.5±0.7 mm Hg and 29.3±2.0 mm Hg, respectively; CGRP(8_ 
3 7 ), 36.8±2.1 mm Hg and 46.0±3.1 mm Hg, respectively, Fig. 3.3B). 
3.3.4. Substance P, neurokinin A, neurokinin B and calcitonin gene-related peptide 
Infusion of neutral endopeptidase inhibitor phosphoramidon (5 gM) alone had no 
detectable effect on either basal V0 2 or perfusion pressure. The co-infusion of 
increasing doses of SP with phosphoramidon produced a concentration-dependent 
increase in V02 (Fig 3.4A and Table 3.2) and induced mild vasoconstriction (Fig 3.4B 
and Table 3.2). Increasing the dose of SP to micromolar concentrations caused some 
attenuation of the V02 increase, while the effect on perfusion pressure plateaued. NKA, 
also co-infused with phosphoramidon, produced similar effects on hindlimb V02 and 
perfusion pressure, but was approximately 10-fold more potent than SP (Fig 3.4 and 
Table 3.2). The infusion of NKB, with phosphoramidon, stimulated a small but 
reproducible change in V02, however, maximum V0 2 was not obtained using 
concentrations of NKB that induced a maximum change in vascular tone (Fig 3.4 and 
Table 3.2). At all concentrations tested, CGRP had no detectable effect on perfused 
hindlimb V02 or perfusion pressure (Fig 3.4). 
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TABLE 3.2. Maximum change in perfusion 'pressure (APP) and oxygen 
consumption (AV02), and concentration producing 50 percent of maximum 
response (EC50) for substance P (SP), neurokinin A (NKA), and neurokinin B 
(NKB) in the perfused rat hindlimb. 
APP AVO2 
Neuropeptide 
Emax 
(mm Hg) 
EC50 
(nM) 
Emax 
(gmol. g. -1 11-1 ) 
ECso 
(nM) 
SP 5 4.33*0.33 352.0±25.70 0.52±0.07 269±23.00 
NKA 4 6.75±1.18 25.5±2.72 0.53±0.08 21.2±2.98 
NKB 5 3.4±0.25 34.4±5.19 71.8±29.20 1 
Values are mean ± s.e. mean 
1 EC50 estimated using mean of E. (AV0 2) for SP and NICA. 
3.3.5. Capsaicin pretreatment 
Results of the weight trials during capsaicin and vehicle pretreatment are 
presented in Appendix 2. Capsaicin pretreated animals showed a statistically significant 
(P<0.05) weight loss on day three of the injection protocol, but only in the groups 
perfused seven and fourteen days after pretreatment. Animals perfused one day after 
capsaicin pretreatment did experience some weight loss on day three of the injection 
protocol, but this did not reach statistical significance (P>0.05). This was possibly due 
to the greater standard error and smaller total sample size of the group. When the 
weights of all animals were pooled (total group), no statistically significant differences 
were observed over the three day pretreatment period. The weight losses induced by 
pretreatment with capsaicin are unlikely to have affected the acute responses to 
capsaicin in the perfused hindlimb since the mean final weight of all groups were very 
similar. 
Figure 3.5 shows V0 2 and perfusion pressure responses to capsaicin in hindlimbs 
perfused 1, 7 and 14 days after vehicle or systemic capsaicin pretreatment. Stimulation 
of V02 induced by submicromolar concentrations of capsaicin was inhibited (P<0.05) 1 
day after capsaicin-pretreatment (maximum AV0 2 ; control, 0.98±0.23 umol. g. -1 11-1 ; 
capsaicin pretreated, 0.080.04 umol. gr i h-1 , Fig 3.5A). However, the increase in 
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perfusion pressure induced by 2 1.1M capsaicin was markedly (P<0.05) enhanced (APP; 
control, 23.2±1.4 mm Hg; capsaicin pretreated, 35.8±3.3 mm Hg, Fig 3.5D). Seven and 
14 days after capsaicin-pretreatment, the stimulation of V02 and vasoconstriction 
induced by low concentrations of capsaicin was completely restored, whereas the 
maximum inhibition of V02 by 2 tiM capsaicin was significantly (P<0.05) enhanced 
compared with vehicle-pretreated controls (AV02; 7 days, control, -3.18±0.06, capsaicin 
pretreated, -4.27±0.46; 14 days, control, -3.02±0.25, capsaicin pretreated, -4.52±0.40 
imol. g. -1 11-1 , Fig 3.5B, C). The maximum vasoconstriction at micromolar 
concentrations of capsaicin was also greatly increased 7 days after capsaicin 
pretreatment, and increased further after 14 days (Fig 3.5E, F and Table 3.4). In 
addition, the half-maximal effective concentration (EC50) for capsaicin, estimated from 
the perfusion pressure concentration-response curves, was significantly (P<0.01) lower 
in animals perfused 7 and 14 days after capsaicin pretreatment (Table 3.3). 
TABLE 3.3. Maximum capsaicin-induced change in perfusion pressure (APP) and 
capsaicin concentration producing 50 percent of maximum response (EC50) in the 
perfused rat hindlimb, 1, 7 and 14 days after vehicle- or capsaicin-pretreatment. 
Pretreatment n 
Days after 
pretreatment 
Emax 
(Amm Hg) 
ECso 
(1101) 
Vehicle 5 1 30.2 ± 2.22 1.07 ± 0.04 
Capsaicin 5 1 35.8 ± 3.28 0.99 ± 0.07 
Vehicle 4 7 31.0 ±1.78 1.02± 0.05 
Capsaicin 4 7 42.3 ± 0.33** 0.74 ± 0.04** 
Vehicle 5 14 29.3 ± 1:80 0.96 ± 0.05 
Capsaicin 5 14 47.0 ± 4.38** 0.66 ± 0.05** 
Values are mean ± s.e. mean. "P<0.01 from corresponding vehicle pretreated controls. 
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Role of Sensory Neuropeptides and Effects of Systemic Capsaicin Pretreatment 	 67 
3.4. Discussion 
To date, there have been few attempts to characterise the post-receptor 
mechanisms involved in the powerful vasoconstrictor and biphasic V0 2 responses 
induced by capsaicin in the perfused rat hindlimb (Cameron-Smith et al., 1990; 
Colquhoun et al., 1995; Chapter 2). Earlier studies have indicated the importance of 
external calcium and mitochondrial function in some of these responses (Colquhoun et 
al., 1995), however the role of capsaicin sensitive primary afferent (sensory) neurons 
and sensory neuropeptides (SP, NKA, NKB and CGRP), and their receptors, has not 
been closely investigated until now. The data presented in this chapter has added to the 
understanding of the mechanisms involved in the acute effects of capsaicin in muscle, 
and has yielded some interesting and unexpected findings. 
3.4.1. Role of the tachykinins 
3.4.1.1. Non-peptide antagonists 
The first report on the use of the selective NK1 receptor antagonist CP-99,994 
showed this agent to possess picomolar affinity (K, = 250 pM) for human NK1 receptors 
(IM-9 cells) labelled with [ 125I]-BHSP (McLean et al., 1993), and similar affinity (IC 50 
= 520 pM) for [311]-SP labelled NK1 receptors in the cat cortex (Lucot et al., 1997). 
However, this compound exhibits only high micromolar affinity (IC50 = >10 liM) for 
NK2 ([ 125 I]-NKA-labelled hamster bladder) and NK3 ([' 251]eledoisin-labelled guinea-
pig cortex) receptors (McLean et al., 1993). These authors also showed CP-99,994 to 
have greatly reduced potency for the non-specific inhibition of Ca 2+ channels in rat heart 
(IC50 = 3-4 p.M), compared to the parent non-peptide NK1 antagonist CP-96,345 (ICso = 
27 nM). Consequently, CP-99,994 represents a highly selective and powerful tool for 
the study of NK1 receptors in individual tissues. 
Data presented in this chapter showed that the stimulation of V02 induced by 
submicromolar concentrations of capsaicin (VNI response) was partly blocked by the 
selective NK1 receptor antagonist CP-99,994 in a concentration-dependent manner (Fig 
3.1) indicating a potential role for NK1 receptors in this response. Based on this data 
alone, an estimation of the potency (e.g. pA 2 or IC50) of CP-99,994 for inhibiting the 
V02 response could not be made as insufficient concentrations of the antagonist were 
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used. Nonetheless, it appears from figure 3.1 that CP-99,994 possesses submicromolar 
to micromolar potency for inhibiting the effects of capsaicin in the hindlimb 
preparation, and differs from the in vitro affinity estimates of CP-99,994 for human and 
feline NK1 receptors reported above. However, the affinity estimates for CP-99,994 at 
rat NK1 receptors (IC 50 = 127 nM) also differs markedly from that in the human and cat 
by at least 2-3 orders of magnitude (McLean and Lowe, 1994). Similarly, the affinity of 
this antagonist for NK1 receptors in the mouse (pA 2 = 6.06) is markedly reduced in 
comparison to the rat NK1 receptor antagonist RP 67580 (pA2 = 8.41) (Allogho et al., 
1997). Furthermore, concentrations of CP-99,994 similar to those used in the present 
study have been used to selectively block NK1 receptors in a variety of functional 
assays including: the relaxant and contractile responses to various tachykinin agonists in 
the guinea-pig trachea (Figini et al., 1996); electrically-evoked SP release in the rat 
spinal cord (Malcangio and Bowery, 1994); capsaicin-induced hyperalgesia in the rat 
knee joint (Davis and Perkins, 1996); and septide- and [Sar 9, Met(0-2) 11 ]-SP-induced 
dilatation of submucosal arterioles (Moore et al., 1997). 
In the rat hindlimb preparation, the NK2 receptor antagonist SR48968 produced 
similar effects to CP-99,994, but also enhanced the inhibition of V0 2 induced by 
micromolar concentrations of capsaicin (VN2 response), and potentiated 
vasoconstriction over the entire capsaicin concentration range (Fig 3.2). This 
potentiation of capsaicin-induced vasoconstriction indicates that endogenously released 
tachykinins, acting via NK2 receptors, may be dilators of the perfused hindlimb 
vasculature. As for CP-99,994, the apparent potency of SR 48968 for producing these 
effects on capsaicin-mediated responses appears to be reduced compared to that in in 
vitro studies (Emonds-Alt et al., 1992). However as for CP-99,994, similar 
concentrations of SR 48968 to those used in the present study have been used to inhibit 
the actions of capsaicin and NK2 receptor agonists in other tissue preparations (Lou et 
al., 1993; Huber et al., 1993; Maggi and Giuliani, 1996), while the inactive enantiomer 
for SR 48968 (SR 48965) is without effect (Maggi and Giuliani, 1996). Nonetheless, 
results obtained from the use of micromolar concentrations of these non-peptide 
antagonists should be interpreted with caution since SR 48968 has been shown to be a 
highly potent NK2 receptor antagonist with picomolar to low nanomolar affinity in 
several tissue preparations (Qian et al., 1994; Advenier, 1995; Croci et al., 1995), 
including NK2 receptor bioassays (Maggi et al., 1993c). In addition, micromolar 
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concentrations of SR 48968 exhibit local anaesthetic (Wang et al., 1994) and opioid 
receptor agonist properties (Martin et al., 1993). SR 48968 also shows sub-micromolar 
affinity for cloned human, but not rat, NK3 receptors (Chung et al., 1994), and both SR 
48968 and CP-99,994 have been shown to interact with the phenylalkamine binding site 
on L-type voltage-sensitive Ca 2+ channels (Lombet and Spedding, 1994). Nonetheless, 
the results presented in this chapter using the non-peptide tachykinin antagonists, whilst 
not conclusive, do suggest the possibility that the tachykinins and their receptors are 
involved in the responses mediated by capsaicin in perfused muscle. Further evidence 
for the involvement of these neurotransmitters was obtained by the use of tachykinin 
peptide agonists in this preparation. 
3.4.1.2. Peptide agonists 
Infusion of SP, NKA or NKB, in the presence of the neutral endopeptidase 
inhibitor phosphoramidon, induced mild, concentration-dependent vasoconstriction and 
stimulated VO2 (Fig 3.4). The use of phosphoramidon in these studies was considered 
essential as neutral endopeptidase is a prime mediator in the degradation of tachykinins 
in skeletal muscle tissue (Russell et al., 1996). In the perfused hindlimb, NKA was at 
least 10-fold more potent than SP at stimulating VO 2 and vasoconstriction (Table 3.2) 
and its activity is comparable to that in the NK2 receptor bioassay (rabbit pulmonary 
artery) described by Regoli et al. (1987). The potency of SP in the present study is at 
least 1000-fold lower than in the NK1 receptor bioassay (dog carotid artery) and more 
closely resembles its activity on NK2 receptors in the rabbit pulmonary artery (Regoli et 
al., 1987). However, the use of BSA as an essential colloid in the perfused hindlimb 
preparation may account for the apparent low potency of SP as this protein is notorious 
for binding various agents. However, assuming that peptide binding, if any, by BSA 
occurs equally for all the tachykinins, the rank order of potency for these peptides in the 
rat hindlimb preparation was NKA>NKB>SP and supports the notion of NK2 receptor 
involvement. Nonetheless, a role for NK1 receptors cannot be excluded for several 
reasons including: a) CP-99,994 was effective at partly blocking capsaicin-induced 
stimulation of V02 (Fig. 3.1); b) NKA has a strong affinity for NK1 receptors (Regoli et 
al. ,1994); and c) autoradiographic studies indicate that NK1 receptors are present in 
hindlimb skeletal muscle (soleus), possibly on blood vessels (see Appendix 1). 
Although the NK3-preferring peptide, NKB, stimulated VO2 and vasoconstriction in the 
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present study, it is unlikely that NK3 receptors play a role in the capsaicin-mediated 
effects in muscle since their peripheral distribution is limited (Mastrangelo et al., 1987; 
Guard et al., 1990). 
Taken together, these findings using neuropeptide agonists and antagonists 
provide strong evidence that stimulation of V0 2 by submicromolar concentrations of 
capsaicin is partly mediated by the endogenous release of SP and NKA which then 
stimulate V02 via an action on peripheral NK2 receptors, and possibly NK1 receptors. 
3.4.2. Role of CGRP 
CGRP, which is released in skeletal muscle in response to capsaicin (Santicioli et 
al., 1992), may act as a potent vasodilator in this preparation since the CGRP receptor 
antagonist CGRP (8 _37) greatly potentiated the capsaicin-induced vasoconstriction and 
inhibition of V0 2 (Fig 3.3). However, infused CGRP (with phosphoramidon) did not 
produce a measurable effect on basal hindlimb V0 2 and vascular tone (Fig 3.4). This 
observation is unusual since CGRP has been shown to be a potent vasodilator in many 
tissues including striated muscle (White et al., 1993; Kim et al., 1995). In addition, it 
has recently been shown that CGRP, released from capsaicin-sensitive primary 
afferents, contributes partly to the hyperaemic response to skeletal muscle contraction 
(via sciatic nerve stimulation) in the rat hindlimb (Yamada et al., 1997a; 1997b). 
However, basal hindlimb perfusion pressure in the present study probably represents 
near-maximum arteriolar dilatation since, at the flow rate used (4 ml. min -1 ), the potent 
vasodilator nitroprusside has no measurable effect on vascular tone (Colquhoun et al., 
1988; Ye et al., 1990). This may limit the scope of action of SP, NKA, NKB and/or 
CGRP and, therefore, any vasodilator action by these peptides would not be observed. 
Indeed, this possibility is examined in the studies presented in Chapter 4. 
3.4.3. The role of capsaicin-sensitive neurons 
Capsaicin possesses a well-documented ability to both stimulate and then 
desensitise peptide-containing sensory neurons (Holzer et al., 1991; Szolcsanyi, 1993; 
section 1.3.5.). Indeed capsaicin is a widely used research tool that selectively blocks 
C-type and M-type primary afferents. In the present studies, an attempt was made to 
define a role for capsaicin-sensitive neurons in the acute metabolic and vascular effects 
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of vanilloids in perfused muscle by studying the effects of systemic capsaicin 
pretreatment. 
Capsaicin pretreatment produced dramatic changes in capsaicin-induced V0 2 and 
perfusion pressure changes in the perfused hindlimb (Fig 3.5). One day after capsaicin 
pretreatment, the stimulation of V0 2 and mild increase in perfusion pressure produced 
by submicromolar concentrations of capsaicin (VNi response) was almost completely 
abolished. However, 7 days after capsaicin pretreatment, the VNI response had 
returned and the magnitude of V0 2 stimulation was identical to that of the control. The 
acute sensory neuron block described by Szolcsanyi (1993) (see section 1.3.5.1.) may 
explain the absence of the VNI response 1 day after capsaicin-pretreatment. The re-
establishment of the VNi response after 7 days may be due to a small population of 
intact C-fibres which recover from the block and release sufficient neuropeptides to 
stimulate V02. 
In contrast to the effects of capsaicin pretreatment on VN I responses, the 
inhibition of V0 2 (VN2 response) was marginally enhanced 1 day, and significantly 
enhanced 7 and 14 days after capsaicin pretreatment. A progressive increase in the 
vasoconstrictor response to capsaicin mirrored the enhancement of V02 inhibition, with 
maximum perfusion pressure to 2 jiM capsaicin infusion almost doubling 14 days after 
capsaicin pretreatment. Further analysis of the data revealed that the concentration of 
capsaicin producing a half-maximal increase in perfusion pressure (EC 50) was 
significantly (P<0.01) decreased 7 and 14 days after capsaicin pretreatment (Table 3.3). 
Why the maximum vasoconstrictor response progressively increased in capsaicin 
pretreated rats is unclear. This was an unexpected finding since capsaicin-pretreatment 
normally leads to a blunting of non-vascular, smooth muscle responses to capsaicin 
(Maggi and Meli, 1988). This observation, when combined with the decrease in ECso 
for capsaicin, suggests either up-regulation of VN2 receptors and/or sensitisation of 
vascular smooth muscle to the constrictor action of capsaicin. Alternatively, the 
apparent increased sensitivity of the vasculature to the vasoconstrictor action of 
capsaicin may be due to the absence of sufficient vasodilator peptides (eg. CGRP) to 
counteract the receptor-mediated vasoconstrictor action of the vanilloid. Indeed 
denervation of cat cerebral arteries by "cold storage" (Saito et al., 1988), or capsaicin 
pretreatment and trigemminal ganglionectomy (Edvinsson et al., 1990) attenuates 
capsaicin-induced vasodilatation but not vasoconstriction, presumably by depleting 
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vasodilator peptides from sensory neurons. Similar results have been obtained in the 
guinea-pig thoracic aorta and carotid artery after capsaicin pretreatment where 
subsequent application the vanilloid induces vasoconstriction, rather than dilatation 
(Duckles, 1986). 
A vasodilator role for endogenously released sensory peptides is not supported by 
the present findings where the infusion of SP, NKA and NKB resulted in a mild 
vasoconstrictor effect, and CGRP did not alter vascular tension. However, it remains to 
be seen whether or not SP, NKA and CGRP can vasodilate in the constant flow perfused 
hindlimb under vascular tension using a strong vasoconstrictor (eg. noradrenalin, 
serotonin, angiotensin II). The data presented in Chapter 4 explores this possibility. 
Effects of Neuropeptides under NOR-Induced Vascular Tension 	 73 
Chapter 4 
Effect of the Sensory Neuropeptides on the Perfused Rat Hindlimb 
Vascular Bed Preconstricted with Noradrenalin. 
4.1 Introduction 
In the results shown in Chapter 3, CGRP was without effect in the perfused rat 
hindlimb under basal conditions, an observation that was possibly due to the reduced 
basal vascular tone in the constant-flow preparation. Indeed, CGRP is renowned for its 
potent vasodilator effect, particularly with respect to its role in cutaneous neurogenic 
inflammation where the peptide is a prime mediator of vasodilatation in response to 
sensory nerve stimulation (reviewed by Brain, 1996; Holzer, 1998). In addition, CGRP 
has been shown to play an important role in inflammatory responses in the knee joint of 
the rat (Cambridge and Brain, 1992) and rabbit (Ferrell et al., 1997) where it induces 
strong local vasodilatation that is attenuated by the CGRP antagonist CGRP(8-37) 
(McMurdo et al., 1997), and may also act synergistically with other mediators to 
increase plasma extravasation (Cambridge and Brain, 1992). The ability of CGRP to 
relax blood vessels from a variety of species in various tissues, both in vitro and in situ, 
is further testament to the vasodilatory action of this peptide (reviewed by Poyner, 1992; 
Bell and McDermott, 1996). Furthermore, the in vivo administration of low doses of 
CGRP (0.1-10 nmol . i.v.) in the rat causes a reduction in mean arterial blood 
pressure, increased heart rate and cardiac output, and decreased resistance in the 
vascular beds of the kidney, mesentery and hindquarter (Siren and Feuerstein, 1988). 
Of particular interest to the present study is the latter observation by Siren and 
Feurerstein (1988) which demonstrates the ability of CGRP to induce dilatation in a 
skeletal muscle vascular bed. Indeed others have shown a similar response to CGRP in 
skeletal muscle tissue (White et al., 1993; Kim et al., 1995; Didion and Mayhan, 1997), 
including that of the rat hindlimb (Yamada et al., 1997a; 1997b). 
Under conditions of reduced basal vascular tone, the tachykinins SP, NKA and 
NKB are mild vasoconstrictors in the perfused rat hindlimb and induce a concomitant 
increase in muscle oxygen consumption (Chapter 3, Fig. 3.4). SP, NKA and NKB 
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display similar effects on vascular tone in rabbit isolated pulmonary artery segments 
where, in the absence of endothelium, these peptides induce concentration-dependent 
vasoconstriction by the stimulation of tachykinin (possibly NK2) receptors on vascular 
smooth muscle (D'Orleans-Juste et al., 1985). A more recent study by Shirahase et al. 
(1995) further supports the involvement of smooth muscle NK2 receptors where the 
endothelium-independent constriction of isolated rabbit pulmonary artery by 
submicromolar concentrations of SP was inhibited by SR 48968, but not by the NK1 
antagonists CP-96,345, CP-99,994, and SR-140,333. Interestingly, these authors also 
showed endothelium-dependent constriction of these vessels by nanomolar 
concentrations of SP acting via NK1 receptors. Similarly, an NK1-mediated 
vasoconstrictor action in response to tachykinins has been reported in the rabbit jugular 
vein (Nantel et al., 1990). Hence, vasoconstriction by these peptides is not strictly 
limited to the stimulation of smooth muscle tachykinin (NK2) receptors. 
The studies presented in Chapter 3, where the hindlimb preparation was 
essentially fully dilated, further support the notion of tachykinin-induced 
vasoconstriction by the stimulation of smooth muscle NK2 receptors, since the rank 
order of potency for the tachykinins in these experiments was NKA>NKB>SP. 
However, the tachykinins, most notably SP, are better known for their potent vasodilator 
action via the stimulation of NK1 receptors on the endothelium (Regoli et al., 1987; 
Couture et al., 1989; Stewart-Lee and Burnstock, 1989; Delay-Goyet et al., 1992). 
Similar observations have been made in skeletal muscle preparations in the rat (Brock 
and Joshua, 1991; Huang and Koller, 1996), rabbit (Persson et al., 1991; Gustafsson et 
al., 1994), hamster (Hall and Brain, 1994) and human (Casino et al., 1995; Newby et 
al., 1997b). 
Given the strong vasodilator nature of CGRP and the tachykinins in skeletal 
muscle and other preparations (see above), and since the tachykinins are able to 
vasoconstrict via stimulation of endothelial NK1 or smooth muscle NK2 receptors, the 
aim of the present chapter was to examine the effect of these peptides in the perfused rat 
hindlimb under near-physiological vascular tone. Increased vascular tone was achieved 
by the use of the vasoconstrictors noradrenalin (NOR) or 5-hydroxytryptamine 
(serotonin, 5-HT), the actions of which have been well characterised in this preparation 
(reviewed by Clark et al., 1995; 1997). These experiments were designed to add to the 
current knowledge of neuropeptide action in the unstimulated perfused rat hindlimb 
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where they either vasoconstrict (with an increase in V0 2) or do little to alter vascular 
tone (see Chapter 3, Fig. 3.4). In addition, an attempt was made to assess the 
involvement of nitric oxide (NO) production, by nitric oxide synthase (NOS), in the 
vasodilator responses to neuropeptides. This was achieved by the infusion of CGRP, SP 
and MCA in the presence of Nw-nitro-L-arginine methyl ester (L-NAME), a known 
NOS inhibitor (Rees et al., 1990), in the perfused hindlimb preparation stimulated with 
NOR. The ability of this inhibitor to block NO production was assessed by co-infusing 
it with the NO-dependent vasodilator carbamyl choline (carbachol or CCh). 
Furthermore, the effect of low and high concentrations of capsaicin were examined in 
this preparation under NOR-induced vascular tone to determine the actions of this 
sensory nerve stimulant under near-physiological pressures. 
4.2. Methods 
4.2.1. Rat hindlimb perfusion. 
Animals were anaesthetised with pentobarbitone sodium (60 mg/kg) and their left 
hindlimbs perfused according to the method described previously (section 2.2.1, 
Ruderman et al., 1971; Colquhoun et al., 1988). Hindlimb vascular tone (perfusion 
pressure) was increased by the infusing 0.6 11M NOR or 0.8 1.1M 5-HT after basal steady 
state conditions were attained (approximately 30 minutes). The infusion of other agents 
did not commence until steady state vasoconstrictor-stimulated V02 and perfusion 
pressure were reached. 
4.2.2. Materials 
Substance P, neurokinin A, and calcitonin gene-related peptide were purchased 
from Auspep (Australia); capsaicin, carbamyl choline (carbachol or CCh), 5- 
hydroxytryptamine (serotonin or 5-HT), Nw-nitro-L-arginine methyl ester (L-NAME), 
noradrenalin (NOR), Sigmacote ® and phosphoramidon from the Sigma Chemical 
Company; bovine serum albumin (Fraction V) from Boehringer Mannheim (Australia), 
pentobarbitone sodium (Nembutal, 60 mg/ml) from Bomac Laboratories (Australia), 
and heparin sodium (5000 IU.m1-1 ) from David Bull Laboratories (Australia). All other 
reagents were of analytical grade. 
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Tachykinins were dissolved into 20 lil aliquots using a 0.01 M acetic acid 
solution containing 1% P-mercaptoethanol and stored at -20°C to maintain chemical 
stability. The aliquots were then diluted, as needed, with 0.9% NaC1 so that the acetate 
and P-mercaptoethanol concentrations were negligible. Due to the lipophilic nature of 
capsaicin, it was dissolved in 50% ethanol; thus care was taken to keep the infusion 
rates low (usually below 10 [tl/min) to avoid vehicle-induced effects. All other agents 
were dissolved in normal saline (0.9% w/v). 
4.2.3 Agent infusion 
Infusion of all agents occurred by the use of methods and equipment described in 
sections 2.2.4 and 3.2.3. In perfusions using SP, NKA or CGRP, all glassware in 
contact with these peptides was thoroughly cleaned with a strong alkaline solution (1M 
NaOH), rinsed and silanised with Sigmacote ® (prior to infusion) to prevent peptide 
adhesion to glass surfaces. 
4.2.3.1. Neuropeptide experiments 
For experiments with the neuropeptides, NOR (0.6 tiM) or 5-HT (0.8 1.1M) were 
first infused during steady state basal venous P02 (and therefore V02) and perfusion 
pressure. After the establishment of a new steady state V0 2 and vascular tone, the 
neutral endopeptidase inhibitor phosphoramidon (5 1.tM) was co-infused with either 
vasoconstrictor. In experiments using NOR, phosphoramidon caused mild dilatation 
that was overcome by increasing the NOR concentration to 0.8 i.tM. Either SP (50 nM), 
NKA (20 nM) or CGRP (20 nM) were then infused until steady state conditions were 
again observed. In separate experiments, L-NAME (10 j.tM) was infused after 
phosphoramidon. The protocol was otherwise identical to the control experiments 
described above in the absence of L-NAME. 
4.2.3.2. Carbachol experiments 
For experiments using CCh, NOR (0.6 tiM) was first infused and new steady state 
V02 and perfusion pressure were attained. A submicromolar concentration of CCh (0.5 
tiM) was co-infused with NOR for at least 20-30 minutes to fully observe the effects of 
this acetylcholine mimetic. All drugs were then removed, and the hindlimb preparation 
was allowed to recover to basal V02 and perfusion pressure. In the same experiment, 
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the above protocol was repeated with the addition of L-NAME (10 ilM) prior to the 
infusion of CCh to observe any effects that the NOS inhibitor alone may have on NOR-
induced V02 and perfusion pressure changes. CCh was infused for at least 45 minutes 
to observe its overall effect in the presence of L-NAME. 
4.2.3.3. Capsaicin experiments 
In the experiments with capsaicin a similar protocol to those with CCh was used 
in that NOR (0.6 gM) was first infused followed by capsaicin after the achievement of 
NOR-stimulated steady state VO2 and perfusion pressure. A low concentration of 
capsaicin (50 nM) was co-infused with NOR, followed by the testing of a higher 
capsaicin concentration (0.5 iiM). Both capsaicin concentrations were infused until the 
re-establishment of steady state VO 2 and perfusion pressure. 
4.3.4. Data analysis 
Statistical analysis was performed using Student's t-test, one-way analysis of 
variance (ANOVA) or ANOVA on ranks (Kruskal-Wallis analysis), or by one-way 
repeated measures ANOVA or one-way repeated measures ANOVA on ranks (Friedman 
analysis), where applicable. All ANOVAs were subjected to Student-Newman-Keuls 
multiple comparisons. P<0.05 was considered statistically significant. 
4.3 Results 
For all data presented in this chapter, the basal VO 2 and perfusion pressure values, 
as well as those for all concentrations of NOR and 5-HT, are presented in Table 4.1. 
The concentrations of NOR and 5-HT used (0.6-0.8 p,M) were chosen to give 
approximately physiological hindlimb perfusion pressure values under steady state 
conditions (90-120 mm Hg). These vasoconstrictors also induced a concomitant 
stimulation (NOR) or reduction (5-HT) in hindlimb V02 similar to that seen previously 
in this preparation (reviewed by Clark et al., 1995; 1997). 
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TABLE 4.1. Basal and serotonin (5-HT)- or noradrenalin (NOR)-stimulated oxygen 
consumption (V02) and perfusion pressure (PP) in the perfused rat hindlimb. 
Parameter n V02 	g. -1 111 ) 	PP (mm Hg) 
Basal 37 9.22 ± 0.10 28.49 ± 0.50 
0.6 uM NOR 27 12.76 ± 0.10 94.30 ± 2.65 
0.8 uM NOR + 5 uM 
phosphoramidon 
25 12.86 ± 0.10 95.00 ± 2.39 
0.8 uM 5-HT 4 5.55 ± 0.19 106.50 ± 6.40 
All values are mean ± s.e. mean steady state V02 or PP. 
4.3.1. Effect of calcitonin gene-related peptide (CGRP) in serotonin (5-HT)-stimulated 
perfused hindlimb. 
The infusion of 5-HT (0.8 uM) into the perfused rat hindlimb induced a 
characteristic inhibition of V02 (AV02, -2.85±0.27 umol. g. -1 II I ) coupled with strong 
vasoconstriction (APP, 75.8±7.0 mm Hg) (Fig. 4.1). The subsequent infusion of the 
neutral endopeptidase inhibitor phosphoramidon (5 uM) did not have a statistically 
significant (P>0.05, Table 4.2) effect on either 5-HT-induced V02 or vascular effects 
(AV02, -2.73±0.27 tmol. g. -1 11-1 ; APP, 74.3 ± 8.4 mm Hg). 
The co-infusion of CGRP (20 nM) with 5-HT and phosphoramidon caused a small 
reversal of 5-HT-induced inhibition of V02 (AV02, -2.35±0.15 p.mol. g. -1 11 1 ) and mild 
dilatation (APP, 59.8 ± 9.6 mm Hg). The V02 and vascular changes induced by CGRP 
were reproducible and showed statistical significance by repeated measures ANOVA 
and Student-Newman-Keuls comparisons (P<0.05, Table 4.2). 
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TABLE 4.2. One-way repeated measures analysis of variance (ANOVA) and 
pairwise multiple comparisons (Student-Newman-Keuls method) of the data 
presented in Fig. 4.1 for CGRP-induced changes in oxygen consumption (AV02), 
and perfusion pressure (APP). 
Test 	 AVO2 	 APP 
ANOVA P value 	 0.047 	 0.003 
F statistic 	 5.33 	 18.14 
1 S-N-K comparisons: 
5-HT vs. phosphoramidon 	 ns 	 ns 
5-HT vs. CGRP 
5-HT + phos vs. CGRP 	 ns 
i Student-Newman-Keuls P value significant at P<0.05, * = significant, ns = not significant. 
4.3.2 Effects of calcitonin gene-related peptide (CGRP) in noradrenalin (NOR)-
stimulated perfused hindlimb 
4.3.2.1. Time course for CGRP-induced effects 
The infusion of NOR (0.6 [tM) into the perfused rat hindlimb preparation results 
in a rapid decrease in venous P02 (increase in hindlimb V02) and a concomitant 
increase in arterial perfusion pressure (indicative of vasoconstriction) (Fig. 4.2A, B). 
Both venous P02 and perfusion pressure reached steady state before the infusion of 
phosphoramidon (5 11M) which did little to alter the NOR-induced venous PO2 change, 
but induced mild dilatation (decrease in perfusion pressure). The infusion of CGRP (20 
nM), in the presence of NOR and phosphoramidon, caused strong dilatation that was 
sustained until the removal of the peptide (Fig. 4.2B). In addition, the reduction in 
venous P02 produced by NOR was partly reversed by CGRP, and this effect was also 
sustained for the duration of the peptide infusion (Fig. 4.2A). The infusion of CGRP 
concentrations greater than 20 nM did not cause stronger dilatation or reversal of NOR-
induced venous PO2 (V02) effects, while picomolar concentrations did little to NOR-
induced effects (data not shown). Hence 20 nM CGRP was considered to be a near-
maximal effective concentration. 
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Fig. 4.2. Typical tracing of the actions of 20 nM calcitonin gene-related peptide 
(CGRP) and phosphoramidon (phos) on venous partial pressure of oxygen (P02) 
(panel A) and arterial perfusion pressure (panel B), in the perfused rat hindlimb 
stimulated with noradrenalin (NOR). 
4.3.2.2. CGRP-induced effects and the importance of nitric oxide formation 
A submicromolar concentration of NOR (0.6 [IM) stimulated basal hindlimb V02 
(AV02, 3.45 ± 0.13 limol. g. -1 h-1 , Fig. 4.3A) and produced a marked increase in 
perfusion pressure (APP, 59.5 ± 3.8 mm Hg, Fig. 4.3C). In contrast to the data obtained 
using 5-HT as the vasoconstrictor, the infusion of phosphoramidon (also 5 iiM) caused a 
small but statistically significant dilatation (P<0.05, Table 4.3), but had no apparent 
effect on NOR-induced stimulation of V02 (AV02, 3.33 ± 0.21 gmol. g. -1 11 1 ; APP, 
44.3 ± 2.7 mm Hg Figs. 4.2 and 4.3A, C). Due to the unexpected vascular effects of 
phosphoramidon, the concentration of NOR was increased to 0.8 RA4 to restore 
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perfusion pressure (APP, 57.8 ± 2.8 mm Hg), with no change in V0 2 (AV02, 3.33 ± 
0.21 gmol. 	W I , Fig. 4.2 and 4.3). 
The subsequent infusion of CGRP (20 nM) caused a significant (P<0.05, Table 
4.3) reversal of the NOR-induced perfusion pressure increase, indicative of 
vasodilatation (APP, 27.0 ± 1.1 mm Hg, Fig. 4.3C), and reversed NOR-induced 
stimulation of V02 (AV02, 2.23 ± 0.28 gmol. V I , Fig. 4.3A). 
In a separate set of perfusions, the above protocol was repeated but with the 
addition of the nitric oxide synthase inhibitor L-NAME (10 gM). Again, the infusion of 
NOR (0.6 gM) induced strong stimulation of VO2 (AV02, 3.40 ± 0.20 gmol. 
Fig. 4.3B) and increased perfusion pressure (APP, 63.0 ± 1.0 mm Hg). However, in this 
set of experiments the co-infusion of phosphoramidon (also 5 gM) did not significantly 
(P>0.05, Table 4.3) alter vascular tone (APP, 61.5 ± 2.5 mm Hg) (Fig. 4.3D). The 
infusion of L-NAME, for approximately 10 minutes prior to the infusion of CGRP, had 
no apparent effect on NOR-induced VO2 or perfusion pressure changes (P>0.05, Table 
4.3; data not shown in Fig 4.3). Due to the apparent lack of dilatation by 
phosphoramidon, increasing the concentration of NOR to 0.8 gM raised the perfusion 
pressure above that seen with the infusion of 0.6 gM NOR (APP, 82.0 ± 6.4 mm Hg, 
Fig. 4.3D), but did little to further alter V02 (AV02, 3.33 ± 0.16 gmol. 	11-1 , Fig. 
4.3B). The infusion of CGRP (20 nM) into the perfused hindlimb preparation caused a 
significant (P<0.05, Table 4.3) reversal of NOR-induced V02 effects (AV02, 2.13 ± 
0.38 gmol. g." 1 V I , Fig. 4.3B) and strong vasodilatation (APP, 32.5 ± 1.8 mm Hg, Fig. 
4.3D), very similar to that seen in the absence of L-NAME (Fig. 4.3A, C). 
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Fig. 4.3. Effect of calcitonin gene-related peptide (CGRP) and phosphoramidon 
(phos) on noradrenalin (NOR)-induced oxygen consumption (top panels) and 
perfusion pressure (bottom panels) changes in the perfused rat hindlimb (n = 4). 
Responses to CGRP were examined in the absence (panels A and C) and presence 
(panels B and D) of the nitric oxide synthase inhibitor No-nitro-L-arginine methyl 
ester (L-NAME). Statistical analysis of the data by one-way repeated measures 
ANOVA and pairwise comparisons (Student-Newman-Keuls method) is presented 
in Table 4.3. 
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TABLE 4.3. One-way repeated measures analysis of variance (ANOVA) and 
pairwise multiple comparisons (Student-Newman-Keuls method) of the data 
presented in Fig. 4.3 for CGRP-induced changes in oxygen consumption (AV02), 
and perfusion pressure (APP) in the absence and presence of L-NAME. 
Test Figure AVO2 APP 
I ANOVA P value 4.3A, C <0.001 <0.001 
F statistic 4.3A, C 65.64 58.54 
I ANOVA P value 4.3B, D 0.002 <0.001 
F statistic 4.3B, D 8.24 27.79 
2S-N-K comparisons: 
3NOR vs. NOR + phos 4.3A, C ns * 
4NOR + phos vs. CGRP + NOR + phos 4.3A, C * * 
3NOR vs. NOR + phos 4.3B, D ns ns 
3NOR + phos vs. L-NAME + NOR + phos ns ns 
4NOR + phos + L-NAME vs. CGRP + 	4.3B, D * * 
NOR + phos + L-NAME 
'ANOVA P value significant at P<0.05 
2Student-Newman-Keuls P value significant at P<0.05, * = significant, ns = not significant. 
3NOR concentration = 0.6 p1S1 
4NOR concentration = 0.8 11M 
4.3.3 Effect of substance P (SP) in noradrenalin-stimulated perfused hindlimb 
4.3.3.1. Time course for SP-induced effects 
Due to the mild CGRP-induced dilatation in the 5-HT-stimulated perfused 
hindlimb, and the strong dilatation by this peptide in NOR-stimulated hindlimb, it was 
decided that the latter vasoconstrictor was more appropriate for providing the necessary 
vascular tone to examine the actions of other neuropeptides in this preparation. Hence, 
Figure 4.4 shows a typical tracing for the effects of SP on VO2 and perfusion pressure 
changes induced by NOR in a single hindlimb perfusion experiment. As for some 
experiments with CGRP, the infusion of phosphoramidon caused mild vasodilatation 
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4.3.3.2. SP-induced effects and the importance of nitric oxide formation 
In several repeat experiments of the data shown in Figure 4.4, NOR (0.6 gM) 
stimulated basal hindlimb V02 (AV02, 3.44 ± 0.19 prnol. g. -1 II-1 , Fig. 4.5A) and raised 
perfusion pressure (APP, 61.4 ± 3.3 mm Hg, Fig. 4.5C) in a manner very similar to the 
data presented in section 4.3.2.1. Again, phosphoramidon (5 gM) did not alter NOR-
induced V02 changes, but caused mild dilatation (APP, 50.8 ± 3.4 mm Hg) that was 
overcome by increasing the concentration of NOR to 0.8 pM (AV02, 3.38 ± 0.22 gmol. 
g. -1 h-1 ; APP, 62.4 ± 4.1 mm Hg). The subsequent infusion of SP (50 nM) significantly 
(P<0.05, Table 4.4) reversed NOR-induced stimulation of VO2 (peak AV02, 2.56 ± 0.25 
prnol. g. -1 11 1 ) and dilated the hindlimb vasculature (peak APP, 36.0 ± 2.1 mm Hg). 
However, these effects were not sustained throughout the duration of SP infusion and 
gradually returned to the steady state V02 and perfusion pressure values seen before 
peptide infusion (AV0 2 , 3.28 ± 0.16 pmol. g. 1 11-1 ; APP, 60.0 ± 4.2 mm Hg). 
Repetition of the experiments just described in the presence of L-NAME (10 gM) 
yielded similar, but not identical results (Fig. 4.5B, D). Again, the NOR-induced 
perfusion pressure (APP, 54.0 ± 2.7 mm Hg, Fig. 4.5D), but not V0 2 (AV02, 3.55 ± 
0.16 gmol. g. -1 h-1 , Fig. 4.5B), changes were significantly (P<0.05, Table 4.4) altered by 
phosphoramidon (AV0 2 , 3.53 ± 0.13 gmol. g. -1 11 1 ; APP, 46.5 ± 3.1 mm Hg). The co-
infusion of L-NAME with phosphoramidon and NOR did not further alter VO2 or 
perfusion pressure (AV02, 3.45 ± 0.16 pmol. g. -1 h-1 ; APP, 46.0 ± 3.3 mm Hg). A 
higher concentration of NOR (0.8 pM) was again used to restore vascular tension, but 
had no greater effect on V02 (AV02, 3.48 ± 0.16 pmol. g. -. 1 11 1 ; APP, 60.3 ± 3.6 mm 
Hg). The subsequent infusion of SP (50 nM) induced a statistically significant (P<0.05, 
Table 4.4) peak reversal of NOR-induced VO2 and perfusion pressure changes very 
similar to that seen in the absence of L-NAME (peak AV02, 2.8 ± 0.04 lAmol. g. -1 h-1 ; 
peak APP, 35.8 ± 1.3 mm Hg). Similar to previous experiments, the effect of SP on 
V02 was not sustained (AV02, 3.28 ± 0.08 pmol. g. -1 h-1 ), nor was that on perfusion 
pressure which, interestingly, plateaued at a level above that seen with the infusion of 
NOR (0.8 gM), phosphoramidon and L-NAME alone (APP, 69.5 ± 5.9 mm Hg). This 
increase in steady state perfusion pressure by SP in the presence of L-NAME, from that 
induced by 0.8 gM NOR, was statistically significant by repeated measures analysis of 
variance and subsequent Student-Newman-Keuls analysis (P<0.05, Table 4.4). 
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Fig. 4.5. Effect of substance P (SP) and phosphoramidon (phos) on noradrenalin 
(NOR)-induced oxygen consumption (top panels) and perfusion pressure (bottom 
panels) changes in the perfused rat hindlimb (n = 4-5). Responses to SP were 
examined in the absence (panels A and C) and presence (panels B and D) of the 
nitric oxide synthase inhibitor Noo-nitro-L-arginine methyl ester (L-NAME). 
Statistical analysis of the data by one-way repeated measures ANOVA and 
pairwise comparisons (Student-Newman-Keuls method) is presented in Table 4.4. 
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TABLE 4.4. One-way repeated measures analysis of variance (ANOVA) and 
pairwise multiple comparisons (Student-Newman-Keuls method) of the data 
presented in Fig. 4.5 for SP-induced changes in oxygen consumption (AV02), and 
perfusion pressure (APP) in the absence and presence of L-NAME. 
Test Figure AVO2 APP 
l ANOVA P value 4.5A, C <0.001 <0.001 
F statistic 4.5A, C 29.41 23.36 
l ANOVA P value 4.5B, D <0.001 <0.001 
F statistic 4.5B, D 14.50 28.02 
2S-N-K comparisons: 
3NOR vs. NOR + phos 4.5A, C ns * 
4NOR + phos vs. SP (peak) + NOR + phos 4.5A, C * * 
4NOR vs. SP (steady state)+ NOR + phos 4.5A, C ns ns 
3NOR vs. NOR + phos 4.5B, D ns * 
3NOR + phos vs. L-NAME + NOR + phos ns ns 
4NOR + L-NAME + phos vs. SP (peak) + 4.5B, D * * 
NOR + L-NAME + phos 
4NOR + L-NAME + phos vs. SP (steady 4.5B, D ns * 
state)+ NOR + L-NAME + phos 
lANOVA P value significant at P<0.05 
2Student-Newman-Keuls P value significant at P<0.05, * = significant, ns = not significant. 
3NOR concentration = 0.6 ftM 
4NOR concentration = 0.8 tiM 
4.3.4 Effect of neurokinin A (NKA) in noradrenalin-stimulated perfused hindlimb 
4.3.4.1. Time course for NKA -induced effects 
A typical tracing of the effects of NKA in a single perfused hindlimb experiment 
is presented in Figure 4.6. A low concentration of NKA (20 nM) caused alteration of 
the NOR-induced V02 and perfusion pressure responses, similar to the effects seen with 
SP. As for SP and CGRP, the concentration of NKA chosen was maximally effective 
since higher concentrations did not induce further changes. NKA transiently reversed 
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Fig. 4.6. Typical tracing of the peak and steady state actions of 20 nM neurokinin 
A (NKA) on venous partial pressure of oxygen (P02) (panel A) and arterial 
perfusion pressure (panel B), under noradrenalin (NOR) stimulation, in the 
perfused rat hindlimb. 
the reduction in venous PO2 (stimulation of V0 2) by NOR (Fig. 4.6A), and produced a 
strong peak vasodilator response that, unlike SP, eventually reached steady state at a 
perfusion pressure below that seen with 0.8 piM NOR and phosphoramidon alone (Fig. 
4.7B). The removal of NKA and phosphoramidon, but not NOR, resulted in a rapid 
increase in perfusion pressure, while venous P0 2 remained relatively constant. 
4.3.4.2. NKA -induced effects and the importance of nitric oxide formation 
Repeat experiments examining the effects of NKA in NOR-stimulated perfused 
hindlimb confirmed the preliminary experiment described above (Fig. 4.7A, C). Once 
again, the infusion of 0.6 1.1M NOR stimulated hindlimb VO 2 (AV02, 3.53 ± 0.11 gmol. 
g. -1 h-1 ) and increased arterial perfusion pressure (APP, 68.0 ± 5.2 mm Hg), with the 
pressure, but not V02, being reduced by the subsequent infusion of phosphoramidon 
(AV02, 3.53 ± 0.16 umol. g. -1 h-1 ; APP, 56.5 ± 5.1 mm Hg). These data are not shown 
in Fig 4.7 due to alterations in the protocol (using L-NAME). Perfusion pressure was 
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again restored by increasing the NOR concentration (0.8 gM NOR: AV02, 3.48 ± 0.13 
-I gmol. g.-1 n; APP, 70.5 ± 7.0 mm Hg, Fig. 4.7). A low concentration of NKA (20 nM) 
partly reversed the NOR-induced stimulation of VO2 (peak AV02 , 2.73 ± 0.14 gmol. g: 
1 11 1 , Fig. 4.7A), and induced a strong, statistically significant (P<0.05, Table 4.5) peak 
vasodilatation (peak APP, 39.3 ± 5.3 mm Hg, Fig. 4.7C). However, under continued 
NKA infusion, the VO2 response returned to previous NOR-stimulated levels (AV02, 
3.33 ± 0.14 gmol. g. -1 h-1 ) and perfusion pressure partly recovered to, though still 
remained below, the previous NOR-stimulated pressure (APP, 59.5 ± 5.0 mm Hg, Fig 
4.7C). 
The experiments with NKA in the presence of L-NAME were simplified by 
altering the infusion protocol to begin with the infusion of 0.8 gM NOR and 5 gM 
phosphoramidon, eliminating the initial concentration of NOR (0.6 gM) (Fig. 4.7B, D). 
This maximised the use of the peptidase inhibitor for its intended purpose, to preserve 
NKA during its infusion. The improved protocol was not adopted in previous 
experiments as it was necessary to confirm the vasodilatory effect of phosphoramidon, 
given the ambiguity of the response to this inhibitor in the experiments with CGRP and 
L-NAME. The minor alteration to the protocol yielded very similar V02 and perfusion 
pressure responses to 0.8 gM NOR, in the presence of phosphoramidon, to those seen in 
the previous experiments without L-NAME (AV02, 3.35 ± 0.16 gmol. g. -1 h-1 ; APP, 
71.8 ± 5.6 mm Hg). The infusion of L-NAME (10 gM) did not cause any apparent 
alteration in these VO2 and pressure values (AV02, 3.35 ± 0.16 gmol. g. -1 h-1 ; APP, 72.5 
± 5.8 mm Hg, P>0.05, Table 4.5). Unlike the data in the absence of L-NAME (Fig. 
4.7A), the infusion of NKA into the preparation in the presence of L-NAME did not 
induce a peak reversal of the stimulation of V02 by NOR (AV02, 3.18 ± 0.27 gmol. g. -1 
11 1 ), nor was there an observed change in VO 2 by NKA under steady state conditions 
(AV02, 3.38 ± 0.17 gmol. g. -1 111 , Fig. 4.7B). This was confirmed by the lack of 
statistical significance in both repeated measures ANOVA, and subsequent post-hoc 
tests of the data (Table 4.5). 
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Control 
	
+ L-NANE 
= 0.8"A1 NOR+5011 phos 
Fra 0.8 livi NOR+5pM Ors 
+ 20 nM 1st% (peak) 
ISM as pm NCR+51.INI phos 
+ 20 nM WA (steady state) 
NCR+5pM phos 
+10.M LAME 
ma 0.8M NOR+5pM phos+101.1V1 
L-NNVE + 23 nM WA (peak) 
ESSS1 0.131A1 NOR+5pM phcs+10pM 
UWE + 20 nM NKA (steaciy state) 
Fig. 4.7. Effect of neurokinin A (NKA)' and phosphoramidon (phos) on 
noradrenalin (NOR)-induced oxygen consumption (top panels) and perfusion 
pressure (bottom panels) changes in the perfused rat hindlimb (n = 4). Responses 
to NKA were examined in the absence (panels A and C) and presence (panels B 
and D) of the nitric oxide synthase inhibitor Nw-nitro-L-arginine methyl ester (L-
NAME). Statistical analysis of the data by one-way repeated measures ANOVA 
and pairwise comparisons (Student-Newman-Keuls method) is presented in Table 
4.5. 
Effects of Neuropeptides under NOR-Induced Vascular Tension 	 92 
TABLE 4.5. One-way repeated measures analysis of variance (ANOVA) and 
pairwise multiple comparisons (Student-Newman-Keuls method) of the data 
presented in Fig. 4.7 for NKA-induced changes in oxygen consumption (AV02), 
and perfusion pressure (APP) in the absence and presence of L-NAME. 
Test 	 Figure 	AVO2 	APP 
1 ANOVA P value 	 4.7A, C 	<0.001 	<0.001 
F statistic 	 4.7A, C 	69.30 	61.57 
I ANOVA P value 	 4.7B, D 	0.247 	<0.001 
F statistic 	 4.7B, D 	1.56 	16.50 
2S-N-K comparisons: 
3NOR + phos vs. NKA (peak) + NOR + phos 	4.7A, C 
3NOR + phos vs. NKA (steady state) + NOR + 4.7A, C 	ns 
phos 
3NOR + phos vs. L-NAME + NOR + phos 	4.7B, D 	ns 	ns 
3NOR + phos + L-NAME vs. NKA (peak) + NOR 4.7B, D 	ns 
+ phos + L-NAME 
3NOR + phos + L-NAME vs. NKA (steady state) + 4.7B, D 	ns 
NOR + phos + L-NAME 
'ANOVA P value significant at P<0.05 
2Student-Newman-Keuls P value significant at P<0.05, * = significant, ns = not significant. 
NOR concentration = 0.8 AM 
Conversely, NKA did cause a peak dilatation in the presence of L-NAME (APP, 
54.5 ± 5.98 mm Hg, Fig., 4.7D) that achieved statistical significance (P<0.05, Table 
4.5). However, this reduction in NOR-induced pressure was calculated to be 42% less 
than the peak NKA-induced dilatation in the absence of L-NAME. In addition, steady 
state perfusion pressure in the presence of NOR, NKA and L-NAME was significantly 
(P<0.05, Table 4.5) greater than that induced by NOR in the absence of the peptide 
(APP, 96.3 ± 9.7 mm Hg, Fig. 4.7D). Hence in the presence of the NOS inhibitor, NKA 
caused steady state vasoconstriction, rather than dilatation. 
oxide synthase inhibitor L-NAME (10 AM) was examined. 
then repeated in the presence of L-N 
B), under noradrenalin (NOR) stimulation, in the perfused rat hindlimb. 
E (10 1.1M) to inhibit NO formation. The repeat 
unstimulated (basal) steady state levels. The protocol of NOR and CCh infusion was 
infusion of NOR caused an almost identical steady state decrease in venous P02 and  
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4.3.5.1. Time course for the actions of carbachol  
The actions of the NO-dependent vasodilator CCh (0.5 iiM) in a perfused  
4.3.5. Carbachol-induced effects in noradrenalin-stimulated perfused hindlimb 
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increase in perfusion pressure. The absence of a peak decrease in venous P02 during 
the second NOR infusion is probably due to the lack of erythrocyte wash-out from 
previously underperfused regions of the muscle, seen only in the initial NOR infusion. 
The temporary presence of erythrocytes in the venous outflow would undoubtedly cause 
a transient decrease the amount of oxygen dissolved, and therefore detected, in the 
extracellular perfusate. The co-infusion of L-NAME with NOR into the preparation did 
not produce detectable changes in either venous P02 or perfusion pressure. The 
addition of CCh in the presence of NOR and L-NAME caused distinctly different 
changes in venous P02 and pressure to those seen in the first infusion without L-NAME 
present. CCh stimulated a transient reversal of the NOR-induced decrease in venous 
P02 that, unlike its effect in the absence of L-NAME, reached a steady state value 
below that seen with NOR alone. Similarly, peak dilatation by CCh was still evident in 
the presence of L-NAME, however this dilatation was not sustained and perfusion 
pressure gradually increased to a level above that induced by NOR alone, resulting in 
increased vascular tone. 
4.3.5.2. Sensitivity of carbachol-induced dilatation to L-NAME 
Figure 4.9 shows the results of several experiments using a protocol identical to 
that seen in Figure 4.8. As for previous experiments, NOR (0.6 ptM) stimulated 
hindlimb V02 (AV02, 3.38 ± 0.09 gmol. Fig. 4.8A) and markedly increased 
perfusion pressure (APP, 89.3 ± 2.8 mm Hg, Fig. 4.8B). The infusion of CCh (0.5 piM) 
elicited a peak reversal of NOR-induced V0 2 (AV02 , 1.85 ± 0.15 grnol. g." 1 that 
eventually reached steady state (AV0 2, 2.9 ± 0.16 ptmol. g." 1 1 ), both of which were 
statistically significant from NOR-induced VO2 change (P<0.05, Table 4.6). CCh also 
stimulated a sustained, statistically significant (P<0.05, Table 4.6) decrease in hindlimb 
vasculature tension (i.e. dilatation) (APP, 34.0 ± 2.0 mm Hg) compared to the increased 
pressure during NOR infusion. 
After the return to steady state basal V02 and perfusion pressure, a repeat infusion 
of NOR stimulated V0 2 and increased perfusion pressure in an almost identical manner 
to the first NOR infusion (AV02, 3.45 ± 0.07 jimol. g." 1 11 1 ; APP, 92.0 ± 5.7 mm Hg). 
The infusion of L-NAME (10 ptM) did not significantly (P>0.05, Table 4.6) alter any of 
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Control 
	 + L-NAME 
0.6 pM NOR + 
0.5 pM CCh (peak) 
0.6 pM NOR + 0.5 pM 
CCh (steady state) 
7 A 0.6 pM NOR + 10 pM L-NAME 
0.5 pM CCh (peak) 
0.6 pM NOR + 10 pM L-NAME 
+ 0.5 pM CCh (steady state) 
\ N 
Fig. 4.9. Effect of carbamyl choline (carbachol, CCh) on noradrenalin (NOR)-
induced oxygen consumption (panel A) and perfusion pressure (panel B) changes 
in the perfused rat hindlimb (n = 4). Statistical analysis of the data by one-way 
repeated measures ANOVA and pairwise comparisons (Student-Newman-Keuls 
method) is presented in Table 4.6. 
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TABLE 4.6. One-way repeated measures analysis of variance (ANOVA) and 
pairwise multiple comparisons (Student-Newman-Keuls method) of the data 
presented in Fig. 4.9 for carbachol-induced changes in oxygen consumption 
(AV02), and perfusion pressure (APP) in the absence and presence of L-NAME. 
Test Figure AVO2 APP 
1 ANOVA P value 4.9 <0.001 <0.001 
F statistic 4.9 48.93 201.44 
2 S-N-K comparisons: 
NOR vs. NOR + CCh (peak) 4.9 * * 
NOR vs. NOR + CCh (steady state) 4.9 * * 
3NOR vs. L-NAME + NOR 4.9 ns ns 
3NOR + L-NAME vs. 4CCh (peak) + NOR + L-NAME 4.9 * * 
3NOR + L-NAME vs. 4CCh (45 min) + NOR + L-NAME 4.9 * * 
'ANOVA P value significant at P<0.05 
2Student-Newman-Keuls P value significant at P<0.05, * = significant, ns = not significant 
3Repeat NOR infusion 
4Repeat CCh infusion 
these parameters (AV02, 3.45 ± 0.07 gmol. g.-1  h'; -I; APP, 93.0 ± 5.2 mm Hg). The 
repeat infusion of CCh (0.5 1.1M) elicited a significant (P<0.05, Table 4.6) peak reversal 
of NOR-induced VO2 and vascular effects (AV0 2, 2.15 ± 0.18 mol. fi l ; APP, 33.5 
± 1.7 mm Hg). Contrary to the data obtained in the absence of L-NAME, these effects 
of CCh in the presence of the NOS inhibitor were not sustained. Indeed the steady state 
V02 change under CCh-stimulation in these circumstances was similar to that induced 
by NOR alone (Fig. 4.9A). Conversely, perfusion pressure under CCh stimulation in 
the presence of L-NAME did not reach steady state with up to 45 minutes infusion time, 
and gradually increased over this period. Perfusion pressure readings taken at 45 
minutes, however, were significantly (P<0.05, Table 4.6) greater than those stimulated 
by NOR alone (APP, 107.0 ± 4.9 mm Hg, Fig. 4.9B). 
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(panel B), under noradrenalin stimulation, in the perfused rat hindlimb. 
g 
venous partial pressure of oxygen (P02) (panel A) and arterial perfusion pressure 
Fig. 4.10. Typical tracing of the actions of 50 nM and 0.5 1,1M capsaicin (Caps) on 
NOR-induced venous P02 change at this concentration of capsaicin. Interestingly, the 
observed prior to vanil loid infusion. In addition, there was a sustained reversal of  
vasoconstriction that peaked and then returned 
A ten-fold higher concentration of capsaicin (0.5 uM) induced a rapid, strong 
in perfusion pressure (vasoconstriction), but had no apparent effect on venous P02 (Fig . 
decreased venous P02, a low concentration of capsaicin (50 ogramuI ppm r posnro ( 
In the perfused rat hindlimb preparation under NOR-induced vascular tension, and 
4.3.6.1. Time course for the actions of capsaicin 
4.3.6. Effect of capsaicin in noradrenalin-stimulated perfused h indlimb 
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Fig. 4.11. Effect of capsaicin on noradrenalin (NOR)-induced oxygen consumption 
(panel A) and perfusion pressure (panel B) changes in the perfused rat hindlimb (n 
= 4). Statistical analysis of the data by one-way repeated measures ANOVA and 
pairwise comparisons (Student-Newman-Keuls method) is presented in Table 4.7. 
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removal of both NOR and capsaicin resulted in a peak decrease in venous P02, before 
returning to a basal (unstimulated) level. 
4.3.6.2. Capsaicin-induced vasoconstriction under noradrenalin-induced vascular 
tension 
The actions of capsaicin just described (Fig. 4.10) were confirmed in further 
experiments, the results of which are shown in Figure 4.11. NOR (0.611M) stimulated a 
characteristic increase in hindlimb V02 (AV02, 3.88 ± 0.15 [tmol. g. -1 11-1 , Fig. 4.11A) 
and raised perfusion pressure well above that seen under basal conditions (APP, 65.5 ± 
8.1 mm Hg, Fig 4.11B). The co-infusion of 50 nM capsaicin with NOR did not 
TABLE 4.7. One-way repeated measures analysis of variance (ANOVA) and 
pairwise multiple comparisons (Student-Newman-Keuls method) of the data 
presented in Fig. 4.11 for capsaicin-induced changes in oxygen consumption 
(AV02), and perfusion pressure (APP). 
Test Figure AVO2 APP 
'ANOVA P value 4.11 <0.001 <0.001 
F statistic 4.11 20.82 124.53 
2S-N-K comparisons: 
NOR vs. 50 nM capsaicin 4.11 ns ns 
NOR vs. 0.5 1.1M capsaicin (peak) + NOR 4.11 * * 
NOR vs. 0.5 gM capsaicin (steady state) + NOR 4.11 * ns 
'ANOVA P value significant at P<0.05 
2Student-Newman-Keuls P value significant at P<0.05, * = significant, ns = not significant 
significantly (P>0.05, Table 4.7) alter VO2 or perfusion pressure (AV02, 3.83 ± 0.07 
ilmol. g. -1 11 1 ; APP, 69.0 ± 8.0 mm Hg), although a mild perfusion pressure increase, 
similar to that shown in Figure 4.10, was consistently observed. A higher concentration 
of capsaicin (0.5 i.tM) elicited a significant (P<0.05, Table 4.7) peak reversal of NOR-
induced VO2 change (AV02, 1.90 ± 0.27 mol. g. -1 h-1 ), and further increased perfusion 
pressure (APP, 116.0 ± 6.9 mm Hg). 
t: 
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While the effect of 0.5 tM capsaicin on V02 was partly sustained (AV02, 2.68 ± 
0.22 gmol. II I ), its effect on perfusion pressure was not and gradually attained a 
steady state value that was not statistically significant (P>0.05, Table 4.7) from that 
induced by NOR alone (APP, 60.5 ± 3.5 mm Hg). 
4.4 Discussion 
4.4.1. Calcitonin gene-related peptide-induced vasodilatation and NO-dependence 
In the perfused rat hindlimb under NOR-induced vascular tension, a low 
concentration of CGRP induced a strong, sustained dilatation that was evident as a 54% 
decrease in hindlimb perfusion pressure (vascular resistance). CGRP caused 
comparatively weak dilatation (20% decrease in vascular resistance) in the perfused 
hindlimb stimulated with the vasoconstrictor 5-HT, although this dilatation was also 
sustained. However, there is now strong evidence to suggest that NOR and 5-HT, 
although both vasoconstrictors, cause opposite changes in the distribution of perfusate 
flow in the rat hindlimb that is reflected in their opposite effect on hindlimb V02 
(reviewed in Clark et al., 1995; 1997). Indeed under constant-flow conditions, 5-HT 
has been shown to increase non-nutritive flow in the perfused hindlimb by redistributing 
perfusate to connective tissue vessels, reducing flow to nutritive vessels within muscle 
(Newman et al., 1997). Consequently, CGRP probably has limited access to its 
receptors under 5-HT stimulation, whereas access is likely to be greater during the 
increased nutritive flow seen under stimulation by NOR, and may explain the apparent 
increase in CGRP efficacy during catecholamine stimulation. Similar flow-dependent 
changes in efficacy have been observed in this preparation by infusing a type A 
vasoconstrictor (All) under conditions of predominantly non-nutritive flow induced by 
5-HT (Newman et al., 1998). When 5-HT is infused prior to All, the thermogenic and 
vasoconstrictor effects of the latter are greatly reduced compared to the infusion of All 
alone. On the other hand, if Au. infused prior to 5-HT, the vasoconstriction and 
decreased VO2 by the latter are enhanced when compared to the infusion of 5-HT alone. 
This probably reflects an increase in nutritive flow by All and, therefore, greater access 
of 5-HT to its receptors. 
In the studies presented in this chapter, CGRP-induced dilatation was shown to be 
independent of NO formation given the inability of the NOS inhibitor L-NAME to 
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block the effects of the neuropeptide. Conversely, the same concentration of L-NAME 
(10 iiM) was effective in blocking the sustained vasodilatation and VO 2 effects induced 
by the ACh mimetic CCh. In fact, in the presence of L-NAME, CCh caused a slow-
onset vasoconstrictor effect in the perfused hindlimb. The inability of L-NAME to 
block the peak vasodilator response to CCh was not unexpected since ACh, the 
endogenous analogue of this dilator, has L-NAME-sensitive and an L-NAME-
insensitive components to its vasorelaxing effect (Doyle and Duling, 1997). 
Similar to the findings presented in this chapter for CGRP are those of Kim et al. 
(1995) who showed that CGRP- and capsaicin-induced arteriolar dilatation in rat 
striated muscle (cremaster) were not inhibited by a high concentration of L-NAME (104 
M), however venous dilatation by the peptide was sensitive to the NOS inhibitor. In 
addition, exercise-induced active hyperaemia in the rat hindlimb is sensitive to CGRP(8_ 
37), but not to L-NAME suggesting the presence of NO-independent dilatation mediated 
by the release of endogenous CGRP (Yamada etal., 1997a; 1997b). On the other hand, 
studies by Didion and Mayhan (1997) in rats with impaired arterial reactivity, due to 
chronic myocardial infarction, suggest that arteriolar dilatation by CGRP in skeletal 
muscle is dependent on the formation of NO. In myocardial-infarcted rats, ACh- and 
CGRP-induced (but not SP- or nitroprusside-induced) dilatation in the rat spinotrapezius 
muscle is reduced when compared to control rats, but is partly restored by the suffusion 
of L-arginine, an essential substrate for the formation of NO by NOS. Hence there is 
ambiguity in the involvement of NO in CGRP-induced dilatation in skeletal muscle, an 
observation that is not unusual since it is well known that CGRP employs both NO-
dependent and NO-independent signal transduction mechanisms to stimulate 
vasorelaxation (reviewed by Bell and McDermott, 1996). An excellent example of the 
heterogeneity of CGRP-NO interactions is evident in two different tissue types where 
CGRP is the major mediator of afferent nerve mediated vasodilatation - namely the skin 
and gastric mucosa of the rat (Holzer et al., 1995). It has been demonstrated in the 
stomach microcirculation that CGRP-induced vasodilatation occurs by the stimulation 
of endothelial CGRP receptors and synthesis and release of NO, although an NO-
independent mechanism is observed at higher CGRP concentrations (Holzer et al., 
1993). However, in the cutaneous microcirculation in the rat, CGRP stimulates 
vasodilatation by a direct mechanism that is not blocked by L-NAME and therefore 
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does not involve NO synthesis (Ralevic et al., 1992; Holzer and Jocic, 1994), but 
instead stimulates vascular smooth cell cAMF' production (Marshall, 1992). 
4.4.2. Tachykin in-induced vasodilatation and NO-dependence 
Vascular responses to the tachykinins SP and NKA in the perfused hindlimb under 
NOR-induced vascular tension were quantitatively and qualitatively similar. Both 
peptides induced a strong peak dilatation that was partly sustained with NKA, but fully 
reversed under continuous SP infusion. The reversal of the NOR-induced increase in 
V02 by both peptides was also transient and was not sustained for the duration of 
peptide infusion. A similar vascular effect by SP has been observed in the rat cremaster 
muscle preparation where the peptide stimulates strong but brief dilatation of small 
resistance vessels, lasting less than 5 minutes (Brock and Joshua, 1991). Repeated 
exposure to a picomolar concentration of SP in the rat cremaster, separated by 20 
minute recovery periods, still caused significant dilatation, however continuous 
exposure to SP substantially decreased the magnitude of dilatation. A similar 
tachyphylactic response to SP was observed in an earlier study by Lembeck and Holzer 
(1979) where the increased flow in the rat hindpaw following SP infusion into the 
femoral artery eventually disappeared under continuous peptide infusion. Hence in the 
data presented in this chapter, the transient nature of tachykinin-induced dilatation may 
be due to rapid desensitisation (tachyphylaxis), a frequently observed phenomenon that 
is likely to be due to the internalisation of tachykinin receptors (Bowden et al., 1994). 
Alternatively, SP or NKA may stimulate the release of an endogenous vasoconstrictor in 
a similar manner to that seen in the isolated rabbit intrapulmonary artery where SP 
stimulates vasoconstriction by the secondary release of thromboxane A2 (Shirahase et 
al., 1995). If such a mechanism occurs in muscle then reversal (either partly or fully) of 
the initial vasodilator effect of the tachykinins would be expected. 
In the studies presented in this chapter, it appears that the vascular actions of the 
tachykinins in the NOR-stimulated perfused rat hindlimb are partly mediated by the 
formation of NO by NOS, particularly with respect to NKA. Both the peak and steady 
state vasodilatation induced by NKA were sensitive to the NOS inhibitor L-NAME, 
however the former was not completely abolished. Nonetheless, NICA caused steady 
state vasoconstriction, rather than dilatation, in the presence of L-NAME and it is likely 
that NO plays a significant role in the vascular response to this peptide. Although the 
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initial peak vasodilator response to SP was not altered by L-NAME, steady state 
vascular tone in the presence of SP + L-NAME was consistently higher than that prior 
to peptide infusion. Thus, under NOS inhibition SP is a steady state vasoconstrictor and 
it appears that NO may play a role in the maintenance of vascular tone, but not the 
initial transient dilatation by this peptide. The mechanisms underlying the peak 
dilatation by SP in this preparation are unclear at present, but may involve the release of 
other factors such as endothelium-derived hyperpolarising factor (EDHF). Indeed, 
similar findings have been observed by others where SP induced a biphasic 
vasorelaxation, with the initial peak dilatation being insensitive to NOS inhibition, but 
the steady state response being completely ablated (Kuroiwa et al., 1995). Furthermore, 
these authors showed that eliminating the effects of EDHF (with 40 mM K+- 
depolarisation) also abolished the initial peak dilatation caused by SP. 
While it is widely accepted that tachykinin-induced vasodilatation, particularly by 
SP, is mediated by the stimulation of endothelial NK1 receptors (reviewed by Maggi et 
al., 1993b; Lundberg, 1996) there is ambiguity with regard to the role of NO formation 
in these vasodepressor responses. Vasodilatation by tachykinins is blocked by NOS 
inhibition in tissues from the rat (Whittle et al., 1989; Brock and Joshua, 1991; Huang 
and Koller, 1996), hamster (Hall and Brain, 1994), pig (Kuroiwa et al., 1995) and rabbit 
(Persson et al., 1991; Gustafsson et al., 1994). However, in other preparations, SP can 
evoke vasodilatation under NOS inhibition (Kerezoudis et al., 1993; Shiramoto et al., 
1997), and its vasodilator action is not affected by vascular dysfunction in rat 
spinotrapezius muscle arterioles, unlike some NO-dependent dilators (Didion and 
Mayan, 1997). 
Recent studies in the human forearm have highlighted an interesting example of 
the uncertainty surrounding NO involvement in tachykinin-mediated vasodilatation. 
Shiramoto and his co-workers have shown similar increases in forearm blood flow in 
response to ACh, ATP sodium nitroprusside (SNP) and SP, however only the dilatation 
induced by ACh was sensitive to the NOS inhibitor N°-monomethyl-L-arginine (L-
NMMA) (Shiramoto et al., 1997). In addition, the infusion of L-arginine, the substrate 
for NOS, did not augment the vasodilator response to SP. Furthermore, the same group 
have published data showing that in patients with endothelial dysfunction due to heart 
failure, the vasodilator response to ACh, but not SP or SNP, was diminished and was 
restored by infusion of L-arginine (Hirooka et al., 1992). 
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In contrast to the studies of Shiramoto et al. (1997), Newby et al. (1997a) have 
published data using the same preparation but drew more or less opposite conclusions 
on the role of NO in SP-induced vasodilatation. The two studies showed strong 
similarity in both resting and ACh-stimulated forearm blood flow, however the latter 
study showed a markedly reduced response to SP that showed greater sensitivity to L-
NMMA than did ACh. These findings are consistent with other studies in the human 
forearm where L-NMMA was effective at blocking the vasodilator response to SP 
(Cockcroft et al., 1994; Panza et al., 1994), but did not further reduce vasodilator 
responses to SP in patients with endothelial dysfunction due to hypertension (Panza et 
al., 1994). However, in the studies of Newby et al. (1997a) and Cockcroft et al. (1994) 
the observed dilator response to SP was markedly lower than that seen by Shiramoto's 
group, who showed some reduction in SP-induced vasodilatation by L-NMMA that did 
not achieve statistical significance. On the other hand, Shiromoto et al. did not infuse 
L-NMMA continuously in their study, although Panza et al. followed the same protocol 
and were able to block vasodilator responses to SP that were similar in magnitude. 
Thus, the apparent discrepancies with regard to NO involvement in SP-induced 
vasodilatation in this preparation are not likely to be due to differences in the 
experimental protocol adopted by the various study groups, but may instead be due to 
the source of SP used (Wallace, 1997) or racial differences (Shiramoto and Imaizumi, 
1997). 
4.4.3. Capsaicin-induced vasoconstriction under NOR-stimulated vascular tone 
Despite capsaicin's well-documented ability to stimulate the release of sensory 
neuropeptides (reviewed by Holzer, 1991; Maggi, 1993) and the demonstrated ability of 
the sensory peptides to induce vasodilatation in the present studies, the infusion of 
capsaicin into the hindlimb preparation under NOR-induced vascular tone elicited. 
strong vasoconstriction. However, the vasoconstriction induced by capsaicin was not 
sustained and perfusion pressure slowly returned to that induced by NOR alone. Why 
the vasoconstrictor response was transient is unclear since similar concentrations of 
capsaicin cause sustained vasoconstriction in the unstimulated perfused hindlimb 
preparation (Cameron-Smith et al. 1990; Colquhoun et al., 1995; Chapter 1, Fig. 1.2). 
However, under NOR-induced vasoconstriction, this concentration of capsaicin was 
markedly more potent and may have elicited rapid desensitisation. Furthermore, under 
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stimulation by NOR, the perfusion pressure in these studies prior to capsaicin infusion 
was much greater than the maximum capsaicin-induced perfusion pressure response 
normally seen in the unstimulated perfused hindlimb. 
4.4.4. Capsaicin and neuropeptide effects on V02 in the vasoconstrictor-stimulated 
perfused hindlimb 
A continuing pattern to emerge from the studies presented in this chapter was that 
NOR-induced increases in V02 in the constant-flow perfused rat hindlimb were 
reversed by the subsequent infusion of either vasodilator (CCh, CGRP, SP, NKA) or 
vasoconstrictor (capsaicin) agents. Thus, at the concentrations used in this study, NOR-
induced stimulation of V02 probably represents near-maximal nutritive vascular flow, 
particularly since in all experiments increasing the concentration of NOR from 0.6 liM 
to 0.8 gM did not further increase V02 but, in some cases, partly reversed V02 
stimulation. Hence any alteration of this nutritive/non-nutritive flow distribution, either 
by peptide- or CCh-induced dilatation, or capsaicin-induced vasoconstriction, results in 
the reversal of NOR-induced V02 effects. Conversely, under conditions of 
predominantly non-nutritive flow presumed to occur with the infusion of 5-HT, a 
change in vascular tension by the infusion of CGRP resulted in an increase in hindlimb 
V02, and probably reflects a redistribution of perfusate flow to nutritive vascular beds. 
Whether or not the flow redistribution by stimulatory concentrations of NOR is 
indicative of that which occurs in vivo, under basal conditions, is unclear at present. 
Indeed, it seems more likely that perfused hindlimb flow distribution under type A 
concentrations of NOR (i.e. those which stimulate V02) more closely resembles that 
which occurs during maximal exercise since type A vasoconstrictors are able to improve 
hindlimb muscle contraction (Dora et al., 1994; Rattigan et al., 1996). Consequently, 
from the experiments presented in this chapter, it is difficult to draw any firm 
conclusions about the likely actions of sensory neuropeptides or capsaicin on skeletal 
muscle V02 in vivo since their effects on muscle metabolism in the perfused hindlimb 
may be masked by the strong thermogenic effect of NOR. Their actions on the 
hindlimb vasculature in these studies, however, were more conclusive since arterial 
pressure under NOR-stimulation more closely resembles in vivo arterial pressure. 
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Chapter 5 
General Discussion and Conclusions 
5.1. Summary and Discussion of Major Findings 
5.1.1. Further evidence for vanilloid receptor subtypes in the perfused rat hindlimb 
Capsaicin-induced vasoconstriction in isolated arteries has been attributed in the 
past to non-selective effects that occur via the direct physicochemical interaction of 
capsaicin with smooth muscle plasma membranes, and do not exhibit desensitisation 
(reviewed by Maggi and Meli, 1988; Holzer, 1991). While the repeated infusion of 
vanilloids in the rat hindlimb does not produce acute desensitisation (Eldershaw et al., 
1994), a hallmark of the specific capsaicin action on sensory neurons, the findings 
presented in Chapter 2 clearly indicate that the effects produced by capsaicin in this 
preparation are highly selective and very likely to be receptor-mediated. Moreover, 
using specific competitive and non-competitive vanilloid receptor antagonists, further 
evidence has been obtained in support of the hypothesis proposed by Colquhoun et al. 
(1995) that vanilloid receptor subtypes (VN I and VN2 receptors) control the biphasic 
V02 responses to capsaicin in the perfused rat hindlimb. A low concentration (100 nM) 
of the non-competitive antagonist ruthenium red was used to selectively block the V02 
and vasoconstrictor effects caused by the infusion of high capsaicin concentrations into 
this preparation (Chapter 2, Fig. 2.5). These findings may be indicative of capsaicin 
cation channel heterogeneity where the putative VN2 receptor/channel complex is more 
sensitive to ruthenium red blockade. Low concentrations of capsazepine were used to 
selectively block the stimulation of V02 by capsaicin, but also potentiated the inhibition 
of V02 by the vanilloid (Chapter 2, Fig. 2.2). A model of overlapping but opposing 
receptor subtypes (Szabadi, 1977; Rovati and Nicosia, 1994) was explored as a possible 
explanation for these observations with capsazepine. Using a logistic equation 
described by Rovati and Nicosia (1994) and actual maximum responses, EC50, and IC50 
estimates derived from perfused hindlimb studies with capsaicin, theoretical V02 
concentration-response curves for putative VN 1 and VN2 receptors were developed. 
The sum of these two curves produced a biphasic curve (Chapter 2, Fig. 2.9) that was 
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very similar to that induced by the infusion of increasing concentrations of capsaicin 
into the perfused rat hindlimb. Furthermore, the model of Szabadi (1977) predicts that 
in a dual receptor system where an antagonist has greater affinity for one receptor type, 
the effect of the opposing receptor will be potentiated, as seen in the studies presented in 
Chapter 2 using submicromolar concentrations of capsazepine (Fig. 2.2). Similar 
observations have been made in earlier studies on preparations expressing both a- and 
13-adrenoreceptors, where P-adrenoreceptor blockade using low antagonist 
concentrations potentiated the effects of adrenergic agonists (Burks and Cooper, 1967). 
However, higher antagonist concentrations capable of inhibiting both receptor types 
were effective at blocking all catecholamine-induced responses in these studies (Burks 
and Cooper, 1967). 
Cooperativity of capsaicin binding to a single vanilloid receptor was considered a 
possible mechanism to explain the biphasic V0 2 response in perfused hindlimb studies 
since similar biphasic curves have been observed in radioligand binding studies 
(Szallasi et al., 1993b, Acs and Blumberg, 1994b). The present studies with the 
synthetic vanilloid analogue PPAHV, a compound found to bind to vanilloid receptors 
in a non-cooperative manner (Szallasi et al., 1996), produced very similar results to 
those seen with capsaicin in this preparation. These findings gave a preliminary 
indication that cooperative receptor binding is not the cause of the biphasic V02 
response to capsaicin in the perfused hindlimb. However, in the absence of radioligand 
binding studies on hindlimb vanilloid receptors, this hypothesis is yet to be proven 
conclusively. Furthermore, there may be different conformers of the same receptor that 
display different affinities for capsaicin and related compounds. Indeed, this 
explanation has been proposed, in favour of a receptor subtype hypothesis, to account 
for the binding of SP, NKA and septide to NK1 receptors where these compounds do 
not readily compete with each other in radioligand binding assays (Maggi and Schwartz, 
1997). Nonetheless, there is mounting evidence in favour of the existence of vanilloid 
receptor subtypes in the literature (see section 1.3.2.) and there is now strong evidence 
that the perfused rat hindlimb represents a system where these subtypes coexist. 
Although the effects of capsaicin in the rat hindlimb are likely to be receptor and 
cation channel-mediated, it was found that the post-receptor mechanisms are not entirely 
like those summarised by Maggi (1993) and described in the functional studies of Lou 
et al. (1992). Indeed, the actions of both low and high concentrations of capsaicin were 
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found to be TTX-resistant in the perfused rat hindlimb. Thus, the dual post receptor 
mechanisms described by Lou et al. (1992) in guinea-pig lung CSPANs are not a likely 
explanation for the biphasic effect on V02 induced by capsaicin in perfused rat muscle. 
However, the studies presented in Chapter 2 gave little indication as to whether or not 
the mechanisms of capsaicin action in rat hindlimb involve the stimulation of CSPANs 
and subsequent release of sensory neuropeptides. 
5.1.2. The unique findings revealed by capsaicin pretreatment 
The remarkable yet unexpected effects of capsaicin pretreatment shown in Chapter 
3 (Fig. 3.5) have further strengthened the idea that the effects of low (VN I -mediated) 
and high (VN2-mediated) concentrations of infused capsaicin occur by separate 
mechanisms. Of particular interest was the effects induced by high concentrations of 
capsaicin which showed marked potentiation 7 and 14 days after capsaicin pretreatment, 
while the effects of low concentrations of capsaicin remained unaltered. Indeed there 
are very few, if any, reports of capsaicin-mediated effects being augmented after 
capsaicin pretreatment. 
The implications of the studies presented in Chapter 3 are that capsaicin, when 
infused into the perfused rat hindlimb, stimulates higher affinity vanilloid receptors 
(1/N1) which release thermogenic (V02 stimulating) peptides. These receptors appear 
to be neuronal (on CSPANs) given that systemic pretreatment with a high dose of 
capsaicin, known to ablate CSPANs (reviewed by Holzer, 1991; Szolcsanyi, 1993), 
diminishes the acute V02 stimulation response to infused capsaicin (Chapter 3, Fig. 
3.5). Whether this diminution of the low-dose response was brought about by VN1 
receptor loss or sensory peptide depletion, or both, is unclear from these studies. 
An interesting observation made from past perfused hindlimb studies (Cameron-
Smith et al., 1990; Colquhoun et al., 1995) is that the perfusion pressure response to 
infused capsaicin does not show a distinct dual receptor effect (eg. by a point of 
inflection in the perfusion pressure concentration-response curves). It is plausible that 
the inflection may be masked by an overlap in the 1/N1 and 1/N 2 responses that produce 
the same positive effect on vascular tension. However, in the present studies the 
pretreatment of rats with capsaicin resulted in a marked, selective potentiation of the 
hindlimb perfusion pressure and V0 2 responses to high caPsaicin concentrations 
(putative 1/N2 receptor). Conversely, the vasoconstrictor and V0 2 effects seen at lower 
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infused concentrations (putative VN I receptor) was either inhibited (1 day after 
pretreatment) or unaltered (7 and 14 days after pretreatment). These findings have 
provided an initial indication that it may be possible to separate the vasoconstrictor 
effects induced by nanomolar and micromolar concentrations of capsaicin. Nonetheless, 
the contribution of each putative receptor subtype to the maximum capsaicin-induced 
increase in vascular resistance (perfusion pressure) is still unclear as the data presented 
in this thesis is not entirely consistent with the observations of Colquhoun etal. (1995). 
The suggestion by Colquhoun et al. (1995) that the majority of the capsaicin-
induced vasoconstriction was due to the stimulation of the putative VNI receptor (see 
table 2.5) was based on the interesting observation that there was little vasoconstriction 
but strong inhibition of V02 (VN2 effect) in the absence of external calcium. However, 
it is possible that the remaining vasoconstriction observed in the absence of external 
calcium may be sufficient to induce a functional vascular shunt resulting in decreased 
nutrient delivery and, therefore, reduced hindlimb V02. Others have also shown that 
capsaicin is able to inhibit co-enzymes in the electron transport chain, which may also 
explain some of the capsaicin-induced inhibition of VO 2 in the absence of strong 
vasoconstriction (Shimomura et a/., 1989; Satoh et a/., 1996). In addition, the present 
study has shown that the competitive antagonist capsazepine, at low concentrations, was 
able to selectively block the capsaicin-induced stimulation of V02 (VN I effect) but did 
not alter the perfusion pressure response (Chapter 2, Fig 2.2). Moreover, 
submicromolar concentrations of the functional vanilloid antagonist ruthenium red 
selectively blocked both the inhibition of V02 and perfusion pressure responses induced 
by micromolar concentrations of capsaicin (VN 2 effect) (Chapter 2, Fig. 2.5). In view 
of these findings, and those from the capsaicin pretreatment studies described above, it 
appears more likely that the putative VN2 receptor is responsible for the majority of the 
vasoconstrictor action of vanilloids in the hindlimb preparation. Alternatively, the 
above discrepancies may indicate the presence of complex vanilloid receptor expression 
in muscle, although there is little evidence to support this at present. 
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5.1.3. The role of the sensory neuropeptides 
5.1.3.1. Tachykinins 
The stimulation of V02 by capsaicin was selectively blocked by non-peptide 
tachykinin antagonists of NK1 and NK2 receptors (Chapter 3, Figs 3.1 and 3.2), and 
infused SP, NKA and NKB stimulate V02 and mild vasoconstriction with a rank 
potency order of NKA>NKB>SP (Chapter 3, Fig 3.4). Hence, capsaicin may stimulate 
V02 by releasing endogenous tachykinins which interact primarily with NK2 receptors. 
The vasoconstriction induced by SP, NKA and NKB in the present study may have 
resulted from direct stimulation of smooth muscle cell NK2 receptors after diffusion of 
the peptides across the endothelium. Indeed, others have shown that SP, NKA and 
NKB are able to induce strong vasoconstriction, in the absence of endothelium, by a 
mechanism involving the stimulation of smooth muscle NK2 receptors (D'Orleans-Juste 
et al., 1985; Shirahase et al., 1995). However, in the noradrenalin (NOR)-stimulated 
perfused hindlimb, SP induced strong but transient vasodilatation (Chapter 4, Figs. 4.4 
and 4.5) at concentrations that were ineffective when infused into the unstimulated 
hindlimb preparation (Chapter 3, Fig. 3.4). This observation may reflect the stimulation 
of endothelial NK1 receptors by SP to induce vasodilatation that could not be observed 
in the unstimulated preparation, where an NK2 receptor-mediated vasoconstrictor effect 
of SP predominates. Indeed, SP has been shown to dilate rat cremaster muscle 
vasculature by a mechanism that is believed to involve the stimulation of NK1 receptors 
(Brock and Joshua, 1991). In addition, the vasodilatation induced by stimulation of the 
rabbit tenuissimus muscle nerve is blocked by the SP antagonist spantide (Persson et al., 
1991) and the NK1 receptor antagonist CP 96,345 (Gustafsson et al., 1994). 
Alternatively, the increase in the potency of SP could be the result of the vascular 
changes induced by NOR, which is thought to redistribute flow to nutritive vascular 
beds in muscle (Clark et al., 1995; 1997). The redistribution of flow may account for 
the observations of Newby et al. (1997a), who showed a marked increase in the potency 
of SP to induce human forearm vasodilatation when co-infused with NOR. However, 
NKA, which also induces a transient dilatation, shows similar potency in both NOR-
stimulated and unstimulated hindlimb preparations (Chapter 4, Figs 4.6 and 4.7), which 
could involve the stimulation of either NK1 or NK2 receptors given that this peptide 
retains good affinity for both types (Regoli et al., 1987). 
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A role for NK1 receptors in the responses to the tachykinins and capsaicin in the 
perfused hindlimb cannot be excluded since the NK1 receptor antagonist CP-99,994 was 
able to partly block the effects mediated by capsaicin, although the concentrations used 
may have been sufficient to block NK2 receptors also. In addition, preliminary 
autoradiographic studies indicated the presence of specific [ 125I]-BHSP binding sites in 
sections of soleus muscle that are likely to correspond to the presence of NK1 receptor 
in this tissue (see Appendix 1). However, the exact location of these binding sites (eg. 
vascular endothelium, vascular smooth muscle) was not determined in these studies due 
largely to the poorly defined skeletal muscle tissue morphology caused by the 
autoradiographic process. A more refined technique that preserves tissue morphology 
may involve the use of specific labelled antibodies to NK1 receptors (Vigna et al., 
1994). 
5.1.3.2. Cakitonin gene-related peptide 
Contrary to the actions of the tachykinins, CGRP had no detectable effect on basal 
V02 or pressure when infused into the unstimulated perfused hindlimb (Chapter 3, Fig. 
3.4). This apparent lack of effect seen with the infusion of CGRP, a known potent 
vasodilator, is unlikely to be due to the absence of CGRP receptors in this tissue, but 
instead probably relates to the lack of vascular tone in this preparation. Indeed, CGRP 
receptor expression has been demonstrated in cultured L6 rat skeletal muscle cells 
(Kreutter et al., 1989; Poyner et al., 1992) and whole rat skeletal muscle (Popper and 
Micevych, 1989; Pittner et al., 1996). In addition, capsaicin elicits vasodilatation in a 
rat skeletal muscle preparation (cremaster) by stimulating the endogenous release of 
CGRP (White et al., 1993; Kim et al., 1995) and CGRP itself is able to decrease 
vascular tone in skeletal muscle (Didion and Mayhan, 1997; Yamada et al., 1997a; 
1997b). Hence, it was not unexpected that nanomolar concentrations CGRP elicited a 
potent vasodilator effect in the perfused hindlimb under NOR-induced vascular tension 
(Chapter 4, Figs 4.2 and 4.3), a finding that is consistent with its well-documented 
vasorelaxing properties. This dilatation does not appear to involve the formation of NO 
as the inhibition of NOS using L-NAME did not alter the vascular response to CGRP, 
but did inhibit the sustained NO-dependent vasodilatation caused by CCh (Chapter 4, 
Figs. 4.8 and 4.9). Conversely, the quantitatively and qualitatively similar vascular 
effects of the tachykinins SP and NKA in the NOR-stimulated perfused hindlimb were 
General Discussion and Conclusions 	 112 
partly sensitive to L-NAME (Chapter 4, Figs. 4.5 and 4.7). This was particularly 
evident with the NKA-induced effects which showed a reduction in peak dilatation, 
while both peptides caused strong steady state vasoconstriction when co-infused with 
the NOS inhibitor. 
Further to the dilatation seen with the infusion of CGRP in the NOR-stimulated 
perfused hindlimb, the CGRP antagonist, CGRP(8_37), enhanced capsaicin-induced 
vasoconstriction and inhibition of V0 2 in the unstimulated hindlimb (Chapter 3, Fig. 
3.3), suggesting that the vasoconstrictor action of capsaicin is opposed by a vasodilator 
action of endogenous CGRP. Interestingly, similar observations were made in 
capsaicin-pretreated rats where the vasoconstrictor and inhibitory V0 2 responses to 
infused capsaicin were enhanced in the perfused hindlimb, indicating that these 
observations may be due to a reduction in the release of CGRP from sensory neurons. 
Thus, in the perfused rat hindlimb, the overall degree of capsaicin-induced 
vasoconstriction may be the sum of the indirect actions of vasoactive peptides (eg. SP, 
NKA, CGRP) released from sensory neurons, plus the vasoconstrictor action of 
capsaicin on vascular smooth muscle via vanilloid receptor stimulation. In cats, "cold 
storage denervation" potentiates capsaicin-induced vasoconstriction of large cerebral 
arteries which correlates with degeneration of SP and CGRP-containing perivascular 
nerves (Saito et al., 1988). These authors suggested that although capsaicin releases 
vasodilator peptides (presumably SP, CGRP, etc.) from perivascular nerves of cat 
cerebral arteries, a direct vasoconstrictor effect of capsaicin predominates. This 
hypothesis is supported by the work of Edvinsson et al. (1990) who showed that the 
vasodilatation induced by capsaicin in cat cerebral arteries was attenuated by repeated 
capsaicin application or by trigeminal ganglionectomy, whereas the vasoconstrictor 
effect was unaltered. Similarly, Duckles (1986) has shown that capsaicin applied to the 
isolated carotid artery and thoracic aorta of the guinea-pig causes vasoconstriction, 
rather than dilatation, after systemic in vivo capsaicin pretreatment. The augmented 
vasoconstrictor action of capsaicin observed in the perfused hindlimb studies presented 
in Chapter 3 (Fig 3.5) may also be explained by the absence of sufficient sensory 
vasodilator peptides after capsaicin pretreatment. However, the studies of Saito et al., 
Edvinsson et al. and Duckles suggest that the vasoconstrictor action of capsaicin occurs 
by a non-specific effect on the plasma membrane of vascular smooth muscle cells. 
Conversely, the vascular and metabolic effects of capsaicin in the perfused rat hindlimb 
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are likely occur via the stimulation of specific vanilloid receptors since both can be 
blocked by the competitive vanilloid receptor antagonist capsazepine (Chapter 2, Fig 
2.2). 
5.2. Capsaicin Mechanisms of Action in Perfused Rat Skeletal Muscle 
The previous (Cameron-Smith et al., 1990; Colquhoun et al., 1995) and current 
findings on the vascular and metabolic actions of capsaicin in perfused muscle represent 
a novel insight into the effects of vanilloids in peripheral tissues. Exactly how capsaicin 
and the sensory neuropeptides produce their vascular and V0 2 effects in perfused rat 
muscle is now becoming clearer and is represented in the models shown in figures 5.1 
and 5.2. One of the major findings to emerge from these studies is that the actions of 
capsaicin in this tissue are complex and appear to involve both direct and indirect 
receptor-mediated effects in the hindlimb preparation. The direct effect of capsaicin 
appears to involve putative smooth muscle VN 2 receptors which induce strong 
vasoconstriction and inhibition of VO 2 (Fig. 5.2), while the indirect effect occurs by the 
more classical vanilloid mechanism involving the stimulation of neuronal (CSPAN) 
VN I receptors and release of sensory neuropeptides (Fig. 5.1). Thus the biphasic effect 
of capsaicin on hindlimb V02 occurs by the stimulation of separate mechanisms. 
However, unlike the effects of capsaicin in other tissues (e.g. lung) neither mechanism is 
sensitive to TTX and only one is likely to involve the release of sensory neuropeptides 
from CSPANs. 
Although the tachykinins SP and NKA play at least a partial role in capsaicin-
induced stimulation of V02 in the perfused hindlimb preparation, the mechanisms 
underlying this response are not yet fully understood. The concept of site specific 
vasoconstriction, leading to increased 'nutritive' flow, was summarised in Chapter 1 
(section 1.2.2.2) and has been proposed to explain the large increases in hindlimb V02 
seen with the infusion of other potent vasoconstrictors, such as NOR, All and 
vasopressin (reviewed in Clark et al., 1995; 1997). Based on this flow redistribution 
model, it appears plausible that submicromolar concentrations of capsaicin may 
stimulate V02 (VNI response) by selectively constricting (via a receptor-mediated 
effect on smooth muscle) or dilating (by release of neuropeptides) blood vessels leading 
to increased perfusate flow to 'nutritive' vessels (Fig. 5.1). However, a direct effect of 
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capsaicin and the sensory neuropeptides to stimulate muscle V02 cannot be ruled out 
since, in the present study, NK1 and NK2 receptor antagonists decreased capsaicin-
induced stimulation of V0 2 , but did not cause appreciable changes in perfusion pressure 
(Chapter 3, Figs 3.1 and 3.2). 
There is convincing evidence that strong vasoconstrictors that inhibit V0 2 in the 
perfused hindlimb (eg. 5-HT) do so by shunting perfusate away from nutritive vessels to 
non-nutritive vessels supplying hindlimb connective tissue (septa and tendons) 
(Newman et al., 1997). Therefore, increased non-nutritive flow may explain the 
inhibition of V02 that accompanies the strong vasoconstriction induced by high 
concentrations of capsaicin. This hypothesis is strengthened by the observation that the 
augmentation of capsaicin-induced vasoconstriction 1, 7 and 14 days after capsaicin 
pretreatment (Chapter 3, Fig. 3.5) produced a concomitant potentiation of V0 2 
inhibition. 
It seems unlikely that endogenously released tachykinins would have a major role 
in producing the steady state changes in vascular tone induced by capsaicin given the 
transient nature of the vasodilatation seen with the infusion of these peptides in the 
present studies (see Chapter 4). However, the sustained vasodilator effect of CGRP in 
the NOR-stimulated perfused hindlimb (Chapter 4, Figs. 4.2 and 4.3) is in good 
agreement with the findings in Chapter 3 where CGRP (8 _ 37) augmented the 
vasoconstrictor effect of capsaicin, further supporting a vasodilator role for 
endogenously released CGRP (Chapter 3, Fig. 3.3). Moreover, the present results in the 
NOR-stimulated perfused hindlimb further support the notion that capsaicin is a potent 
vasoconstrictor in this tissue (Chapter 4, Figs. 4.10 and 4.11). Thus, while capsaicin 
probably stimulates the release of potent vasodilator peptides, such as CGRP, the 
vasoconstrictor action of this pungent spice principle is the predominant effect in the 
perfused rat hindlimb. 
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Fig. 5.1. Proposed mechanisms of action for the vascular and V02-stimulating 
effects of capsaicin in the perfused rat hindlimb via stimulation of putative VNI 
receptor/channels. This subtype shows high sensitivity to capsazepine (CPZ) but 
low sensitivity to ruthenium red (RR). The VN I -mediated mechanism is likely to 
involve CSPANs given that capsaicin pretreatment ablates the stimulatory 
response on V02. VNI stimulation may have a direct vasoconstrictor effect and 
also stimulates the release of neuropeptide transmitters which induce 
vasodilatation and/or vasoconstriction. These vascular effects are likely to increase 
nutritive muscle flow and, therefore, increase V02. A direct V02-stimulating effect 
of the tachykinins cannot be ruled out since non-peptide tachykinin receptor 
antagonists (CP-99,994 or SR 48968) partly blocked capsaicin-induced V02, but 
not PP. Broken arrows indicate release or neuromodulators or endothelium-
derived factors, solid arrows show consequence. 
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Fig. 5.2. Proposed mechanisms of capsaicin-induced vasoconstriction and 
inhibition of V02 via stimulation of the putative muscle VN2 receptor. VN2 
receptors are possibly non-neuronal (smooth muscle) given that high 
concentrations of capsaicin induce strong vasoconstriction which is enhanced, 
rather than inhibited, by capsaicin pretreatment. Alternatively, VN2 may represent 
a previously unidentified type of neuronal vanilloid receptor/channel that is not 
subject to tachyphylaxis with capsaicin pretreatment, has low sensitivity to 
capsazepine (CPZ), and high sensitivity to ruthenium red (RR). It is proposed that 
the strong vasoconstriction induced by high concentrations of infused capsaicin, 
acting via VN2 receptors, increases non-nutritive flow in the perfused hindlimb 
preparation, thus decreasing V02. Potentiation of the observed VN2-mediated 
vasoconstriction and V02 inhibition after capsaicin pretreatment is likely to be due 
to the depletion of vasodilator neuropeptides, or may result in upregulation of VN2 
receptors or receptor-coupling mechanisms. Broken arrows indicate 
neuromodulator release, solid arrows show consequence. 
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5.3. Vanilloid Receptor Nomenclature 
The data presented in this thesis, and the work of others in the perfused rat 
hindlimb (Colquhoun et al., 1995), has added further to the mounting evidence in favour 
of vanilloid receptor subtypes from radioligand binding studies, Ca 2+ uptake studies, and 
whole cell patch-clamp studies on rat DRG and trigeminal ganglion neurons. Although 
quite compelling, such evidence is indirect and it is difficult to estimate the true number 
of vanilloid receptor subtypes at present. However, the recent breakthrough in vanilloid 
receptor cloning (Caterina et al., 1997) may lead to a rapid proliferation of knowledge in 
this area and, potentially, the cloning of receptor subtypes distinct from those already 
cloned from rat DRG neurons. 
In view of the results in Chapter 3 showing reduced responses to low 
concentrations of infused capsaicin 1 day after capsaicin pretreatment, it follows that the 
putative VN I receptor may be expressed on CSPANs in this tissue. As these neurons 
have their cell bodies in the DRG, it is plausible to suggest that this receptor is similar to 
the VR1 vanilloid receptor cloned by Caterina et al. (1997) from DRG neurons. 
However, a large body of evidence obtained from the radioligand binding studies of 
Szallasi, Blumberg and their co-workers have shown that peripheral vanilloid receptors 
display non-cooperative binding characteristics while those that are central in origin, 
such as in the DRG, bind cooperatively (review by Szallasi, 1994). The studies using 
12-phenylacetate 13-acetate 20-homovanillate (PPAHV) presented in Chapter 2 (Fig. 
2.6) indicate that capsaicin binds to hindlimb vanilloid receptors in a non-cooperative 
manner and therefore displays characteristics that are likely to be different from the 
cloned CNS VR 1 receptor. Without further characterisation of muscle vanilloid 
receptors by radioligand binding and/or molecular cloning studies it is difficult to assign 
these receptors to putative subtypes proposed by others. 
Whereas vanilloid receptors described by others are neuronal in origin and are 
subject to tachyphylaxis, the putative VN 2 receptor subtype may be a non-neuronal, 
smooth muscle vanilloid binding site. This is based on the evidence presented in 
Chapter 3 where VN2-mediated effects were not attenuated by capsaicin pretreatment 
and appear to be largely responsible for the strong vasoconstrictor effect of capsaicin in 
the hindlimb preparation. Hence, this receptor may be unlike any other vanilloid 
receptor described previously, but again this hypothesis requires confirmation with 
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receptor binding and/or molecular cloning studies. Alternatively, the muscle VN2 
receptor may represent a subtype of neuronal vanilloid receptor that displays reduced 
susceptibility to desensitisation. Indeed, recent patch-clamp studies in rat trigeminal 
ganglia with the synthetic vanilloid analogue PPAHV have indicated the presence of 
vanilloid receptor subtypes with different activation and desensitisation kinetics (Liu et 
al., 1998). With the membrane potential held at -60 mV, rapidly-activating inward 
currents induced by PPAHV were eliminated by repeated applications of 3 p.M of the 
synthetic analogue, whereas distinct slowly-activating currents were only partly 
reduced. Moreover, some of the currents induced by PPAHV were insensitive to 
treatment with capsazepine providing further evidence for vanilloid receptor subtypes 
on these neurons (Liu et al., 1998). However, it was not clear from these studies which 
currents (i.e. fast- or slow-activating) were sensitive and which were insensitive to the 
vanilloid antagonist. 
5.4. Vanilloid effects in vivo 
The systemic administration of capsaicin is well known for its excitatory and 
long-lasting analgesic effect at high doses (greater than 10 mg/kg), the latter resulting 
from functional and neurotoxic impairment of CSPANs (reviewed by Holzer, 1991; 
Szolcsanyi, 1993). However, other in vivo actions of capsaicin have been described in 
rat tissues where sensory neurons play an important regulatory role and where capsaicin 
induces cell non-selective effects (reviewed by Campbell et al., 1993). Briefly, these 
effects include a reduction in core body temperature (Hayes et al., 1984), effects on the 
airways including bronchial and tracheal constriction (reviewed by Lundberg, 1993), 
contraction of the urinary bladder (reviewed by Maggi, 1992), as well as inhibitory 
effects on cardiac muscle (Franco-Cereceda and Lundberg, 1988). When administered 
systemically, capsaicin has other profound effects on the cardiovascular system in the 
rat. Cardiovascular responses to the acute administration of capsaicin differ depending 
on the strain of rat studied, however a vagally mediated reduction blood pressure has 
been consistently observed (Donnerer and Lembeck, 1982; Chahl and Lynch, 1987, 
Campbell et al., 1993). Others have shown that this reflex fall in blood pressure 
induced by capsaicin is inhibited by the intrathecal administration of an SP antagonist 
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suggesting that the release of SP from the CNS is involved in the response (Donnerer 
and Lembeck, 1983). 
An important consideration to draw from studies on the vascular and metabolic 
effects of capsaicin in the perfused rat hindlimb (Cameron-Smith et al., 1990; 
Eldershaw et al., 1992; 1994; Colquhoun et al., 1995; Chapters 2, 3 and 4) is whether or 
not these actions are likely to occur in vivo, and whether or not they have any 
physiological significance. The studies presented in Chapter 4 in the NOR-stimulated 
perfused hindlimb indicate that capsaicin is still a potent vasoconstrictor in skeletal 
muscle at near physiological vascular tone (Figs. 4.10 and 4.11). However, the actions 
of NOR itself on hindlimb nutritive/non-nutritive flow distribution must be considered 
(reviewed by Clark et al., 1995; 1997) as this may not be the same as the flow 
distribution in vivo. Furthermore, NOR has a potent action on hindlimb muscle V02 
making it difficult to draw conclusions regarding the likely action of capsaicin on 
muscle metabolism in vivo. Nonetheless, others have shown that the in vivo 
administration of capsaicin has a vasoconstrictor effect in the autoperfused hindlimbs of 
the dog where basal perfusion pressure is held at a physiological level (Webb-Peploe et 
al., 1972; Pelletier and Shepherd, 1975). It has also been shown that the vasoconstrictor 
effect in the dog hindlimb seen with the injection of capsaicin into the iliac arteries was 
not affected by sciatic or femoral nerve sectioning, while the concomitant reflex 
vasoconstriction seen in the aorta and splenic vessels was attenuated (Webb-Peploe et 
al., 1972). Thus the hindlimb vasoconstriction was due to local stimulation by capsaicin 
rather than an axon reflex, as shown in the perfused rat hindlimb (Cameron-Smith et al., 
1990). Interestingly, it has been suggested that the reflex cardiovascular responses seen 
with the activation of capsaicin-sensitive skeletal muscle receptors may be the same 
receptors that are activated during muscular contraction to cause a redistribution of 
blood flow to working skeletal muscle (Webb-Peploe et al., 1972; Crayton et al., 1981). 
Thus an in vivo function may potentially be ascribed to skeletal muscle vanilloid 
receptors involving reflex cardiovascular responses to exercise in addition to local 
metabolic and vascular effects. However, it is unclear which of the putative muscle 
vanilloid receptors (i.e. VI\11, VN2 or both) are likely to be involved in the reflex 
cardiovascular responses. Capsaicin has been shown to activate group IV (C-type) 
afferent fibres in hindlimb muscles of the dog (Kaufman et al., 1982) which may 
indicate the involvement of neuronal VN i receptors, although such suggestions are 
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purely speculative at present. It is interesting to note that these authors showed a 
resistance of muscle C-type afferents to the acute tachyphylactic response normally 
induced by repeated capsaicin application. A similar resistance to acute vanilloid 
desensitisation has been observed in the perfused rat hindlimb (Eldershaw et al., 1994). 
5.5. Therapeutic Potential of Vanilloids 
There are few reports describing the effects of capsaicin and other vanilloids on 
oxygen consumption in individual tissues. Understanding how vanilloids alter skeletal 
muscle metabolism is essential for the use of these compounds as therapeutic agents for 
the stimulation of whole body oxygen consumption and thermogenesis. The likelihood 
that skeletal muscle metabolism may be controlled by stimulatory (VN I ) and inhibitory 
(VN2) receptors may provide a means by which whole body energy expenditure can be 
increased by synthetic vanilloids that selectively stimulate VN I receptors, or selectively 
inhibit VN2 receptors in the presence of capsaicin. Preliminary in vitro and in vivo 
structure-activity investigations using a synthetic vanilloid agents have shown 
favourable thermogenic activity, however all of the synthetic compounds tested were 
unable to selectively stimulate putative hindlimb VN I or VN2 receptors (T.P.D. 
Eldershaw, PhD Thesis, University of Tasmania, 1996). Nonetheless, the potential of 
these compounds in the treatment of metabolic disorders is encouraging and is 
compounded by recent preliminary experiments showing that hindlimb insulin-mediated 
glucose uptake (IMGU) in the rat can be acutely influenced by capsaicin (T.P.D. 
Eldershaw, E.Q. Colquhoun and C.D. Griffiths, unpublished observations). Indeed 
other vasoconstrictors that induce similar effects to capsaicin on hindlimb V02 also 
affect muscle IMGU in a similar manner (Rattigan et al., 1993; 1995; 1996). Thus 
vanilloids may also have implications for the treatment of other human disorders where 
defective muscle vascular control may have pathogenic implications. 
The in vivo actions of capsaicin described above (section 5.4) raise concerns 
regarding its use as a therapeutic agent and encourage the need for the development of 
synthetic vanilloid agents that are devoid of nociceptive and other undesirable side-
effects. Interest in vanilloids as non-steroidal anti-inflammatory agents has focused 
more recently on the Euphorbium spice principle RTX, a compound that is less likely to 
induce unwanted cardiovascular and respiratory reflexes (Appendino and Szallasi, 
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1997). RTX also has the added advantages of high potency and a greater efficacy for 
inducing desensitisation than for inducing pain (reviewed by Blumberg et al., 1993; 
Appendino and Szallasi, 1997). However, the promotion of this ultrapotent capsaicin 
analogue as a therapeutic agent has also been hampered by the undesired side-effects 
caused by its administration in vivo. Most notably, RTX causes a profound reduction in 
body temperature at doses required to induce analgesia (Szallasi and Blumberg, 1989). 
More recently, the development of synthetic phorbol-based vanilloids has yielded 
encouraging compounds (eg. PPAHV) which are only mildly pungent and fail to induce 
a measurable hypothermic response at doses that protect against neurogenic 
inflammation (Appendino et al., 1996). 
Earlier structure-activity studies with synthetic vanilloid analogues possessing 
long chain C-regions identified promising compounds such as olvanil which showed 
reduced or abolished activity in pungency assays, but retained antinociceptive and 
'desensitising' properties (Brand et al., 1987). Modification of this compound by 
aromatic ring substitution produced nuvanil, an agent that showed improved solubility 
but, like olvanil, only produced analgesic effects at oral-administered doses where 
profound hypothermic effects were observed (Campbell et al., 1993). Subsequent 
structure-activity studies by Walpole and coworkers have delineated the structural 
features of the capsaicin molecule that are necessary for agonist and antinociceptive 
activity (Walpole et al., 1993a-c). Combinations of the optimal structural features from 
the three regions of the capsaicin molecule have recently yielded a series of highly 
potent agonists with improved in vivo pharmacokinetic profiles (Wrigglesworth et al., 
1996). Thus, these molecules represent potential candidates for the development of oral 
analgesic agents and may overcome the problems of natural analogues such as capsaicin 
and dihydrocapsaicin, and synthetic analogues such as olvanil, which are rapidly 
metabolised before entering the systemic circulation (Donnerer et al., 1990; Sietsema et 
al., 1988). It would be interesting to determine the effects of these compounds on 
muscle and/or whole body thermogenesis to examine their potential for development as 
orally-administered stimulators of metabolism. 
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5.6. Future Directions for Vanilloid Studies 
Within the vanilloids field of research there is undoubtedly an urgent need to gain 
further understanding of vanilloid receptor subtype diversity. The cloning of a DRG 
vanilloid receptor (Caterina et al., 1997) has promoted further interest and excitement in 
this field that may rapidly lead to the cloning of an entire new receptor family. If 
vanilloid receptor subtypes do exist then it follows that the genes encoding these 
proteins may occupy different loci. It would also be likely that different genes encoding 
the various vanilloid receptor subtypes would contain highly conserved regions that may 
be potential targets for the development of specific DNA probes, or primers to enable 
amplification of the genes by polymerase chain reaction (PCR) techniques. Indeed, the 
study of vanilloid pharmacology may follow a similar path to that of the tachykinins 
where to the cloning and recognition of receptor subtypes for these neuromodulators has 
contributed significantly to the understanding of tachykinin pharmacology (Yokota et 
al., 1989; Hershey et al., 1991; Ingi et al., 1991). Furthermore, it has permitted a 
greater understanding of the binding characteristics of selective agonists and antagonists 
for NK1, NK2 and NK3 receptors, as well as enabling the development of specific 
receptor antibodies for improved pharmacological studies (Vigna et al., 1994). Such 
knowledge would be highly valuable for the development of selective ligands or 
antagonists for the putative V1\1 1 and VN2 hindlimb receptors. 
It is a widely accepted that any pharmacological study attempting to conclusively 
prove the existence of a receptor family or type, that three lines of evidence are 
important: a) cloning of the receptor(s) and identification of the gene(s) responsible for 
its production; b) radioligand binding and/or autoradiographic studies for tissue 
distribution analysis and determination of receptor kinetics; and c) functional studies to 
characterise the receptor(s), and to ascribe it a physiological function. While all three 
forms have now been described for DRG vanilloid receptors, only the latter two have 
been studied with respect to peripheral vanilloid receptors, and only the final criterion 
has been studied with regards to rat hindlimb vanilloid receptors. For studies in rat 
skeletal muscle, radioligand binding experiments should confirm the presence of 
specific [ 3H]-RTX (vanilloid) binding sites and may further add to the evidence in 
favour of vanilloid receptor subtypes in this tissue. Competition binding studies using 
capsaicin analogues and capsazepine should reveal more about the binding kinetics of 
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these compounds to vanilloid receptors (i.e. cooperative versus non-cooperative binding 
behaviour). In addition, autoradiographic studies on skeletal muscle will reveal more 
about the tissue distribution of these novel binding sites, and since capsazepine binds 
selectively to putative VN1 receptors at low concentrations (Chapter 2, Fig 2.2), this 
antagonist may enable the determination of VNI/VN2 receptor locations. 
The encouraging positive results obtained with synthetic vanilloids in vivo (T.P.D. 
Eldershaw, PhD Thesis, University of Tasmania, 1996) warrants further investigation to 
confirm the potential of capsaicin-like molecules as whole-body metabolic stimulators. 
If our future knowledge of vanilloid receptors permits the synthesis of selective VN I 
agonists or VN2 antagonists then in vivo studies in the rat will be of great importance for 
the development of thermogenic drugs for subsequent trials in humans. An important 
consideration in the structural design of compounds for future in vivo studies is their 
bioavailability after oral administration, given the reported metabolic degradation of 
capsaicin-like molecules (see section 5.5). 
5.7. Conclusions 
The mechanisms underlying the vascular and metabolic effects of vanilloids in 
perfused rat skeletal muscle have been further defined. The studies undertaken support 
the notion of putative vanilloid receptor subtypes controlling the biphasic V0 2 effect, 
and the alterations in vascular tone, induced by capsaicin and structurally related 
compounds. The effects of capsaicin in this tissue may result from a combination of 
NO-dependent and —independent vasodilatation, vasoconstriction and V02 stimulation 
induced by endogenous sensory neuropeptides, and the overriding vasoconstrictor effect 
of capsaicin via vanilloid receptor stimulation. It is likely that the direct and indirect 
vascular effects of these compounds are able to alter the distribution of nutrient access 
to muscle, thus altering resting metabolic rate. However an effect of capsaicin and its 
neuromodulators to directly alter muscle metabolism cannot be ruled out. These 
findings underline the complex nature of capsaicin's novel actions in perfused rat 
skeletal muscle. 
It is not yet clear whether the favourable thermogenic effects of capsaicin seen in 
the perfused hindlimb preparation will also result in the stimulation of muscle, and 
whole body, thermogenesis in vivo. Thus, these compounds remain potential 
therapeutic agents for the treatment of metabolic disorders. Nonetheless, the perfused 
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rat hindlimb studies have revealed a very interesting discovery in terms of vanilloid 
receptor nomenclature. That is, the presence of putative vanilloid receptor subtypes in 
muscle which can, potentially, be exploited to favourably alter skeletal muscle 
metabolism. 
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Appendix 1 
NK1 receptor autoradiography 
The results presented in Chapter 3 suggest that the vasoconstriction and 
stimulation of V02 by capsaicin in the perfused rat hindlimb may be partly 
mediated by endogenous tachykinins acting on NK2 receptors. However, a role for 
NK1 receptors cannot be dismissed since the NK1 receptor antagonist CP-99,994 
partly blocked the stimulation of V02 produced by capsaicin (Chapter 3, Fig. 3.1). 
Hence, the present studies have attempted to establish the presence of NK1 
receptors in skeletal muscle tissue by examining [ 1251]-Bolton-Hunter substance P 
([
125I]-BHSP) binding in rat soleus muscle sections. Furthermore, the effects of 
capsaicin pretreatment on [ 125I]-BHSP binding, previously shown to increase [ 1251] 
BHSP binding in guinea-pig vas deferens (Mussap et al., 1989), was examined in 
this tissue. 
[ 1251]-BHSP (2,200 Ci/mmol) was purchased from New England Nuclear 
(Boston, MA, USA). Chymostatin, leupeptin, bacitracin, bestatin and 
phosphoramidon were purchased from the Sigma Chemical Company. Tachykinin 
peptides were obtained from the sources mentioned in section 3.2.2. 
Longitudinal sections (15 j.tM) of tissue were cut frotit the soleus muscles of 
vehicle and capsaicin pretreated animals (see Chapter 3, section 3.2.4 for 
pretreatment protocol) using a cryostat (Leica, Germany) set at -16 to -18°C. 
Sections were thaw-mounted onto gelatine-coated glass slides in duplicate, and 
desiccated overnight under vacuum to be used immediately, or stored at -70°C for 
later use. Autoradiographic studies were performed using the method of Lew et al. 
(1990). Sections were equilibrated to room temperature and preincubated twice for 
5 minutes in 170 mM Tris buffer (pH 7.4, 25°C), containing 0.02% BSA, to 
remove bound endogenous tachykinins. A further 10 minute incubation in the 
above buffer containing MnC12 (3 mM), bacitracin (40 tig.m1 1 ), chymostatin (4 
pg.m1-1 ), leupeptin (4 tig.m1 -1 ), bestatin (10 1.1M), and phosphoramidon (5 tiM) 
ensured the inhibition of endogenous peptidases. Sections were then incubated for 
45 minutes with 90 pM [ 1251]-BHSP, washed (4 x 2 minutes) in ice-cold 170 mM 
Tris (pH 7.4, 4°C) with 0.02% BSA and MnC12 (3 mM), then rinsed in ice-cold 
distilled water. Non-specific binding was determined by incubating sections with 
[ 1251]-BHSP in the presence of 1 [IM unlabelled SP. 
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Labelled sections were dried and apposed to 3H Hyperfilm (Amersham, 
Buckinghamshire, UK) for 3 weeks at 4°C. Hyperfilms were developed under 
light-safe conditions in Ilford Phenisol x-ray developer (4.5 minutes at 7°C), and 
fixed in Ilford Hypam x-ray rapid fixer containing Ilford Hypam x-ray hardener (5 
minutes at 25°C). The films were then washed, dried and used as negatives to 
generate corresponding positive black and white photographic prints. 
Figure 1 shows the presence of localised, specific binding of [ 125I]-BHSP to 
rat soleus muscle sections that may indicate the presence of NK1 receptors in this 
tissue. Histological examination of the sections suggested that the binding was 
associated with blood vessels (data not shown). However, the morphology of the 
tissue was poor and it was not possible to determine whether the binding was 
located on the endothelium, vascular smooth muscle, or both. 
Multiple measurements of relative optical density (R.O.D) were made over 
areas where binding was localised, in sections from both vehicle and capsaicin 
pretreated rats, using Analytical Imaging Station (AIS) software (Fig. 2). Mean 
values (± s.e.) were calculated for each set of sections from individual animals and 
these show an increase in specific [ 125I]-BHSP binding in soleus muscle sections 
from rats pretreated with capsaicin. However, this increase was not statistically 
significant by Student's t-test (P<0.05), an observation that may be due to the low 
number of experiments performed. Nonetheless, these findings are similar to those 
of Mussap et al. (1 989) who suggested that the increase in [ 125I]-BHSP binding in 
the outer longitudinal smooth muscle of the guinea-pig vas deferens may have been 
due NK1 receptor upregulation in response to sensory neuron loss. 
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Appendix 1 Fig.l. Photomicrographs taken directly from 3H-Hyperfilm images of 
1 12511-Bolton-Hunter substance P (1 1251-BHSP) binding to longitudinal sections of 
soleus muscle obtained from rats pretreated 14 days previously with vehicle or 
capsaicin. White represents areas of high binding density (arrows). Panels A and 
B show total and non-specific binding, respectively, in vehicle pretreated controls, 
whereas panels C and D show total and non-specific binding, respectively, in 
capsaicin pretreated rats. Note that non-specific binding is uniformly low for both 
treatment groups, whereas total binding appears to be greater in the capsaicin 
pretreated rats. Bar = 1 mm. 
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Appendix 1 Fig. 2. Multiple measurements of relative optical density (R.O.D.) of 
total, non-specific (NSB) and,: therefore, specific (SB) [ 1251]-Bolton-Hunter 
substance P ([' 251]-BHSP) binding to longitudinal sections of soleus muscle 
obtained from rats pretreated 14 days previously with vehicle or capsaicin. 
Measurements were made over areas of localised binding from 2-3 experiments. 
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Appendix 2 
Weight trials of animals pretreated systemically with capsaicin (125 mg. kg -1 ) or 
vehicle (10% Tween 80, 10% ethanol in normal saline) over the 3-day injection 
protocol, and just prior to perfusion (final weight). Experimental methods are 
given in detail in Chapter 3, section 3.2.4. Capsaicin pretreatment. 
Pretreatment 
group 
Pretreatment 
type 
in Weight during protocol (g) 2Final 
weight (g) 
Day 1 Day 2 Day 3 
1 Day Vehicle 5 173.0±6.1 177.2±6.5 171.8±5.6 171.0±4.2 
Capsaicin 5 178.2±5.0 180.0±5.4 166.0±6.8 168.0±4.2 
7 Days Vehicle 5-6 151.8±2.3 154.3±3.4 152.8±3.3 194.0±1.8 
Capsaicin 5-6 157.7±2.2 160.0±3.2 145.2±3.4*t 196.2±2.9 
14 Days Vehicle 5-9 97.8±1.0 103.0±1.6* 101.1±1.6 187.4±5.2 
Capsaicin 5-9 104.1±1.3 104.7±2.1 96.0±2.4**1 184.0±4.5 
Total Vehicle 15-20 132.8±7.7 138.7±7.7 136.1±7.4 184.1±3.4 
Capsaicin 15-20 138.7±7.5 144.1±8.1 133.3±8.1 182.7±3.7 
Values are mean ± s.e. mean. *P<0.05 "P<0.01 from day 1 weight. tP<0.05 from day 2 
weight (Student's t-test). 
'Number of animals vary due to a 25% total mortality rate during pretreatment protocol. 
2Final weight not included in statistical analysis. 
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Summary 
Previous studies with the vanilloid spice principle capsaicin have demonstrated a biphasic 
VO2 response, with vasoconstriction, in the perfused rat hindlimb that has led to suggestions 
of vanilloid receptor subtypes (VNI/VN2) in this preparation (1). In the present study, the 
known competitive vanilloid antagonist capsazepine inhibited the above capsaicin-mediated 
effects in a manner that was indicative of binding at specific vanilloid recognition sites. Low 
concentrations of capsazepine selectively inhibited the increased VO 2 produced by the 
putative VN I receptor at submicromolar concentrations of capsaicin, while the inhibition of 
VO2 produced by high concentrations of capsaicin (putative VN2) was enhanced. These 
observations, showing different susceptibilities to blockade by capsazepine, further support 
the presence of two vanilloid receptor subtypes in the rat hindlimb. Schild plots of the data 
yielded variable slopes that approach unity at greater responses to capsaicin (mean Kg = 8.44 
± 2.08 nM and 7.28 ± 0.78 11M for V02 and perfusion pressure curves, respectively). Low 
concentrations of the capsaicin antagonist ruthenium red selectively blocked the putative 
VN2 receptor-mediated effects produced by high concentrations of capsaicin. The non-
competitive nature of this inhibitor suggests an operation through separate receptor-coupled 
ion channel complexes at high and low concentrations of the vanilloid. Tetrodotoxin failed to 
attenuate any changes produced by capsaicin, suggesting that the mechanism of action of 
capsaicin in the rat hindlimb may differ from other tissues. 
Key Words: capsaicin, capsazepine, ruthenium red, receptor subtypes, oxygen consumption, vasoconstriction 
The mechanism by which vanilloid spice principles elicit their effects on a variety of target tissues 
has received particular attention in recent reviews (2, 3). Most studies on the actions of the 
vanilloids have been restricted largely to capsaicin, from the fruit of Capsicum sp., a compound best 
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known for its excitatory, desensitising and toxic effects on a subset of unmyelinated (C-) or thinly 
myelinated (A8-) sensory neurones (4). The sensitivity of these neurones to capsaicin is likely to be 
due to the presence of a cation channel that, when stimulated by vanilloids, allows the influx of 
various cations facilitating the release of several neuropeptides (2, 5). 
Substantial evidence has now accumulated indicating that the actions of both capsaicin and the 
ultrapotent analogue resiniferatoxin (RTX) are mediated via a specific vanilloid recognition site that 
is believed to be related intimately with the capsaicin-operated cation channel (6). This notion has 
been strengthened by the recent development of capsazepine, the first competitive antagonist shown 
to be selective for the actions of capsaicin on central nerve endings in the rat (7, 8), in functional 
studies on capsaicin-mediated ion uptake in the same neurones (9), and contraction of smooth 
muscle (10). 
Radioligand binding studies using [ 311]-RTX have permitted the biochemical characterisation of the 
vanilloid receptor (11-13) and have demonstrated species heterogeneity, as well as possible 
intraspecies receptor subtypes (14). Peripheral vanilloid receptors in the urinary bladder (15), colon 
(16), and urethra (17) of the rat all bind [ 3I-1]-RTX in a non-cooperative fashion, and show 
decreased affinity for RTX, that is distinct from the positive cooperativity of [ 311]-RTX binding 
central receptors (13, 15). Additionally, capsaicin inhibits specific [ 31-1]-RTX binding to central 
vanilloid receptors with a 7 to 10-fold higher affinity than the competitive antagonist capsazepine 
(18), while at peripheral receptors in the colon, the order of potency is reversed (16). 
The evidence for peripheral vanilloid receptor subtypes is limited to RTX showing some differential 
affinity for receptor binding in the colon (16). On the other hand, Liu and Simon (19) have provided 
evidence for multiple central nervous system vanilloid receptor types where patch-clamped rat 
trigeminal neurones exhibit two types of inward current (one fast and one slow 
activating/inactivating) in response to capsaicin, both of which are sensitive to capsazepine and 
ruthenium red. 
In our laboratory, capsaicin, and a range of other vasoconstricting vanilloids, have been shown to 
stimulate oxygen consumption (V0 2) in the perfused iliac bed of the rat at high nanomolar 
concentrations, while rnicromolar concentrations of vanilloid reduce V02 to levels well below basal 
values (20-22). Both effects are associated with concentration-dependent increases in perfusion 
pressure, indicating constriction of the hindlimb vasculature. The biphasic action on V0 2 in the 
hindlimb is not solely a concentration-dependent feature of capsaicin and other vanilloids. Studies 
from our laboratory (23) and similar work by others (24, 25) have confirmed a similar biphasic 
response to noradrenaline, but with stronger responses at comparatively lower concentrations than 
those observed with the vanilloids. While no definitive link between V0 2 and perfusion pressure 
responses has been established, two possible explanations from our studies in the hindlimb centre on 
either working (contracting) vascular smooth muscle as oxygen consuming tissue, or site-specific 
receptors promoting flow redistribution within skeletal muscle (reviewed in 26). 
Recently, we have postulated the presence of two different vanilloid receptor types (designated 
VN 1 and VN2) in rat hindlimb tissue based on both functional and metabolic evidence (1). Putative 
VN I and VN2 receptors were distinguished on the basis of their differing affinities for capsaicin, 
their different calcium and oxygen dependencies for inducing vasoconstriction, and their ability to 
stimulate or inhibit V02 . In the present communication, we provide further evidence for the 
presence of dual vanilloid receptors in the same preparation. This evidence is the result of studying 
the effects of the selective competitive vanilloid antagonist capsazepine, and the selective non- 
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competitive antagonist ruthenium red on capsaicin-mediated changes in V02 and perfusion 
pressure. Although non-competitive, ruthenium red is thought to selectively impair the vanifloid 
receptor-channel coupling mechanism by a rapid blocking and unblocking of the stimulated cation 
channel (27). These antagonists have proved to be valuable in the present study in determining the 
nature of the biphasic V02 responses produced by vanilloids in the perfused rat hindlimb. 
Additionally, the neurotoxin tetrodotoxin (TTX) was employed to assess the possibility that 
capsaicin acts through specific sensory neurones where dual cellular mechanisms are believed to 
operate (28). Maggi (29) has summarised the available evidence indicating the presence of these 
mechanisms for the release of sensory transmitters from capsthcin-sensitive primary afferent 
neurones, one being TTX-sensitive (low capsaicin concentrations) while the other is TTX-resistant 
(high capsaicin concentrations). In the present study, we have also co-infused tetrodotoxin and 
capsaicin in an attempt to distinguish between these modes of action if they are present in rat 
muscle. 
Methods 
Rat hindlimb perfusion 
All experimental procedures used were approved by the University of Tasmania Animal Ethics 
Committee under the Australian code of practice for the care and use of animals for scientific 
purposes (30). 
Perfusions were conducted using male, 180 to 200g hooded Wistar rats fed a commercial rat chow 
diet containing 21.4% protein, 4.6% lipid, 68% carbohydrate and 6% crude fibre with added 
vitamins and minerals (Gibson's, Hobart). Animals were housed at 21±1°C under a 12h:12h 
light/dark cycle in groups with an accessible and plentiful water supply. 
Anaesthesia, surgery and perfusion procedures were performed as described previously (31). 
Briefly, the left hindlimb of the rat was perfused at 25°C with a modified Krebs-Ringer bicarbonate 
buffer containing 8.3mM glucose, 1.27mM CaCl 2 and 2% w/v dialyzed bovine serum albumin 
(Fraction V). The perfusate reservoir was gassed with 95% 0 2-5% CO2 at 4°C and pumped by a 
peristaltic pump at a constant rate of 4.0±0.1 ml/min through a heat exchange coil, maintained at 
25°C, and a sealed silastic lung continually gassed with the above 02/CO2 mixture. This ensured 
constant perfiusate temperature and arterial P02 levels. The medium entered and exited the rat 
hindlimb via cannulas inserted into the aorta (Surflo I.V. catheter, 20G, Terumo, USA) and vena 
cava (Surflo I.V. catheter, 16G, Terumo, USA) respectively. 
In perfusions involving sympathetic nerve stimulation the lumbar sympathetic trunk was ligated, cut 
and pulled perpendicular to the aorta in contact with two stainless steel electrodes connected to a 
stimulator. Liquid paraffin and parrafin film were placed under the electrodes to prevent stimulation 
of surrounding tissues. The hindlimb was perfused with the above medium containing 1 pM 
tubocurarine to prevent motor neurone activity. After equilibration, the sympathetic trunk was 
stimulated with 5V square waves of 5 ms pulse width with variable frequency. 
The oxygen content of the venous effluent was measured continuously using an in-line 0.5m1 Clark-
type oxygen electrode while perfusion (arterial) pressure was monitored by means of a pressure 
transducer proximal to the aorta. The method of calculation of V0 2 has been described previously 
(31). Values for V02 calculation and perfusion pressure were taken only after steady state 
conditions were obtained. 
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Agent infusion 
The infusion of various agents into the hindlimb occurred only after the perfusion had reached 
steady state V02 and pressure. All agents were either freshly prepared before each experiment, or 
prepared and then stored at 4°C if chemically stable. Due to the lipophilic nature of vanilloids and 
their affinity for silicon-based tubing, capsaicin was dissolved in 50% ethanol and infused using a 
syringe pump (Model 2620, Harvard apparatus, USA) driving a 1.0 ml glass syringe equipped with 
teflon tubing. All other agents were infused with a second pump (Model 355, Sage instruments, 
Orion Research Inc., USA) using an identical 1.0 ml glass syringe. Capsazepine was dissolved in 
70-80% ethanol, ruthenium red and tetrodotoxin in glass-distilled water, the latter with 5 mg citrate 
buffer contained in a sealed vial. Where ethanol was used as the vehicle, special care was taken to 
limit the infusion rate (usually to below 10 pl/min) to avoid the perturbation of effects by this 
organic solvent. 
For all experiments, the concentration-response curves for capsaicin were constructed in a 
cumulative manner with at least two low (submicromolar) doses and two high (tnicromolar) doses. 
The addition of each dose occurred only after V0 2 and perfusion pressure steady state was attained 
with the preceding dose. Where the effects of capsaicin were examined against capsazepine, 
ruthenium red, or tetrodotoxin, the relevant inhibitor was first infused alone to detect any changes 
that these drugs may elicit. Increasing concentrations of capsaicin were subsequently co-infused. 
After the removal of the final capsaicin concentration, the inhibitor was also removed and the 
hindlimb was allowed to return to basal values of steady state V02 and perfusion pressure. 
In a separate set of control perfusions, capsazepine and ruthenium red were tested against the V02 
and perfusion pressure changes induced by serotonin (5-HT) (0.35 jtM), low (50 nM) and high (5 
oM) concentrations of noreadrenaline, and angiotensin II (3 riM) to establish selectivity of the 
antagonists for the effects of capsaicin. Tetrodotoxin (0.3 oM) was infused against the V02 and 
perfusion pressure changes induced by low (0.5 Hz) and high (5 Hz) frequency sympathetic nerve 
stimulation. 
Statistical analysis 
Statistical analysis of the data was performed by use of Student's t-test or by analysis of variance 
(ANOVA), where applicable. All values are given as the mean ± standard error (s.e.) mean. The 
Schild plots were constructed from V02 and perfusion pressure log concentration-response curves. 
Dose ratios were estimated at responses between 15% and 85% of maximum. 
Drugs and chemicals 
Bovine serum albumin (Fraction V) was purchased from Boehringer Mannheim (Australia); 
capsaicin, noradrenaline, angiotensin II, serotonin, ruthenium red, and tetrodotoxin from Sigma 
(USA); capsazepine from Research Biochemicals International (USA); pentobarbitone sodium 
(Nembutal, 60 mg/ml) from Bomac Laboratories Pty. Ltd. (Australia); heparin sodium from David 
Bull Laboratories (Australia); NaC1, KC1, KH 2PO4 , MgSO4 , NaHCO3, CaC12 and D-Glucose from 
Ajax Chemicals Ltd. (Australia). 
Results 
For experiments with capsazepine, the mean basal arterial P02 was 695.7±5.1 mm Hg and the 
unstimulated mean venous P0 2 was 366.9±10.3 mm Hg (n=31). Mean basal oxygen consumption 
(V02) and perfusion pressure were 7.9±0.3 pmol. g. -1 11-1 and 28.5±-0.7 mm Hg respectively 
(n=3 1). 
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Capsaicin produced a concentration-dependent biphasic response in V0 2 (Fig. 1A) and an 
associated vasoconstriction-induced rise in perfusion pressure (Fig. 1B) matching that seen by 
Colquhoun etal. (1). A maximum increase in V02 (1.2±0.1 pmol. g. -I h-I) was observed at 0.5 pM 
capsaicin coupled with an increase in perfusion pressure of 9.0±0.9 mm Hg. The highest 
concentration of capsaicin used (5 tiM) produced a strong inhibition of V02 (1.9±0.2 jmo1. g. -1 h-1 
below basal) with a greater increase in perfusion pressure of 31.6±2.1 mm Hg. 
The infusion of capsazepine alone at the concentrations used to inhibit responses to capsaicin failed 
to alter any basal parameters, and is therefore unlikely to be intrinsically active. Capsazepine did not 
cause statistically significant alterations (P0.05) in V02 and perfusion pressure changes induced by 
serotonin (5-HT), angiotensin II, or low and high concentrations of noradrenaline (data not shown). 
Capsazepine (0.32-32 pM) produced a concentration-dependent rightward shift in the 
concentration response curves to capsaicin, most evident in the perfusion pressure changes (Fig. 
1B) and inhibition of V02 (Fig. 1A). The slopes of Schild plots constructed from dose ratios 
estimated at various levels of V0 2 inhibition show that as the response becomes greater (i.e. greater 
inhibition of V02) the Schild regressions approach a slope close to unity (Fig. 2A.). 
With the infusion of 3.2 ELM and 10 ttM capsazepine, a maximal perfusion pressure response was 
achieved with the addition of 5 ELM of the agonist (capsaicin). This maximal concentration increased 
to 20 JIM capsaicin at the highest dose of capsazepine (32 pM). Schild regressions constructed 
from the perfusion pressure data (Fig. 2B.) showed a similar pattern to those for V0 2 in that a 
decrease in slope is evident from dose ratios estimated at greater responses to capsaicin, although 
they differ in the range of their slopes and the points of intercept on the abscissa. Thus for Fig. 2A 
the slopes decreased progressively from 1.81 to 1.01, whereas the slopes from Fig. 2B decreased 
from 2.04 to 1.45. 
In contrast to Fig. 1B, Fig. 1A shows aberrant behavior with capsaicin in the presence of 
capsazepine. At a low concentration of capsaicin (0.5 pM), low concentrations of capsazepine 
cause an initial fall in response (decreased stimulation of V02), followed by a temporary increase in 
response at higher concentrations of the antagonist (see (i) inset Fig. 1A). A further increase in 
capsazepine concentration caused a second but steady decrease in response. At higher 
concentrations of capsaicin (2-5 pM), the V0 2 response is initially enhanced by low concentrations 
of capsazepine (enhanced inhibition of V02) followed by a steady decrease in response at higher 
concentrations of the antagonist (see (ii) inset Fig. 1A). It appears, therefore, that low 
concentrations of capsazepine are selectively blocking the stimulatory V02 effects produced by low 
concentrations of capsaicin, resulting in the enhancement of the inhibitory V0 2 effects produced by 
high concentrations of the vanilloid. 
Near maximal inhibition of V0 2 was obtained at high concentrations of the agonist with all 
concentrations of capsazepine. Maximal low dose responses (stimulatory on V02) were not 
achieved at capsazepine concentrations of 1, 10 or 32 pM, an observation likely to be a function of 
the capsaicin concentrations chosen in the initial infusion protocol. 
Infusion of ruthenium red (0.01-1.0 pM) alone did not affect mean basal arterial P0 2 (702.6±7.9 
mm Hg), venous P02 (419.3±4.6 mm Hg), V02 (6.8±0.3 pmol. g. -1 h. -1 ), or perfusion pressure 
(24.8±0.3 mm Hg, n=4). The antagonist also failed to show statistically significant inhibition 
(PA.05) of the V02 and perfusion pressure changes induced by serotonin, angiotensin H, and low 
and high concentrations of noradrenaline (data not shown). 
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Fig. 1 
Effect of capsazepine (CPZ) on concentration-response curves for capsaicin-induced 
changes in A. oxygen consumption (V02), and B. perfusion pressure in the isolated 
perfused rat hindlimb: control (0); 0.32 pM CPZ (0); 1.0 ttM CPZ (A); 3.2 pM CPZ (A); 
10.0 pM CPZ (•); and 32.0 iM CPZ (•) in 4-1 1 experiments. All values are mean ± se. 
mean, *13.0.05 **13 0.01 (ANOVA) against control. Inset (panel A) shows the AVO2 
response to (i) 5 x I 0 Tvi and (ii) 5 x 10-6 M capsaicin with increasing concentrations of 
CPZ. The dotted line shows the control AVO2 at these concentrations of capsaicin. 
-5 -4 -6 	-5 	-4 	-7 	-6 
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Fig. 2 
Multiple Schild plots of the data presented in Fig. 1. A. Regressions were constructed from 
dose ratios estimated at four different levels of the inhibitory V02 response: a. 0 gmol. 
W I , slope = 1.87; b. -0.5 limo!. 	slope = 1.61; c. -1.0 gmol. g1 . W I, slope = 1.37; and 
d. -1.5 gmol. 	if', slope = 1.01. The mean Kg derived from the four Schild plots was 
8.44 ± 2.08 04. B. Regressions constructed from dose ratios estimated at four perfusion 
pressure responses: a. 15 mm Hg, slope = 2.04; b. 20 mm Hg, slope = 1.52, c. 23 mm Hg, 
slope = 1.49; and d. 25 mm Hg, slope = 1.45. Mean Kg from the four regressions was 7.28 
± 0.78 gM. Reduction in the number of plot points occurs where some concentration-
response curves were shifted to the left of the control curves. 
Ruthenium red produced a concentration-dependent inhibition of both V02 (Fig. 3A) and perfusion 
pressure (Fig. 3B) responses induced by capsaicin. For both V0 2 and perfusion pressure, the 
maximal response to the vanilloid agonist was markedly depressed in comparison to the control 
curve, and was almost completely abolished by the infusion of 1 gM ruthenium red. The stimulation 
of V02 at 0.5 gM capsaicin was inhibited by only 18% with the infusion of 0.1 p.M ruthenium red. 
The same concentration of the dye attenuated the inhibition of V02 produced by both 2 gM and 5 
gM capsaicin by 87% and 88% respectively. 
A similar response was evident for perfusion pressure changes to the infusion of 0.5 gM and 5 04 
capsaicin in the presence of 0.1 gM ruthenium red. The increase in pressure produced by the lower 
dose of capsaicin was inhibited by 32%, while that for the higher doses was reduced by 82%. 
Tetrodotoxin (0.3gM) failed to inhibit V0 2 and perfusion pressure changes induced by low or high 
concentrations of capsaicin, but was effective at blocking similar changes induced by low and high 
frequency sympathetic nerve stimulation in the rat hindlimb preparation (data not shown). 
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Fig 3 
Effect of ruthenium red on concentration-response curves for capsaicin-induced changes in 
A. Oxygen consumption (V02); and B. perfusion pressure in the isolated perfused rat 
hindlimb: control (0); 0.01 gM ruthenium red (RR) (A); 0.1 gM RR (A); and 1.0 gM RR 
(•) (all n-----4). Values are mean ± s.e. mean. *I3 0.05 **P0•01 (ANOVA) against control. 
Discussion 
Capsaicin-induced vasoconstriction in isolated arteries has been attributed in the past to non- 
selective effects that occur via the direct physicochemical interaction of capsaicin with smooth 
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muscle plasma membranes, and do not exhibit desensitisation (reviewed by 2, 32). There are few 
reports, however, describing the effects of capsaicin on oxygen consumption in individual tissues. 
We believe that our previous (1, 20-22) and current findings represent a novel insight into the 
effects of capsaicin in peripheral tissues. While repeated application of vanilloids in the rat hindlimb 
did not produce desensitisation (22), a hallmark of the specific capsaicin action on sensory 
neurones, the present findings clearly indicate that the effects produced by capsaicin in this 
preparation are highly selective and very likely to be receptor-mediated. 
Infusion of capsazepine into the rat hindlimb produced competitive antagonism of capsaicin-
stimulated changes in V02 and perfusion pressure (Figs. IA and 1B). The inability of capsazepine 
to inhibit other non-vanilloid agonists, that produce effects similar to those of capsaicin, suggests 
that capsazepine is highly specific for the actions of the vanilloid. Similar patterns of specific 
competitive antagonism by capsazepine have been observed in other systems where the effects of 
capsaicin are thought to be receptor-mediated (9, 10). Thus it is likely that capsaicin also operates 
via distinct vanilloid recognition sites in rat hindlimb tissue. 
The reproducible biphasic nature of the capsaicin-induced V0 2 responses suggests the operation of 
a dual vanilloid receptor mechanism in the hindlimb preparation (1). These consistent observations 
are unlikely to be an artefact of these experiments as the perfusion technique used in these studies 
has been validated extensively in the past (see 26 for review). 
The concept of one agonist acting on two opposing receptor types has been recently reviewed by 
Rovati and Nicosia (33) who attempted to distinguish the bell-shaped response curves produced by 
such interactions from those produced by partial agonists. A similar model developed earlier by 
Szabadi (34) proposed that an antagonist acting preferentially on one of the opposing receptor 
types will potentiate the effect produced by the other, and the net effect will be evident in the 
overall dose-response curve. 
In the present investigation, we have been able to demonstrate similar effects by selectively 
inhibiting the stimulatory (low dose/VN 1 ) component of the biphasic V02 response to capsaicin 
with 0.32 I.LM and 1 tM capsazepine. This resulted in potentiation of the inhibitory (high 
doseNN2) V02 component. That is a single agonist (capsaicin) seems to act on two receptor types, 
one stimulatory and one inhibitory, to produce an overall biphasic curve, as demonstrated in Fig. 4. 
The VN I receptor is suggested to be responsible for the increases in V02 seen at submicromolar 
concentrations of capsaicin. The lower affinity VN2 receptor produces a more pronounced 
inhibitory effect on V02 at capsaicin concentrations exceeding 1 AM. The theoretical curve 
VNI+VN2 represents the combined effect of the two receptors and models the biphasic curve 
derived from the infusion of increasing concentrations of capsaicin. We propose that low 
concentrations of capsazepine (0.32 AM and I AM) have selectively inhibited the putative VI‘l i 
receptor and, consequently, the stimulation of V0 2 that it produces. Hence a shift in the balance of 
agonist occupancy has occurred in favour of the putative VN2 (inhibitory) receptor. As a result, the 
inhibitory V02 response has become more pronounced in the overall concentration-response curves 
produced in the presence of low concentrations of capsazepine. 
The complex interaction of agonist and antagonist interacting with two opposing receptor types, 
having different affinities, may have altered the dose ratios sufficiently to account for the steepness 
of some of the Schild regression slopes. We believe that as the inhibition of V0 2 becomes greater 
(by increasing capsaicin concentration) the emphasis of binding is placed in favour of the putative 
VN2 receptor. As a result, the Schad plots derived at higher inhibitory V0 2 responses resemble 
more closely a single receptor-agonist/antagonist interaction. Steepness in Schild plots can also ' 
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A concentration-response curve model of oxygen consumption for putative vanilloid 
subtypes VNI and VN2 in the perfused rat hindlimb. VN I and VN2 curves were constructed 
by applying the four parameter logistic equation used by Rovati and Nicosia (33). EC 50 (0.3 
AM) and IC50 (1.6 iiM) values for this equation were estimated from Fig. 1A. Maximal VI•li 
and VN2 responses were estimated at 1.2 and -3.0 units, respectively. These receptor types 
show different affinities for capsaicin that is reflected in the observed concentration-response 
curve, represented by the sum of the theoretical VN I and 'VN2 curves (VNI+ VN2). The 
inhibition of the VN 1 receptor type by low concentrations of capsazepine shifts the balance 
of agonist occupancy in favour of the opposing VN 2 receptor, hence causing the effect 
produced by this latter receptor type to predominate before it is also inhibited at higher 
capsazepine concentrations. 
represent a non-equilibrium steady state between the antagonist and receptor, or the presence of a 
saturable antagonist removal mechanism (35). In this study, an antagonist removal mechanism may 
be present due to the use of bovine serum albumin (BSA) medium to act as the necessary oncotic 
agent. Recent trials in our laboratory have shown a 10-20 fold greater potency for capsaicin when 
2% BSA is replaced by 4% Ficolle (Phannacia, Sweden) in the perfusion medium (data not 
shown), that is most likely due to the vanilloid binding to BSA. Capsazepine, being a structural 
analog of capsaicin, may also have a similar susceptibility to binding to BSA, however, on this basis 
it is difficult to account for the decreases in Schild plot slope when the dose ratios were estimated 
at greater agonist responses. 
By contrast, Schild regressions obtained for the perfusion pressure data do not fully support our 
dual receptor proposal. These observations may be a result of the inability to distinguish between 
the similar vasoconstriction response produced by putative VNI and VN2 receptors, unlike the 
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opposing responses on V02 where VN I and VN2 effects can be distinguished with the infusion of 
low concentrations of capsazepine. 
In the hindlimb preparation, 1 gM ruthenium red produced a specific but non-competitive inhibition 
of capsaicin-induced responses (Fig. 3) similar to that seen in the rat vas deferens and urinary 
bladder where the maximal responses to the vanilloid are potently antagonised (10). Again, this 
inhibition has been shown to be specific since the above concentration of ruthenium red used to 
block the effects of capsaicin did not alter the actions of other non-vanilloid agonists. 
The infusion of submicromolar concentrations of the dye produced strong inhibition of the V02 and 
perfusion pressure effects of high (tnicromolar) concentrations of capsaicin, while low dose 
capsaicin responses showed only mild inhibition. We believe that the apparent selective antagonism 
of high dose capsaicin responses by low concentrations of ruthenium red further supports the 
notion of a dual vanilloid receptor system. 
Given the suggested intimacy between putative vanilloid receptors and non-selective cation 
channels (6), it follows that if different vanilloid receptor types exist, then there could also be 
heterogeneity in the receptor-channel coupling system as a whole. The pattern of inhibition by low 
dose ruthenium red in rat hindlimb tissue certainly suggests that this may be the case and warrants 
further investigation. 
Our observations with tetrodotoxin (TTX) in the perfused rat hindlimb are in contrast to those 
found by Lou et al. (28) in the perfused guinea-pig lung where the same concentration of the toxin 
(0.3 gM) inhibited the bronchoconstriction produced by low concentrations of capsaicin. The TTX-
resistant nature of capsaicin-mediated changes in the rat hindlimb raises speculation regarding the 
cellular mechanisms promoted by vanilloids in this preparation. In view of recent reports by 
Akopian et al. (36) of a TTX-resistant voltage-gated sodium channel on capsaicin-sensitive rat 
dorsal root ganglion (DRG) neurones, it follows that capsaicin could possibly activate the opening 
of similar channels in rat skeletal muscle. However, attempts by these authors to detect such a 
channel in muscle have not been successful. Consequently, there exists the possibility that the 
cellular mechanisms promoted by capsaicin at low concentrations in the perfused rat hindlimb 
preparation could differ from other tissues, but more evidence is undoubtedly required. 
At present, the role of sensory neuropeptides in capsaicin-mediated changes in the perfused 
hindlimb remains undetermined. Preliminary experiments in our laboratory with non-peptide 
neurokinin (NK, tachykinin) antagonists also suggest that only some of the actions mediated by the 
putative VN receptors are due to the release of tachylcinins from sensory neurones (data not 
shown). Antagonists for other key neuropeptides are currently being examined including calcitonin 
gene-related peptide (CGRP) in light of recent suggestions for a role of this messenger in 
carbohydrate metabolism in skeletal muscle, and its release from sensory neurones in this tissue in 
response to vanilloids (37). 
In conclusion, using specific competitive and non-competitive vanilloid receptor antagonists, we 
have obtained further evidence in support of the hypothesis of dual vanilloid receptors (VN I and 
VN2 receptors) controlling the biphasic V02 responses to capsaicin in the perfused rat hindlimb 
(1). Although the perfusion pressure responses do not show a distinct dual receptor effect (eg. by a 
point of inflection in the perfusion pressure concentration-response curves) we belieye that the 
inflection may be masked by an overlap in the VN I and VN2 responses that produce the same 
positive effect on vascular tension. 
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Although the effects of capsaicin in the rat hindlimb are likely to be receptor and cation channel-
mediated, the possibility exists that the post-receptor mechanisms are not entirely like those 
proposed for other systems given the resistance to TTX at all vanilloid concentrations tested. 
Capsaicin's action in the rat hindlimb may only partially involve the stimulation of sensory 
neurones, and release of neuropeptides, and may include direct interactions with vanilloid receptors 
in locations distinct from sensory neurones, such as vascular smooth muscle cells. However, the 
evidence supporting the above hypotheses is, at present, speculative and requires closer 
investigation. 
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ABSTRACT 
In perfused rat skeletal muscle (hindlimb), capsaicin either stim-
ulates (submicromolar concentrations) or inhibits (micromolar 
concentrations) oxygen consumption (V0 2). Both VO2 effects 
are associated with vasoconstriction, evident as an increase in 
perfusion pressure (PP), under constant flow. We have pro-
posed that these effects are mediated by two vanilloid receptor 
subtypes: VN, (stimulation of V0 2) and VN2 (inhibition of V02) 
(Colquhoun et al., 1995; Griffiths et al., 1996). In the present 
study, the role of capsaicin-sensitive neurons and sensory neu-
ropeptides in the VN 1NN2 receptor actions of capsaicin was 
investigated. The observed maximum stimulation of V0 2 by 
capsaicin (0.4 AM; AV02 , 1.35 -± 0.14 Amol g1 h -1 ) was 
accompanied by mild vasoconstriction (APP, 5.8 ± 0.6 mm 
Hg). In contrast, 2 p.M capsaicin produced strong inhibition of 
VO2 (V0, -2.25 ± 0.23 Amol g -1 11 -1 ) with pronounced 
vasoconstriction (APP, 28.0 ± 1.3 mm Hg). V0 2 stimulation was 
significantly inhibited (P < .05) by the selective NK1 receptor 
antagonist CP-99994 (1 AM) and the NK2 receptor antagonist 
SR 48968 (1 AM) (by 42% and 51%, respectively), but PP was 
not altered. Infused SP and neurokinin A (NKA) stimulated V0 2 
(observed maximum AV02 , 0.52 ± 0.06 and 0.53 ± 0.08 Amol 
g 1 h -1 , respectively; EC,, values, 269 ± 23 and 21.2 ± 3.0 
nM, respectively) and induced mild vasoconstriction (4.30 ± 
0.33 and 6.75 ± 1.18 mm Hg, respectively; EC 50 values, 352 ± 
25.7 and 25.5 ± 2.7 nM, respectively). Neurokinin B (NKB) also 
stimulated V02 (maximum not determined) and vasoconstriction 
(maximum APP, 3.40 ± 0.25 mm Hg; EC 50, 34.4 ± 5.2 nM). The 
rank order of potency for the tachykinins in this preparation was 
NKA > NKB > SP, which suggests stimulation primarily of NK2 
receptors. Although infused calcitonin gene-related peptide 
(CGRP) did not alter hindlimb V0 2 or PP, the selective CGRP 
antagonist CGRID03 _37) markedly potentiated the inhibition of V02 
produced by 1 AM capsaicin (84%) and the maximum capsaicin-
induced vasoconstriction (57%), which indicates that endog-
enously released CGRP may act as a vasodilator. Hindlimbs per-
fused 1 day after capsaicin pretreatment showed attenuation of 
capsaicin - induced (0.4 I.LIV1) stimulation of V02 (92%) (P < .05) and 
vasoconstriction (64%), but this retumed to normal after 7 days. 
The inhibition of V02 by 1 AM capsaicin was significantly (P < .05) 
enhanced 7 and 14 days after pretreatment (66% and 140%, 
respectively), as was the maximum vasoconstriction (64% and 
68%, respectively). These data suggest that capsaicin-sensitive 
neurons, presumably via release of SP and NKA, are involved 
in VN, responses and that capsaicin pretreatment potentiates 
VN2 responses, either by depletion of CGRP reserves or by up-
regulation of putative VN 2 receptors. 
The vanilloid spice principle capsaicin and its structural 
analogs (dihydrocapsaicin, resiniferatoxin, piperine, gin-
gerols and shogaols) produce concentration-dependent vaso-
constriction and a biphasic effect on skeletal muscle VO, in 
the constant-flow perfused rat hindlimb (Cameron-Smith et 
al., 1990; Eldershaw et al., 1992; Eldershaw et al., 1994). 
Work from this laboratory suggests that the dual effect of 
vanilloids on V0 2 (stimulation and inhibition at low and high 
capsaicin concentrations, respectively) is mediated by at 
Received for publication December 19, 1997. 
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Research Council of Australia and the Australian Research Council. 
2 Present address: Department of Biomedical Science, University of Tasma-
nia, Launceston, Australia 7250.  
least two vanilloid receptor subtypes, designated VN, (stim-
ulation of V02) and VN, (inhibition of V02) (Colquhoun et al., 
1995). This dual receptor hypothesis has recently been 
strengthened by the inhibition of the opposing VO, responses 
by selective competitive and noncompetitive vanilloid antag-
onists (Griffiths et al., 1996). The putative VN, receptor 
appears to have a higher affinity for capsaicin and is more 
susceptible to blockade by capsazepine, a known competitive 
vanilloid antagonist (Urban and Dray, 1991; Bevan et al., 
1992). On the other hand, the VN2 receptor has low affinity 
for capsaicin and capsazepine but is particularly sensitive to 
ruthenium red, a selective functional capsaicin antagonist at 
submicromolar concentrations (Amann and Maggi, 1991). 
Although our previous findings show that the dual effects 
ABBREVIATIONS: SP, substance P; NKA, neurokinin A; NKB, neurokinin B; CGRP, calcitonin gene-related peptide; V0 2 , oxygen consumption; 
P02 , partial pressure of oxygen; PP, perfusion pressure; BSA, bovine serum albumin; EC 50 , 50% of maximum response. 
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of capsaicin in perfused muscle are likely to be mediated by 
vanilloid receptor subtypes, the underlying mechanisms by 
which VN, and VN, receptors produce these responses are 
unknown. In other tissues, vanilloid receptors are thought to 
be coupled to nonselective cation channels on certain C-type 
and AS-type sensory neurons (James et al., 1993). In fact, the 
recent cloning of a capsaicin receptor from dorsal root ganglia 
has revealed a 95-kD ion channel that is structurally related 
to members of the transient receptor potential (TRP) family 
of ion channels (Caterina et al., 1997). Stimulation of these 
receptors facilitates the co-release of several neuropeptide 
transmitters, including the tachykinins SP and NKA, and 
CGRP (reviewed by Holzer, 1991). A hallmark of capsaicin 
action on peptide-containing neurons is its ability to induce a 
refractory state of sensory neuron block with prolonged or 
repeated in vitro application or after systemic administration 
(reviewed by Szolcsanyi, 1993). 
Sensory neuropeptides released by capsaicin may produce 
a variety of biological responses, including changes in vascu-
lar tone and permeability, smooth muscle contraction, and 
inflammation (reviewed by Holzer, 1991). The actions of 
tachykinins are mediated by at least three receptor subtypes: 
SP-preferring NK1, NKA-preferring NK2 and NICB-prefer-
ring NK3 receptors (reviewed by Mussap et al., 1993; Maggi 
et al., 1993; Regoli et al., 1994). These receptor preferences 
were originally based on the rank orders of potency of endog-
enous agonists, although each of the tachykinins will stimu-
late all three receptor types with varying affinity (Regoli et 
al., 1994). NK1 receptors are widely distributed in both the 
CNS and peripheral tissues, whereas NK2 receptors are 
found mainly in peripheral tissues (predominantly on smooth 
muscle) and NK3 receptors in the CNS, although the latter 
are expressed in the rat portal vein and guinea pig myenteric 
plexus (Mastrangelo et al., 1987; Guard et al., 1990). At 
present there is little evidence for the presence of tachykinin 
receptors in skeletal muscle cells or skeletal muscle vascula-
ture, although SP dilates the rat cremaster vasculature by a 
mechanism that is believed to involve the stimulation of NK1 
receptors (Brock and Joshua, 1991), and vasodilation induced 
by stimulation of the rabbit tenuissimus muscle nerve is 
blocked by the SP antagonist spantide (Persson et al., 1991). 
Receptors for CGRP are tentatively divided into two dis-
tinct subtypes (CGRP, and CGRP2) on the basis of the dif-
fering ability of C-terminal fragments of the peptide to an-
tagonize the actions of intact CGRP in different preparations 
(reviewed by Poyner, 1995). CGRP receptors are expressed in 
cultured L6 rat skeletal muscle cells (Kreutter et al., 1989; 
Poyner et al., 1992) and whole rat skeletal muscle (Popper 
and Micevych, 1989; Pittner et al., 1996). In addition, capsa-
icin has been shown to elicit vasodilation in a rat skeletal 
muscle preparation (cremaster) by stimulating the endoge-
nous release of CGRP (White et al., 1993). 
The present study attempts to define a role for SP, NKA 
and CGRP in capsaicin-induced responses in the perfused 
hindlimb by 1) employing competitive NK1, NK2 and CGRP 
receptor antagonists (CP-99994, SR 48968 and CGRP (3_37) ), 
2) examining the effects of SP, NKA, NICB and CGRP infu-
sion and 3) examining the role of peptide-containing sensory 
neurons by investigating the effects of capsaicin pretreat-
ment on hindlimb responses to infused capsaicin. 
Materials and Methods 
Rat hindlimb perfusion. All experimental procedures used in 
this study were approved by the University of Tasmania Animal 
Ethics Committee under the Australian Code of Practice for the Care 
and Use of Animals for Scientific Purposes (Australian Government 
Publishing Service, 1990). 
Male Hooded-Wistar rats weighing 180 to 200 g were housed at 
21 -± 1°C under a 12 h:12 h light:dark cycle and fed a commercial rat 
chow diet containing 21.4% protein, 4.6% lipid, 68% carbohydrate 
and 6% crude fiber with added vitamins and minerals. Water was 
supplied ad libitum. 
Animals were anesthetized with pentobarbitone sodium (60 mg/ 
kg) and their left hindlimbs perfused according to the method de-
scribed previously (Colquhoun et al., 1988). In brief, flow was iso-
lated to the left hindlimb by cannulation of the abdominal aorta, 
posterior to the renal vessels, and ligation of the tail, right common 
iliac and cutaneous blood vessels. The hindlimb was perfused under 
constant-flow conditions (4.0 ± 0.1 mi/min) with a modified Krebs-
Ringer bicarbonate buffer containing 8.3 mM glucose, 1.27 mM 
CaCI, and 2% BSA (fraction V) as an essential oncotic agent. All 
perfusions were conducted at 25°C, and the perfusate was continu-
ously gassed with carbogen (95% 0 2/5% CO2) to ensure a constant 
arterial P02 . The oxygen content of the venous effluent was mea-
sured continuously by directing outflow from the cannulated vena 
cave through an in-line 0.5-ml Clark-type oxygen electrode. PP was 
monitored by means of a pressure transducer adjoining the cannu-
lated abdominal aorta. 
The method of calculation of V0 2 has been described previously 
(Colquhoun et al., 1988). Values for V02 calculation and perfusion 
pressure were taken only after steady-state conditions were obtained 
either under basal or drug-induced changes. 
Agent infusion. Neuropeptides were dissolved into 20-id aliquots 
using a 0.01 M acetic acid solution containing 1% p-mercaptoethanol 
and stored at —20°C to maintain chemical stability. The aliquots 
were then diluted, as needed, with 0.9% NaC1 so that the acetate and 
p-mercaptoethanol concentrations were negligible. The neutral en-
dopeptidase inhibitor phosphoramidon (5 uM) was co-infused with 
each neuropeptide (after the infusion of phosphoramidon alone for 5 
min) to prevent enzymatic degradation. Because of the lipophilic 
nature of capsaicin, it was dissolved in 50% ethanol; thus care was 
taken to keep the infusion rates low (usually below 10 Al/min) to 
avoid vehicular perturbation. All other agents were dissolved in 0.9% 
saline. Capsaicin and the neuropeptides were infused with a syringe 
pump (Model 2620, Harvard Apparatus Inc., South Natick, MA) 
driving a 1.0-ml glass syringe (SGE, Australia) equipped with Teflon 
tubing. Other agents were infused with similar infusion pumps 
(Model 355, Sage Instruments, Orion Research Inc., (Beverly, MA or 
Model 11 microinfusion, Harvard Apparatus Inc.) also with an iden-
tical 1.0-ml glass syringe and Teflon tubing. All glass apparatus was 
silanized with Sigmacote before infusion to prevent peptide adhesion 
to glass surfaces. 
In perfusions wherein CP-99994, SR 48968 or CGR13(8 _37) was 
used, a control dose-response curve was first obtained by the cumu-
lative infusion of increasing concentrations of capsaicin, followed by 
a period of recovery after drug removal. After re-establishment of 
basal VO2 and PP, we infused CP-99994, SR 48968 or CGRP (8 ...37) 
alone for approximately 5 min, and then co-infused the antagonist 
while the capsaicin dose-response curve was repeated. When infused 
alone, none of the antagonists induced detectable changes in either 
basal VO2 or PP. 
Capsaicin pretreatment. Desensitization to capsaicin was in-
duced by the method used previously by Cui and Himms-Hagen 
(1992), with a minor modification to the anesthetic used. Briefly, a 
total dose of 125 mg/kg capsaicin was administered, under anesthe-
sia (40-60 mg/kg pentobarbitone), in four s.c. injections over a 3 -day 
period (day 1, 12.5 mg/kg; day 2, 2 x 25 mg/kg; day 3, 62.5 mg/kg). 
Injections were given behind the neck or near the rump where s.c. 
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injection is easier because of the loose skin at these locations. Injec-
tions of the vehicle (10% Tween 80, 10% ethanol in normal saline) 
were given to control animals. The hindlimbs of all animals were 
perfused 1, 7 or 14 days after the final capsaicin (or vehicle) injection, 
and the responses to the infusion of the vanilloid were recorded. 
Drugs and chemicals. SP, NKA, NEB, CGRP and CGRP87 
were purchased from Auspep (Australia); capsaicin, Sigmacote and 
phosphoramidon from the Sigma Chemical Company; BSA serum 
albumin (fraction V) from Boehringer Mannheim (Australia) and 
pentobarbitone sodium (Nembutal, 60 mg/nil) from Bomac Labora-
tories (Australia). Nonpeptide tachykinin antagonists were generous 
gifts: (2S,3S)-3-(2-methoxybenzyl)amino-2-phenylpipericline (CP-
99994) from Dr. S.B. Kadin, Pfizer Inc., Groton, CT, and (S)-N-
methyl-N44-(4-acetylamino-4-phenyl piperidino)-2-(3,4dichlorophe-
nyl) butyllbenzamide (SR 48968) from Dr. X. Emonds-Alt, Sanofi 
Recherche, Montpellier, France. All other reagents were of analytical 
grade. 
Data analysis. Statistical analysis was performed by one-way 
analysis of variance (ANOVA) or ANOVA on ranks (Kruskal-Wallis 
analysis) where applicable. Paired data were analyzed by one-way 
repeated measures ANOVA or repeated measures ANOVA on ranks 
(Friedman analysis) where applicable. All ANOVAs were followed by 
multiple comparisons using the Student-Newman-Keuls method. 
P < .05 was considered statistically significant. The EC50 and Em,u, 
values for SP, NKA and NKB were estimated from V02 and PP 
concentration-response curves for individual experiments. For NKB, 
the maximum VO2 effect was not obtained, so the EC50 for this 
peptide was estimated by using the mean Ema,, from the SP and NKA 
experiments. In capsaicin pretreatment experiments, the EC 50 for 
the acute effects of capsaicin was estimated from individual PP 
concentration-response curves and statistically analyzed by Stu-
dent's t test. 
• Results 
Effects of CP-99994. Concentration-response curves for 
capsaicin were characteristically biphasic for V0 2 , as seen 
previously (Colquhoun et al., 1995; Griffiths et al., 1996), 
with a concentration-dependent increase in PP that is indic-
ative of vasoconstriction (fig. 1). Two consecutive concentra- 
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Fig. 1. Effect of the NK1 receptor antagonist CP-99994 on concentration-
response curves for capsaicin-induced changes in oxygen consumption 
(panels A, B and C) and perfusion pressure (panels D, E and F) in the 
perfused rat hindlimb. Control (0), 0.1 AM (IP), 0.5 AM (II) and 1.0 AM (A) 
CP-99994. Statistical analysis was by one-way repeated measures 
ANOVA or repeated measures ANOVA on ranks (Friedman analysis) 
where applicable, followed by multiple comparisons (Student-Newman-
Keuls method). * P < .05 from control. Values are mean ± S.E.M. of 5 to 
6 experiments. 
tion-response curves for capsaicin obtained in the same per-
fusion were very similar, as indicated by the data obtained 
using a low, ineffective concentration of CP-99994 (0.1 1.1M) 
(fig. 1A, D). However, there is occasionally mild sensitization 
to the V02 stimulatory response at a low capsaicin concen-
tration (0.25 I.L.M) (fig. 1B) that also occurs when a capsaicin 
dose-response curve is repeated in the absence of other 
agents (data not shown). The basis for this sensitization is 
unknown at present, but it may reflect an increase in the VN I 
receptor population or mild up-regulation of postreceptor 
cellular mechanisms. The observed maximum stimulation of 
VO, was produced by 0.4 AM capsaicin (AV0 2, 1.35 ± 0.14 
gmol 1 1). -1 above basal V02) followed by inhibition of VO, 
at concentrations above 1 /LAI, maximum inhibition occurring 
at 2 AM (-2.25 -± 0.35 gmol g -1 11 -1 below basal V0 2 ; fig. 
1C). The nonpeptide NK1 receptor antagonist CP-99994 (0.5 
and 1 I.L.M) selectively inhibited the stimulation of VO 2 pro-
duced by capsaicin (AV02, 0.97 ± 0.03 and 0.78 ± 0.06 gmol 
• h- respectively, P < .05; fig. 1B, C). Some statistically 
significant differences in capsaicin-induced PP changes were 
observed in the presence of CP 99994 (fig. 1, D, E, F), but 
these were not consistent over the three antagonist concen-
trations used. 
Effects of SR 48968. Consecutive concentration-response 
curves for capsaicin were very similar at an ineffective con-
centration of the selective NK2 receptor antagonist SR 48968 
(fig. 2, A and D), a result that confirms the reproducibility of 
capsaicin-induced effects. At a concentration of 1 AM, SR 
48968 significantly inhibited (P < .05) the maximum stimu-
lation of V02 induced by 0.4 p.M capsaicin (AV0 2 : control, 
1.06 ± 0.13 gmol h -1; SR 48963, 0.52 ±0.24 Amol g'.7 1 
• i; fig. 2B). Although the stimulation of V0 2 at a lower 
concentration of capsaicin (0.25 I.L1VI) was potentiated in the 
presence of 1 gM SR 48968 (fig. 2B), this effect is likely to be 
caused not by the antagonist, but rather by the mild sensi-
tization to capsaicin that occurs when doses of the vanilloid 
are repeated in a single perfusion (see above). Furthermore, 
there was not a statistically significant difference in the V0 2 
response to 0.25 AM capsaicin when a higher concentration of 
SR 48968 (10 PI) was used (fig. 2C). However, at this con-
centration of SR 48968, further blockade of the maximum 
capsaicin-induced stimulation of V02 (AV02 : control, 1.03 ± 
0.08 Amol g - ' 11 -1; SR 48968, 0.17 ± 0.30 gmol P < 
.05; fig. 2C) was evident, whereas the inhibition of VO, pro-
duced by a high concentration of the vanilloid (2 p,M) was 
significantly enhanced (AV0 2 : control, -2.07 ± 0.20 Amol 
g ' 	SR 48968, -3.04 ± 0.26 ;Imo' g-' h-i , p < . 05 ) . 
Vasoconstriction at all concentrations of capsaicin was also 
significantly (P < .05) enhanced by 10 AM SR 48968 (fig. 2F). 
Effects of CGRP (8_37) . Infusion of the CGRP antagonist 
CGRP (8 _37) significantly (P < .05) increased the stimulation 
of VO2 induced by 0.25 I.LM capsaicin (AV0 2: control, 0.13 ± 
0.06 Amol h';  0.80 ± 0.09 Amol g' I ) 
but did not significantly increase the observed maximum 
stimulation of VO 2 produced by the infusion of 0.4 gM cap-
saicin (fig. 3A). The inhibition of V0 2 induced by 1 p.M 
capsaicin was significantly enhanced by the co-infusion of 
CGRP(8 _37) (AV0 2: control, -1.13 ± 0.29 gmol g' 	I ; 
CGRP(8 _37) , -2.08 ± 0.15 gmol 	P < .05, fig. 3A), 
whereas APP at 1 and 2 AM capsaicin was markedly in- 
creased (APP: control, 16.5 ± 0.7 mm Hg and 29.3 ± 2.0 mm 
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Fig. 2. Effect of the NK2 receptor antagonist SR 48968 on 
concentration-response curves for capsaicin-induced 
changes in oxygen consumption (panels A, B and C) and 
perfusion pressure (panels D, E and F) in the perfused rat 
hindlimb. Control (0), 0.1 I.L.M (•), 1.0 iLM (0) and 10.0 AM 
(A) SR48968. Statistical analysis was by one-way repeated 
measures ANOVA or repeated measures ANOVA on ranks 
(Friedman analysis) where applicable, followed by multiple 
comparisons (Student-Newman-Keuls method). * P < .05 
from control. Values are mean ± S.E.M. of 5 to 6 experi-
ments. 
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Fig. 3. Effect of the CGRP receptor antagonist CGRP (8 _37) on concentra-
tion-response curves for capsaicin-induced changes in oxygen consump-
tion (panel A) and perfusion pressure (panel B) in the perfused rat 
hindlimb. Control (0) and 1.0 M CGRP(8,7) (•). Statistical analysis was 
by one-way repeated measures ANOVA or repeated measures ANOVA on 
ranks (Friedman analysis) where applicable, followed by multiple com-
parisons (Student-Newman-Keuls method). * P < .05 from control. Val-
ues are mean ± S.E.M. of 5 to 6 experiments. 
Hg, respectively; CGRP(87), 36.8 ± 2.1 mm Hg and 46.0 ± 
3.1 mm Hg, respectively, P < .05). 
Effects of SP, NKA, NEB and CGRP. Infusion of the 
neutral endopeptidase inhibitor phosphoramidon (5 I.L.M) 
alone had no detectable effect on either basal V0 2 or PP. The 
co-infusion of increasing doses of SP with phosphoramidon 
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Fig. 4. Effect of SP (•), NKA (•), NKB (0) and CGRP (0) on oxygen 
consumption (panel A) and perfusion pressure (panel B) in the perfused 
rat hindlimb. In all experiments, SP, NKA, NICB and CGRP were co-
infused with the neutral endopeptidase inhibitor phosphoramidon (5 
/AM). Values are mean ± S.E.M. of 4 to 6 experiments. 
produced a concentration-dependent increase in V0 2 (fig. 4A; 
table 1) and induced mild vasoconstriction (fig. 4B; table 1). 
Increasing the dose of SP to micromolar concentrations 
caused some attenuation of the VO, increase, whereas the 
effect on PP plateaued. NKA, also co-infused with phosphor-
amidon, produced similar effects on hindlimb V02 and PP 
but was approximately 10-fold more potent than SP (fig. 4; 
table 1). The infusion of NKB, with phosphoramidon, stimu- 
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TABLE 1 
Maximum change in perfusion pressure (APP) and oxygen consumption 
(AV02), and concentration producing 50 percent of maximum response 
(EC50) for SP, NKA and NKB in the perfused rat hindlimb 
APP 	 AVO2 
Neuro- 
peptide 	 ECso 	 EC50 
(mm Hg) 
	
(n3/1) (umol 
	
(nM) 
SP 5 4.33 ± 0.33 352 ± 26 0.52 ± 0.07 269 ± 23 
NKA 4 6.75 ± 1.18 25.5 ± 2.7 0.53 ± 0.08 21.2 ± 3.0 
NKB 5 3.40 ± 0.25 34.4 ± 5.2 71.8 ± 29.2t 
Values are mean ± S.E.M. 
t EC 50 estimated using mean of E (V0 2) for SP and NKA. 
lated a small but reproducible change in V02; however, max-
imum V02 was not obtained using concentrations of NKB 
that induced a maximum change in vascular tone (fig. 4; 
table 1). On the other hand, the co-infusion of CGRP (10-500 
nM) and phosphoramidon altered neither basal hindlimb 
V02 nor vascular tension. 
Effects of capsaicin pretreatment. Figure 5 shows V0 2 
and PP responses to capsaicin in hindlimbs perfused 1, 7 and 
14 days after vehicle or systemic capsaicin pretreatment. The 
stimulation of V0 2 induced by submicromolar concentrations 
of caps aicin was significantly inhibited 1 day after capsaicin 
pretreatment (maximum AV0 2: control, 0.98 -± 0.23 Amol 
g 1 11 -1 ; capsaicin-pretreated, 0.08 ± 0.04 limol g -1 P < 
.05; fig. 5A), whereas the increase in PP produced by 2 AM 
capsaicin was markedly enhanced (APP: control, 23.2 ± 1.4 
mm Hg; capsaicin-pretreated, 35.8 ± 3.3 mm Hg, P < .05; fig. 
5D). Seven and 14 days after capsaicin pretreatment, the 
stimulation of V02 and the vasoconstriction induced by low 
concentrations of capsaicin was completely restored, whereas 
the maximum inhibition of V0 2 by 2 ILM caps aicin was sig-
nificantly enhanced compared with vehicle-pretreated con-
trols (V02 : 7 days, control, -3.18 ± 0.06, capsaicin-pre-
treated, -4.27 ± 0.46; 14 days, control, -3.02 ± 0.25, 
capsaicin-pretreated, -4.52 ± 0.40 iimol h'; fig. 3B, C). 
The maximum vasoconstriction at micromolar concentra-
tions of capsaicin was also greatly increased 7 days after 
capsaicin pretreatment, and it was increased further after 14 
1 da 	 7 days 	14 days 
A its 
\ 
, 
_B 
_ 
•
- 	 _ 
- 
- . 
. 
D 
_ 
. 
- F _ 
_ 
-7 	4 	-7 	4 	-7 
log [capsaicin] 
Fig. 5. Concentration-response curves for capsaicin-induced changes in 
oxygen consumption (panels A, B and C) and perfusion pressure (panels 
D, E and F) in the hindlimbs of rats perfused 1, 7 and 14 days after 
pretreatment with vehicle (0) or capsaicin (•). Statistical analysis was by 
one-way ANOVA or ANOVA on ranks (Kruskal-Wallis analysis) where 
applicable, followed by multiple comparisons (Student-Newman-Keuls 
method). * P < .05 from control. Values are mean ± S.E.M. of 4 to 6 
experiments. 
TABLE 2 
Maximum change in perfusion pressure (APP) and concentration 
producing 50 percent of maximum response (EC 50) for capsaicin in the 
perfused rat hindlimb, 1, 7 and 14 days after vehicle- or capsaicin-
pretreatment 
Pretreatment n Days after Pretreatment (mm Hg) 
EC50 
(AM) 
Vehicle 5 1 30.2 ± 2.2 1.07 ± 0.04 
Capsaicin 5 1 35.8 ± 3.3 0.99 ± 0.07 
Vehicle 4 7 31.0 ± 1.8 1.02 ± 0.05 
Capsaicin 4 7 42.3 ± 0.3 0.74 ± 0.04** 
Vehicle 5 14 29.3 ± 1.8 0.96 ± 0.05 
Capsaicin 5 14 47.0 ± 4.4 0.66 ± 0.05** 
Values are mean ± S.E.M. ** P < 0.01 (Student's t test) from corresponding 
vehicle pretreated. 
days (fig. 5; table 2). In addition, the EC 50 for capsaicin, 
estimated from the PP concentration-response curves, was 
significantly (P < .01) lower in animals perfused 7 and 14 
days after capsaicin pretreatment (table 2). 
Discussion 
Capsaicin produced a powerful vasoconstrictor response 
and a biphasic effect on VO, in the perfused rat hindlimb, a 
result that confirmed previous data from this laboratory 
(Cameron-Smith et al., 1990; Colquhoun et al., 1995; Grif-
fiths et al., 1996). The main purpose of the present study was 
to investigate the role of sensory neurons and sensory neu-
ropeptides (SP, NKA, NKB and CGRP) in capsaicin-induced 
changes in vascular resistance and VO, by studying the 
effects of capsaicin pretreatment and neuropeptide antago-
nists. 
Stimulation of V0 2 produced by submicromolar concentra-
tions of capsaicin (VN I response) was partly blocked by the 
selective NK1 receptor antagonist CP-99994 in a concentra-
tion-dependent manner (fig. 1). The NK2 receptor antagonist 
SR 48968 produced effects similar to those of CP-99994 but 
also enhanced the inhibition of V0 2 produced by micromolar 
concentrations of capsaicin (VN 2 response) and potentiated 
vasoconstriction over the entire capsaicin concentration 
range (fig. 2). Infusion of SP, MICA or NKB, in the presence of 
phosphoramidon, produced mild, concentration-dependent 
vasoconstriction and stimulated V0 2 (fig. 4). MICA was at 
least 10-fold more potent than SP at stimulating V02 and 
vasoconstriction (table 1), and its activity is comparable to 
that in an NK2 receptor bioassay (rabbit pulmonary artery) 
(Regoli et al., 1987). The potency of SP in the present study is 
at least 1000-fold lower than in the NK1 receptor bioassay 
(dog carotid artery) and more closely resembles its activity on 
NK2 receptors in the rabbit pulmonary artery (Regoli et al., 
1987). However, the use of BSA as an essential colloid in the 
perfused hindlimb preparation may account for the apparent 
low potency of SP; this protein is known to bind numerous 
agents, including capsaicin. Taken together, these findings 
using neuropeptide agonists and antagonists provide evi-
dence that stimulation of V0 2 by submicromolar concentra-
tions of capsaicin is partly mediated by the endogenous re-
lease of SP and MICA, which then stimulate V0 2 via action on 
peripheral NK2 receptors and possibly NK1 receptors. How-
ever, the data obtained using nonpeptide tachykinin receptor 
antagonists should be interpreted with caution, because the 
submicromolar to micromolar concentrations required to al-
ter the effects of capsaicin may not be specific for one tachy- 
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kinin receptor subtype and may induce nonspecific effects 
(Lombet and Spedding, 1994). Nonetheless, when taken in 
conjunction with the rank order of potency for the tachyki-
nins in this preparation (NKA > NICB > SP), the present 
data support the notion of NK2 receptor involvement, al-
though a role for NK1 receptors cannot be excluded because 
CP-99994 was also effective at blocking some actions of cap-
saicin. In addition, NKA is known to have a strong affinity for 
NK1 receptors, and preliminary autoradiographic studies in-
dicate that NK1 receptors are present on blood vessels in 
hindlimb skeletal muscle (Griffiths, Mazzone, 
Geraghty and Colquhoun, unpublished observations). Al-
though NKB stimulated V0 2 and vasoconstriction in the 
present study, it is unlikely that NK3 receptors play a role in 
the capsaicin-mediated effects in muscle, because their pe-
ripheral distribution is limited (Mastrangelo et al., 1987; 
Guard et a/., 1990). 
The potentiation of capsaicin-stimulated vasoconstriction 
by SR 48968 may indicate that endogenously released tachy-
kinins, acting via NK2 receptors, are dilators of the perfused 
hindlimb vasculature, although the concentration of SR 
48968 required for this effect may have also blocked NK1 
receptors. Similarly, CGRP, which is released in skeletal 
muscle in response to capsaicin (Santicioli et al., 1992), may 
act as a potent vasodilator in this preparation, because the 
CGRP receptor antagonist CGRP(87) greatly potentiated 
the capsaicin-induced vasoconstriction and inhibition of V02 
(fig. 3). These hypotheses are not supported by the infusion, 
in the presence of phosphoramidon, of the tachykinins SP 
and NKA, which act as mild vasoconstrictors in this prepa-
ration (see above).- Infused CGRP • (also with phosphorami-
don) did not produce a measurable effect on basal hindlimb 
V02 or vascular tone (fig. 4). This observation is unusual, 
given that CGRP has been shown to be a potent vasodilator 
in many tissues, including striated muscle (White et al., 
1993; Kim et al., 1995). In addition, it has recently been 
shown that CGRP, released from capsaicin-sensitive primary 
afferents, contributes to the hyperemic response to skeletal 
muscle contraction (via sciatic nerve stimulation) in the rat 
hindlimb (Yamada et al., 1997a, b). However, basal hindlimb 
PP in the present study probably represents near-maximum 
arteriolar dilation, because at the flow rate used (4 ml/min), 
the potent vasodilator nitroprusside has no measurable effect 
on vascular tone (Colquhoun et al., 1988; Ye et al., 1990). This 
may limit the scope of action of SP, NKA, NKB and/or CGRP 
such that any vasodilator action by these peptides would not 
be observed. The vasoconstriction induced by SP, NKA and 
NKB in the present study may have resulted from direct 
stimulation of smooth muscle cell NK receptors after diffu-
sion of the peptides across the endothelium. It remains to be 
seen whether the neuropeptides used in the present study 
can significantly alter vascular tone in the constant-flow 
perfused-hindlimb preparation preconstricted with other va-
soactive agents (e.g., norepinephrine, serotonin and angio-
tensin II). Preliminary results obtained in the perfused rat 
hindlimb under norepinephrine-induced vascular tension in-
dicate that these peptides may induce vasodilation, although 
it is not yet clear which receptors and mechanisms are in-
volved in this response (Griffiths, Geraghty and Colquhoun, 
unpublished observations). 
Capsaicin possesses a well-documented ability to stimulate 
and then desensitize peptide-containing sensory neurons  
with prolonged or repeated application or after systemic ad-
ministration. Indeed, capsaicin is a widely used research tool 
that selectively blocks C-type and A5-type primary afferents. 
In the present investigation, we attempted to define a role for 
capsaicin-sensitive neurons in the acute metabolic and vas-
cular effects of vanilloids in perfused muscle by studying the 
effects of systemic capsaicin pretreatment. Capsaicin pre-
treatment produced dramatically alters capsaicin-induced 
V02 and PP changes in the perfused hindlimb (fig. 5). One 
day after capsaicin pretreatment, the stimulation of VO, and 
the mild increase in PP produced by submicromolar concen-
trations of capsaicin (VN, response) were almost completely 
abolished. However, 7 days after capsaicin pretreatment, the 
VN, response had returned, and the magnitude of V0 2 stim-
ulation was identical to that of the control. 
Szolcsanyi (1993) describes four distinct actions of capsa-
icin pretreatment on sensory neurons: 1) release of neuropep-
tides within minutes; 2) "sensory neuron block," wherein 
sensory neurons are unresponsive to capsaicin (i.e., neu-
ropeptides are not released), which lasts for hours to several 
days; 3) recovery of function of some neurons and degenera-
tion of others over several days to weeks and 4) complete 
degeneration of affected neurons over weeks to months. In 
the present study, acute sensory neuron block may explain 
the absence of the VN, response 1 day after capsaicin pre-
treatment. The re-establishment of the 'S/N1  response after 7 
days may be due to a small population of intact C fibers that 
recover from the block and release sufficient neuropeptides to 
stimulate V02. 
In contrast to the effects of capsaicin pretreatment on VN, 
responses ; the inhibition of V02.(VN2 response) was margin- _ 
ally enhanced 1 day, and significantly enhanced 7 and 14 
days, after capsaicin pretreatment. A progressive increase in 
the vasoconstrictor response to capsaicin mirrored the en-
hancement of V0 2 inhibition, the maximum PP to 2 LM 
capsaicin infusion almost doubling 14 days after capsaicin 
pretreatment. Further analysis of the data revealed that the 
concentration of capsaicin producing a half-maximal increase 
in PP was significantly (P < .01) decreased 7 and 14 days 
after capsaicin pretreatment. Why the maximum vasocon-
strictor response progressively increased in capsaicin-pre-
treated rats is unclear. This was an unexpected finding be-
cause capsaicin pretreatment normally leads to a blunting of 
nonvascular, smooth muscle responses to capsaicin (Maggi 
and Meli, 1988). This observation, when combined with the 
decrease in EC 50 for capsaicin, suggests either up-regulation 
of VN2 receptors and/or sensitization of vascular smooth 
muscle to the direct constrictor action of capsaicin. Alterna-
tively, the apparent increased sensitivity of the vasculature 
to constrict under capsaicin stimulation may be due to the 
absence of sufficient vasodilator peptides (e.g., CGRP) to 
counteract the direct action of the vanilloid on vascular 
smooth muscle. In cats, "cold storage denervation" potenti-
ates capsaicin-induced vasoconstriction of large cerebral ar-
teries that correlates with degeneration of SP- and CGRP-
containing perivascular nerves (Saito et al., 1988). These 
authors suggested that although capsaicin releases vasodila-
tor peptides (presumably SP, CGRP, etc.) from perivascular 
nerves of cat cerebral arteries, a direct vasoconstrictor effect 
of capsaicin predominates. This hypothesis is supported by 
the work of Edvinsson et al. (1990), who showed that the 
vasodilatation induced by capsaicin in cat cerebral arteries 
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was attenuated by repeated capsaicin application or by tri-
geminal ganglionectomy, whereas the vasoconstrictor effect 
was unaltered. Similarly, Duckles (1986) has shown that 
capsaicin applied to the isolated carotid artery and thoracic 
aorta of the guinea pig causes vasoconstriction, rather than 
dilation, after systemic in vivo capsaicin pretreatment. The 
apparent direct vasoconstrictor action observed in this study 
is also believed to be due to the absence of sufficient sensory 
vasodilator peptides after capsaicin pretreatment. However, 
the studies of Saito et al. (1988), Edvinsson et al. (1990) and 
Duckles (1986) suggest that the vasoconstrictor action of 
capsaicin occurs by a nonspecific effect on the plasma mem-
brane of vascular smooth muscle cells. Conversely, the effects 
in the perfused hindlimb are believed to occur via the stim-
ulation of specific vanilloid receptors because the vasocon-
striction can be blocked by the competitive vanilloid receptor 
antagonist capsazepine (Griffiths et al., 1996). 
Exactly how capsaicin and the sensory neuropeptides pro-
duce their vascular and V02 effects in perfused muscle is 
unclear. The concept of site-specific vasoconstriction, leading 
to increased "nutritive" flow, has been proposed to explain 
the large increases in hindlimb V0 2 seen with the infusion of 
other potent vasoconstrictors, such as norepinephrine, angio-
tensin II and vasopressin (reviewed in Clark et al., 1995; 
1997). That is, vasoconstrictors that increase hindlimb V02 
probably do so by redistributing perfusate flow to the net-
work of vessels supplying skeletal muscle cells, which results 
in greater total nutrient exchange. On the basis of this flow 
redistribution model, it appears plausible that submicromo-
lar concentrations of capsaicin may stimulate V0 2 (VN re-
sponse) by selectively constricting (via a direct effect) or 
dilating (by release of neuropeptides) blood vessels, leading 
to increased perfusate flow to "nutritive" vessels. However, a 
direct effect of capsaicin and the sensory neuropeptides to 
stimulate muscle V0 2 cannot be ruled out, because in the 
present study, NK1 and NK2 receptor antagonists decreased 
capsaicin-induced stimulation of V0 2 but did not cause ap-
preciable changes in PP (fig. 1C, F; fig. 2, B and E). 
On the other hand, there is convincing evidence that strong 
vasoconstrictors that inhibit V0 2 in the perfused hindlimb 
(e.g., serotonin) do so by shunting perfusate away from nu-
tritive vessels to non-nutritive vessels supplying hindlimb 
connective tissue (septa and tendons) (Newman et al., 1997). 
Therefore, increased non-nutritive flow may explain the in-
hibition of V02 that accompanies the strong vasoconstriction 
induced by high concentrations of capsaicin. This hypothesis 
is strengthened by the current observation that the augmen-
tation of capsaicin induced vasoconstriction 7 and 14 days 
after capsaicin pretreatment (fig. 5) produced a concomitant 
potentiation of V0 2 inhibition. 
The results of the present study imply that capsaicin, when 
infused into the perfused rat hindlimb, stimulates higher-
affinity vanilloid receptors (VN,) that release thermogenic 
(V02-stimulating) peptides. These receptors appear to be 
neuronal (primary afferent C fiber), given that systemic cap-
saicin pretreatment ablates the acute VO 2 stimulation re-
sponse to infused capsaicin. The stimulation of VO 2 by cap-
saicin is also selectively blocked by nonpeptide tachykinin 
antagonists of NK1 and NK2 receptors, and infused SP, NKA 
and NKB stimulate oxygen consumption and mild vasocon-
striction with a rank potency order of NKA > NKB > SP. 
Hence, capsaicin may stimulate V02 by releasing endoge- 
nous tachykinins that interact primarily with NK2 receptors. 
Conversely, CGRP had no detectable effect on VO, or pres-
sure, which may be due to the use of an almost fully dilated 
preparation. Indeed, the CGRP antagonist CGRP (8 _37) en-
hanced capsaicin-induced vasoconstriction and inhibition of 
V02, which suggests that a direct vasoconstrictor action of 
caps aicin is opposed by the vasodilator action of CGRP. Con-
sequently, the enhanced vasoconstrictor response to capsa-
icin in capsaicin-pretreated rats (7 and 14 days) may be due 
to a reduction in the release of CGRP from sensory neurons. 
Thus in the perfused rat hindlimb, the overall degree of 
capsaicin-induced vasoconstriction may be the sum of the 
indirect actions of vasoactive peptides (e.g., SP, NKA and 
CGRP) released from sensory neurons, plus the direct vaso-
constrictor action of capsaicin on vascular smooth muscle. 
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